PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶:
 C12N 15/31, C07K 14/315, A61K 39/09, C12N 1/21

(11) International Publication Number:

WO 99/42588

(43) International Publication Date:

26 August 1999 (26.08.99)

(21) International Application Number:

PCT/CA99/00114

(22) International Filing Date:

17 February 1999 (17.02.99)

(30) Priority Data:

60/075,425

20 February 1998 (20.02.98) US

1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).

(74) Agents: CÔTE, France et al.; Swabey Ogilvy Renault, Suite

(71) Applicant (for all designated States except US): BIOCHEM VACCINS INC. [CA/CA]; 2323 boulevard du Parc Technologique, Sainte-Foy, Québec G1P 4R8 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BRODEUR, Bernard,
R. [CA/CA]; 2401 rue Maritain, Sillery, Québec G1T
1N6 (CA). RIOUX, Clément [CA/CA]; 1012 Jean-Charles
Cantin, Ville de Cap Rouge, Québec G1Y 2X1 (CA).
BOYER, Martine [CA/CA]; Apt. 204, 25 des Mouettes,
Beauport, Québec G1E 7G1 (CA). CHARLEBOIS, Isabelle
[CA/CA]; 410 Mirabel, St-Nicolas, Québec G7A 2L5
(CA). HAMEL, Josée [CA/CA]; 2401 rue Maritain, Sillery,
Québec G1T 1N6 (CA). MARTIN, Denis [CA/CA]; 4728-G
rue Gaboury, St-Augustin-de-Desmaures, Québec G3A
1E9 (CA).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: GROUP B STREPTOCOCCUS ANTIGENS

(57) Abstract

Group B streptococcus (GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	ТJ	Tajikistan
\mathbf{BE}	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
\mathbf{BF}	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
\mathbf{BG}	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	\mathbf{UG}	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	$\mathbf{z}\mathbf{w}$	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	\mathbf{PL}	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
\mathbf{DE}	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	$\mathbf{s}\mathbf{G}$	Singapore		

GROUP B STREPTOCOCCUS ANTIGENS

5

FIELD OF THE INVENTION

The present invention is related to antigens, more particularly protein antigens of group B streptococcus (GBS) bacterial pathogen which are useful as vaccine components for therapy and/or prophylaxis.

BACKGROUND OF THE INVENTION

15

20

10

Streptococcus are gram (+) bacteria that are differentiated by group specific carbohydrate antigens A through O found on their cell surface. Streptococcus groups are further distinguished by type-specific capsular polysaccharide antigens. Several serotypes have been identified for the Group B streptococcus (GBS): Ia, Ib, II, III, IV, V, VI, VII and VIII. GBS also contains antigenic proteins known as "C-proteins" (alpha, beta, gamma and delta), some of which have been cloned.

25

30

35

Although GBS is a common component of the normal human vaginal and colonic flora this pathogen has long been recognized as a major cause of neonatal sepsis and meningitis, late-onset meningitis in infants, postpartum endometritis as well as mastitis in dairy herds. Expectant mothers exposed to GBS are at risk of postpartum infection and may transfer the infection to their baby as the child passes through the birth canal. Although the organism is sensitive to antibiotics, the high attack rate and rapid onset of sepsis in neonates and meningitis in infants results in high morbidity and mortality.

To find a vaccine that will protect individuals from GBS infection, researches have turned to the type-specific antigens. Unfortunately these polysaccharides have proven to be poorly immunogenic in humans and are restricted to the particular serotype from which the polysaccharide originates. Further, capsular polysaccharide elicit a T cell independent response i.e. no IgG production.

Consequently capsular polysaccharide antigens are unsuitable as a vaccine component for protection against GBS infection.

Others have focused on the C-protein beta antigen which demonstrated immunogenic properties in mice and rabbit models. This protein was found to be unsuitable as a human vaccine because of its undesirable property of interacting with high affinity and in a non-immunogenic manner with the Fc region of human IgA. The C-protein alpha antigen is rare in type III serotypes of GBS which is the serotype responsible for most GBS mediated conditions and is therefore of little use as a vaccine component.

Therefore there remains an unmet need for GBS antigens that may be used as vaccine components for the prophylaxis and/or therapy of GBS infection.

SUMMARY OF THE INVENTION

10

25

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence selected from the group consisting of:

SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5,

SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10,

SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15,

SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19,

```
SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:44 or fragments, analogs or derivatives thereof.
```

In other aspects, there is provided vectors comprising polynucleotides of the invention operably linked to an expression control region, as well as host cells transfected with said vectors and methods of producing polypeptides comprising culturing said host cells under conditions suitable for expression.

In yet another aspect, there is provided novel polypeptides encoded by polynucleotides of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

20

25

```
Figure 1a is the DNA sequence of clone 1 (SEQ ID NO :1) with corresponding amino acid sequences for open reading frames; figure 1b is the amino acid sequence SEQ ID NO: 2; figure 1c is the amino acid sequence SEQ ID NO: 3; figure 1d is the amino acid sequence SEQ ID NO: 4; figure 1e is the amino acid sequence SEQ ID NO: 5; figure 1f is the amino acid sequence SEQ ID NO: 6;
```

Figure 2a is the DNA sequence of clone 2 (SEQ ID NO :7) with corresponding amino acid sequences for open reading frames; figure 2b is the amino acid sequence SEQ ID NO: 8; figure 2c is the amino acid sequence SEQ ID NO: 9; figure 2d is the amino acid sequence SEQ ID NO:10; figure 2e is the amino acid sequence SEQ ID NO:11; figure 2f is the amino acid sequence SEQ ID NO:12;

```
Figure 3a is the DNA sequence of clone 3 (SEQ ID NO :13)
    with corresponding amino acid sequences for open reading
    frames;
    figure 3b is the amino acid sequence SEQ ID NO:14;
    figure 3c is the amino acid sequence SEQ ID NO:15;
    figure 3d is the amino acid sequence SEQ ID NO:16;
    figure 3e is the amino acid sequence SEQ ID NO:17;
    figure 3f is the amino acid sequence SEQ ID NO:18;
    figure 3g is the amino acid sequence SEQ ID NO:19;
10
    figure 3h is the amino acid sequence SEQ ID NO:20;
    figure 3i is the amino acid sequence SEQ ID NO:21;
    Figure 4a is the DNA sequence of clone 4 (SEQ ID NO :22)
    with corresponding amino acid sequences for open reading
15
    frames;
    figure 4b is the amino acid sequence SEQ ID NO:23;
    figure 4c is the amino acid sequence SEQ ID NO:24;
    figure 4d is the amino acid sequence SEQ ID NO:25;
    figure 4e is the amino acid sequence SEQ ID NO:26;
20
    Figure 5a is the DNA sequence of clone 5 (SEQ ID NO :27)
    with corresponding amino acid sequences for open reading
    frames;
    figure 5b is the amino acid sequence SEQ ID NO:28;
    figure 5c is the amino acid sequence SEQ ID NO:29;
    figure 5d is the amino acid sequence SEQ ID NO:30;
    figure 5e is the amino acid sequence SEQ ID NO:31;
    Figure 6a is the DNA sequence of clone 6 (SEQ ID NO :32) ;
    figure 6b is the amino acid sequence SEQ ID NO:33;
30
    figure 6c is the amino acid sequence SEQ ID NO:34;
    figure 6d is the amino acid sequence SEQ ID NO:35;
    figure 6e is the amino acid sequence SEQ ID NO:36;
    Figure 7a is the DNA sequence of clone 7 (SEQ ID NO :37);
35
    figure 7b is the amino acid sequence SEQ ID NO:38;
```

```
figure 7c is the amino acid sequence SEQ ID NO:39; figure 7d is the amino acid sequence SEQ ID NO:40; figure 7e is the amino acid sequence SEQ ID NO:41;
```

5 Figure 8 is the DNA sequence of a part of clone 7 including a signal sequence (SEQ ID NO :42);

Figure 9 is the DNA sequence of a part of clone 7 without a signal sequence (SEQ ID NO :43);

10 Figure 9a is the amino acid sequence (SEQ ID NO:44);

Figure 10 represents the distribution of anti-GBS ELISA titers in sera from CD-1 mice immunized with recombinant GBS protein corresponding to the SEQ ID NO:39.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to novel antigenic polypeptides of group B streptococcus (GBS) characterized by the amino acid sequence selected from the group consisting of:

SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5,

SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10,

SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15,

10 SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19,

SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24,

SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29,

SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34,

SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39,

15 SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:44 or fragments, analogs or derivatives thereof.

A preferred embodiment of the invention includes SEQ ID NO :39 and SEQ ID NO:44.

20

A further preferred embodiment of the invention is SEQ ID NO :39.

A further preferred embodiment of the invention is SEQ ID NO :44.

As used herein, "fragments", "derivatives" or "analogs" of the polypeptides of the invention include those polypeptides in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably conserved) and which may be natural or unnatural.

The terms «fragments», «derivatives» or «analogues» of polypeptides of the present invention also include polypeptides which are modified by addition, deletion,

substitution of amino acids provided that the polypeptides retain the capacity to induce an immune response.

By the term «conserved amino acid» is meant a substitution of one or more amino acids for another in which the antigenic determinant (including its secondary structure and hydropathic nature) of a given antigen is completely or partially conserved in spite of the substitution.

10 For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity, which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. The positively charged (basic) 20 amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

25 Preferably, derivatives and analogs of polypeptides of the invention will have about 70% identity with those sequences illustrated in the figures or fragments thereof. That is, 70% of the residues are the same. More preferably polypeptides will have greater than 95% homology. In another preferred embodiment, derivatives and analogs of polypeptides of the invention will have fewer than about 20 amino acid residue substitutions, modifications or deletions and more preferably less than 10. Preferred substitutions are those known in the art as conserved i.e. the substituted residues share physical or chemical properties such as hydrophobicity, size, charge or functional groups.

Furthermore, in those situations where amino acid regions are found to be polymorphic, it may be desirable to vary one or more particular amino acids to more effectively mimic the different epitopes of the different GBS strains.

Also included are polypeptides which have fused thereto other compounds which alter the polypeptides biological or pharmacological properties i.e. polyethylene glycol (PEG) to increase half-life; leader or secretory amino acid sequences for ease of purification; prepro- and pro- sequences; and (poly) saccharides.

Moreover, the polypeptides of the present invention can be modified by terminal -NH₂ acylation (eg. by acetylation, or thioglycolic acid amidation, terminal carbosy amidation, e.g. with ammonia or methylamine) to provide stability, increased hydrophobicity for linking or binding to a support or other molecule.

20

25

Also contemplated are hetero and homo polypeptide multimers of the polypeptide fragments, analogues and derivatives. These polymeric forms include, for example, one or more polypeptides that have been cross-linked with cross-linkers such as avidin/biotin, gluteraldehyde or dimethyl-superimidate. Such polymeric forms also include polypeptides containing two or more tandem or inverted contiguous sequences, produced from multicistronic mRNAs generated by recombinant DNA technology.

30 Preferably, a fragment, analog or derivative of a polypeptide of the invention will comprise at least one antigenic region i.e. at least one epitope.

In order to achieve the formation of antigenic polymers

(i.e. synthetic multimers), polypeptides may be utilized having bishaloacetyl groups, nitroarylhalides, or the like,

where the reagents being specific for thio groups. Therefore, the link between two mercapto groups of the different peptides may be a single bond or may be composed of a linking group of at least two, typically at least four, and not more than 16, but usually not more than about 14 carbon atoms.

In a particular embodiment, polypeptide fragments, analogs and derivatives of the invention do not contain a methionine (Met) starting residue. Preferably, polypeptides will not incorporate a leader or secretory sequence (signal sequence). The signal portion of a polypeptide of the invention may be determined according to established molecular biological techniques. In general, the polypeptide of interest may be isolated from a GBS culture and subsequently sequenced to determine the initial residue of the mature protein and therefor the sequence of the mature polypeptide.

- According to another aspect, there is provided vaccine compositions comprising one or more GBS polypeptides of the invention in admixture with a pharmaceutically acceptable carrier diluent or adjuvant.
- Suitable adjuvants include oils i.e. Freund's complete or incomplete adjuvant; salts i.e. AlK(SO₄)₂, AlNa(SO₄)₂, AlNH₄(SO₄)₂, Al(OH)₃, AlPO₄, silica, kaolin; saponin derivative; carbon polynucleotides i.e. poly IC and poly AU and also detoxified cholera toxin (CTB) and E.coli heat labile toxin for induction of mucosal immunity. Preferred adjuvants include QuilATM, AlhydrogelTM and AdjuphosTM. Vaccines of the invention may be administered parenterally by injection, rapid infusion, nasopharyngeal absorption, dermoabsorption, or bucal or oral.

Vaccine compositions of the invention are used for the treatment or prophylaxis of streptococcus infection and/or diseases and symptoms mediated by streptococcus infection, 5 in particular group A streptococcus (pyogenes), group B streptococcus (GBS or agalactiae), dysgalactiae, uberis, nocardia as well as Staphylococcus aureus. General information about Streptococcus is available in Manual of Clinical Microbiology by P.R.Murray et al. (1995, 6th Edition, 10 ASM Press, Washington, D.C.). More particularly group B streptococcus, agalactiae. In a particular embodiment vaccines are administered to those individuals at risk of GBS infection such as pregnant women and infants for sepsis, meningitis and pneumonia as well as immunocompromised 15 individuals such as those with diabetes, liver disease or cancer. Vaccines may also have veterinary applications such as for the treatment of mastitis in cattle which is mediated by the above mentioned bacteria as well as E.coli.

The vaccine of the present invention can also be used for the manufacture of a medicament used for the treatment or prophylaxis of streptococcus infection and/or diseases and symptoms mediated by streptococcus infection, in particular group A streptococcus (pyogenes), group B streptococcus (GBS or agalactiae), dysgalactiae, uberis, nocardia as well as Staphylococcus aureus. More particularly group B streptococcus, agalactiae.

Vaccine compositions are preferably in unit dosage form of about 0.001 to 100 µg/kg (antigen/body weight) and more preferably 0.01 to 10 µg/kg and most preferably 0.1 to 1 µg/kg 1 to 3 times with an interval of about 1 to 12 weeks intervals between immunizations, and more preferably 1 to 6

weeks.

30

According to another aspect, there is provided polynucleotides encoding polypeptides of group B

- 5 streptococcus (GBS) characterized by the amino acid sequence selected from the group consisting of:
 - SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5,
 - SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10,
 - SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15,
- 10 SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19,
 - SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24,
 - SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29,
 - SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34,
 - SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39,
- 15 SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:44 or fragments, analogs or derivatives thereof.

Preferred polynucleotides are those illustrated in figures 1a (SEQ ID NO: 1), 2a (SEQ ID NO: 7), 3a (SEQ ID NO: 13), 4a (SEQ ID NO: 22), 5a (SEQ ID NO: 27), 6a (SEQ ID NO: 32), 7a (SEQ ID NO: 37), 8 (SEQ ID NO: 42) and 9 (SEQ ID NO: 43) which correspond to the open reading frames, encoding polypeptides of the invention.

- Preferred polynucleotides are those illustrated in figures 1a (SEQ ID NO: 1), 2a (SEQ ID NO: 7), 3a (SEQ ID NO: 13), 4a (SEQ ID NO: 22), 5a (SEQ ID NO: 27), 6a (SEQ ID NO: 32), 7a (SEQ ID NO: 37), 8 (SEQ ID NO: 42) and 9(SEQ ID NO: 43) and fragments, analogues and derivatives thereof.
 - More preferred polynucleotides of the invention are those illustrated in Figures 7 (SEQ ID NO: 37), 8 (SEQ ID NO: 42) and 9 (SEQ ID NO: 43).
- 35 Most preferred polynucleotides of the invention are those illustrated in Figures 8 (SEQ ID NO : 42) and 9 (SEQ ID NO :

43).

It will be appreciated that the polynucleotide sequences illustrated in the figures may be altered with degenerate codons yet still encode the polypeptides of the invention.

Due to the degeneracy of nucleotide coding sequences, other polynucleotide sequences which encode for substantially the same polypeptides of the present invention may be used in the practice of the present invention. These include but are not limited to nucleotide sequences which are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change.

15

10

Accordingly the present invention further provides polynucleotides which hybridize to the polynucleotide sequences herein above described (or the complement sequences thereof) having 50% and preferably at least 70% identity between sequences. More preferably polynucleotides are hybridizable under stringent conditions i.e. having at least 95% identity and most preferably more than 97% identity.

By capable of hybridizing under stringent conditions is meant annealing of a nucleic acid molecule to at least a region of a second nucleic acid sequence (whether as cDNA, mRNA, or genomic DNA) or to its complementary strand under standard conditions, e.g. high temperature and/or low salt content, which tend to disfavor hybridization of noncomplementary nucleotide sequences. A suitable protocol is described in Maniatis T. et al., Molecular cloning: A Laboratory Manual, Cold Springs Harbor Laboratory, 1982, which is herein incorporated by reference.

35

In a further aspect, polynucleotides encoding polypeptides

of the invention, or fragments, analogs or derivatives thereof, may be used in a DNA immunization method. That is, they can be incorporated into a vector which is replicable and expressible upon injection thereby producing the antigenic polypeptide in vivo. For example polynucleotides may be incorporated into a plasmid vector under the control of the CMV promoter which is functional in eukaryotic cells. Preferably the vector is injected intramuscularly.

10

According to another aspect, there is provided a process for producing polypeptides of the invention by recombinant techniques by expressing a polynucleotide encoding said polypeptide in a host cell and recovering the expressed polypeptide product. Alternatively, the polypeptides can be 15 produced according to established synthetic chemical techniques i.e. solution phase or solid phase synthesis of oligopeptides which are ligated to produce the full polypeptide (block ligation).

20

25

30

For recombinant production, host cells are transfected with vectors which encode the polypeptide, and then cultured in a nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes. Suitable vectors are those that are viable and replicable in the chosen host and include chromosomal, non-chromosomal and synthetic DNA sequences e.g. bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA. The polypeptide sequence may be incorporated in the vector at the appropriate site using restriction enzymes such that it is operably linked to an expression control region comprising a promoter, ribosome binding site (consensus region or Shine-Dalgarno sequence), and optionally an operator (control element). One can select individual components of the 35 expression control region that are appropriate for a given

host and vector according to established molecular biology principles (Sambrook et al, Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor, N.Y., 1989 incorporated herein by reference). Suitable promoters include but are not limited to LTR or SV40 promoter, E.coli lac, tac or trp promoters and the phage lambda $P_{\scriptscriptstyle L}$ promoter. Vectors will preferably incorporate an origin of replication as well as selection markers i.e. ampicillin resistance gene. bacterial vectors include pET, pQE70, pQE60, pQE-9, pbs, 10 pD10 phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A, ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 and eukaryotic vectors pBlueBacIII, pWLNEO, pSV2CAT, pOG44, pXT1, pSG, pSVK3, pBPV, pMSG and pSVL. Host cells may be bacterial i.e. E. coli, Bacillus subtilis, 15 Streptomyces; fungal i.e. Aspergillus niger, Aspergillus nidulins; yeast i.e. Saccharomyces or eukaryotic i.e. CHO,

Upon expression of the polypeptide in culture, cells are 20 typically harvested by centrifugation then disrupted by physical or chemical means (if the expressed polypeptide is not secreted into the media) and the resulting crude extract retained to isolate the polypeptide of interest. Purification of the polypeptide from culture media or lysate may be achieved by established techniques depending on the 25 properties of the polypeptide i.e. using ammonium sulfate or ethanol precipitation , acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, hydroxylapatite 30 chromatography and lectin chromatography. purification may be achieved using HPLC.

COS.

35

The polypeptide may be expressed with or without a leader or secretion sequence. In the former case the leader may be removed using post-translational processing (see US

4,431,739; 4,425,437; and 4,338,397 incorporated herein by reference) or be chemically removed subsequent to purifying the expressed polypeptide.

- According to a further aspect, the GBS polypeptides of the invention may be used in a diagnostic test for streptococcus infection in particular GBS infection. Several diagnostic methods are possible, for example detecting streptococcus organism in a biological sample, the following procedure may be followed:
 - a) obtaining a biological sample from a patient;
 - b) incubating an antibody or fragment thereof reactive with a GBS polypeptide of the invention with the biological sample to form a mixture; and
- 15 c) detecting specifically bound antibody or bound fragment in the mixture which indicates the presence of streptococcus.

Alternatively, a method for the detection of antibody
20 specific to a streptococcus antigen in a biological sample
containing or suspected of containing said antibody may be
performed as follows:

a) isolating a biological sample from a patient;

30

35

- b) incubating one or more GBS polypeptides of the
 invention or fragments thereof with the biological
 sample to form a mixture; and
 - c) detecting specifically bound antigen or bound fragment in the mixture which indicates the presence of antibody specific to streptococcus.

One of skill in the art will recognize that this diagnostic test may take several forms, including an immunological test such as an enzyme-linked immunosorbent assay (ELISA), a radioimmunoassay or a latex agglutination assay, essentially to determine whether antibodies specific for the protein are present in an organism.

The DNA sequences encoding polypeptides of the invention may also be used to design DNA probes for use in detecting the presence of streptococcus in a biological sample suspected of containing such bacteria. The detection method of this invention comprises:

- a) isolating the biological sample from a patient;
- b) incubating one or more DNA probes having a DNA sequence encoding a polypeptide of the invention or fragments thereof with the biological sample to form a mixture; and
- c) detecting specifically bound DNA probe in the mixture which indicates the presence of streptococcus bacteria.
- The DNA probes of this invention may also be used for detecting circulating streptococcus i.e. GBS nucleic acids in a sample, for example using a polymerase chain reaction, as a method of diagnosing streptococcus infections. The probe may be synthesized using conventional techniques and may be immobilized on a solid phase, or may be labeled with a detectable label. A preferred DNA probe for this application is an oligomer having a sequence complementary to at least about 6 contiguous nucleotides of the GBS polypeptides of the invention.

25

10

Another diagnostic method for the detection of streptococcus in a patient comprises:

- a) labeling an antibody reactive with a polypeptide of the invention or fragment thereof with a detectable label;
- 30 b) administering the labeled antibody or labeled fragment to the patient; and
 - c) detecting specifically bound labeled antibody or labeled fragment in the patient which indicates the presence of streptococcus.

35

A further aspect of the invention is the use of the GBS

polypeptides of the invention as immunogens for the production of specific antibodies for the diagnosis and in particular the treatment of streptococcus infection. Suitable antibodies may be determined using appropriate screening methods, for example by measuring the ability of a particular antibody to passively protect against streptococcus infection in a test model. One example of an animal model is the mouse model described in the examples herein. The antibody may be a whole antibody or an antigen-10 binding fragment thereof and may in general belong to any immunoglobulin class. The antibody or fragment may be of animal origin, specifically of mammalian origin and more specifically of murine, rat or human origin. It may be a natural antibody or a fragment thereof, or if desired, a 15 recombinant antibody or antibody fragment. The term recombinant antibody or antibody fragment means antibody or antibody fragment which were produced using molecular biology techniques. The antibody or antibody fragments may be polyclonal, or preferably monoclonal. It may be specific for a number of epitopes associated with the GBS 20 polypeptides but is preferably specific for one.

EXAMPLE 1 Murine model of lethal Group B Streptococcus (GBS)
25 infection

The mouse model of GBS infection is described in detail in Lancefield et al (J Exp Med 142:165-179,1975). GBS strain C388/90 (Clinical isolate obtained in 1990 from the cephalorachidian fluid of a patient suffering from meningitis, Children's Hospital of Eastern Ontario, Ottawa, Canada) and NCS246 (National Center for Streptococcus, Provincial Laboratory of Public Health for Northern Alberta, Edmonton, Canada) were respectively serotyped as type Ia/c and type II/R.

30

35

To increase their virulence, the GBS strains C388/90 (serotype Ia/c) and NCS 246 (serotype II/R) were serially passaged through mice as described previously (Lancefield et al. J Exp Med 142:165-179, 1975). Briefly, the increase of virulence was monitored using intraperitoneal inoculations of serial dilutions of a subculture in Todd-Hewitt broth obtained from either the blood or spleen of infected mice. After the last passage, infected blood samples were used to inoculate Todd-Hewitt broth. After an incubation of 2 hours at 37°C with 7% CO2, glycerol at a final concentration of 10 10% (v/v) was added to the culture. The culture was then aliquoted and stored at -80° C for use in GBS challenge experiments. The number of cfu of GBS present in these frozen samples was determined. The bacterial concentration necessary to kill 100% (LD100) of the 18 weeks old mice were 15 determined to be 3.5X10⁵ and 1.1X10⁵ respectively for GBS strain C388/90 and NCS246, which corresponded to a significant increase in virulence for both strains. Indeed, the LD100 recorded before the passages for these two strains was higher than 10° cfu. 20

In a bacterial challenge, a freshly thawed aliquot of a virulent GBS strain was adjusted to the appropriate bacterial concentration using Todd-Hewitt broth and 1ml was 25 injected intraperitoneally to each female CD-1 mouse. mice used for the passive protection experiments were 6 to 8 weeks old, while the ones used for the active protection experiments were approximately 18 weeks old at the time of the challenge. All inocula were verified by colony counts. 30 Animals were observed for any sign of infection four times daily for the first 48 h after challenge and then daily for the next 12 days. At the end of that period, blood samples were obtained from the survivors and frozen at -20°C. spleen obtained from each mouse that survived the challenge was cultured in order to identify any remaining GBS. 35

EXAMPLE 2 Immunization and protection in mice with formaldehyde killed whole GBS cells

Formaldehyde killed GBS whole cells were prepared according to the procedures described in Lancefield et al (J Exp Med 142:165-179,1975). Briefly, an overnight culture on sheep blood agar plates (Quelab Laboratories, Montreal, Canada) of a GBS strain was washed twice in PBS buffer (phosphate buffered-saline, pH7.2), adjusted to approximately 3X10° cfu/mL and incubated overnight in PBS containing 0.3% (v/v) formaldehyde. The killed GBS suspension was washed with PBS

and kept frozen at -80°C.

- 15 Female CD-1 mice, 6 to 8 weeks old (Charles River, St-Constant, Québec, Canada), were injected subcutaneously three times at two weeks interval with 0.1 ml of formaldehyde killed cells of GBS strain C388/90 (~6X107 GBS), or 0.1 ml of PBS for the control group. On the day before the immunization, AlhydrogelTM (Superfos Biosector, Frederikssund, Denmark) at a final concentration of 0.14 mg or 0.21 mg of Al, was added to these preparations and incubated overnight at 4°C with agitation. Serum samples were obtained from each mouse before the beginning of the immunization protocol and two weeks after the last injection. The sera were frozen at -20°C.
- Eight mice in each control group injected with PBS and the group immunized with formaldehyde killed whole cells GBS strain C388/90 (Ia/c) were challenged with 1.5X10⁴ cfu of GBS strain C388/90 (Ia/c) one week after the third injection. All mice immunized with the formaldehyde killed GBS whole cells survived the homologous challenge while, within 5 days after the challenge, only 4 out of the 8 mice injected with PBS survived from the infection. In order to increase the mortality rate in the control groups, the

bacterial suspension had to be adjusted according to the age of the mice at the time of the bacterial challenge. In subsequent challenge experiments, when mice were older than 15 weeks, the bacterial inoculum was increased to concentrations between 3.0X10⁵ and 2.5X10⁶ cfu.

Table 1 Immunization of CD1 mice with formaldehyde killed whole cells of GBS and subsequent homologous challenge [strain C388/90 and heterologous challenge [strain NCS246 (II/R)].

antigenic preparations used for immunization ¹	number of living mice 14 days after the bacterial challenge (% Survival)				
	homologous challenge: strain C388/90 (la/c)	heterologous challenge: strain NCS246 (II/R)			
1st infection					
formaldehyde killed cells of GBS strain C388/90 (la/c) ²	8/8 (100) ³	n.d.⁵			
control PBS	4/8 (50)	n.d.			
2nd infection	and infection				
formaldehyde killed cells of GBS strain C388/90 (la/c)	6/6 (100)⁴	0/6 (0) ⁶			
control PBS	2/6 (33)	0/6 (0)			

¹ alhydrogel™ at a final concentration of 0.14 mg or 0.21mg of Al was used;

² approximately 6X10⁷ cfu;

10

15

20

2.5

5

In another experiment, one group of 12 mice corresponding to a control group was injected with PBS, while a second group of 12 mice was immunized with formaldehyde killed whole cells of GBS strain C388/90 (Ia/c). Six mice from each of these two groups were challenged with 2.1X106 cfu of the GBS strain C388/90 (Ia/c) (Table I). As the first challenge experiment, all mice immunized with the GBS strain C388/90 (Ia/c) survived the homologous challenge. Only two out of the 6 mice injected with PBS survived the infection.

³ intraperitoneal challenge with 1 mL Todd-Hewitt culture medium containing GBS C388/90 (la/c) suspension adjusted to 1.5X10⁴ cfu;

⁴ intraperitoneal challenge with 1 mL Todd-Hewitt culture medium containing GBS C388/90 (la/c) suspension adjusted to 2.1X10⁶ cfu; ⁵ not done;

⁶ intraperitoneal challenge with 1 mL Todd-Hewitt culture medium containing GBS NCS246 (II/R) suspension adjusted to 1.2X10⁵ cfu.

The remaining 6 mice in both groups were then used one week later to verify whether this antigenic preparation could confer cross protection against strain NCS246 (II/R) which produce a serologically distinct capsule. 5 the mice infected with this second GBS strain survived the infection. The later result suggested that most of the protective immune response induced by formaldehyde killed strain C388/90 is directed against the capsular polysaccharide and that it could be restricted to strains 10 of that particular serotype. These results clearly indicated that this particular model of infection can be efficiently used to study the protection conferred by vaccination.

15

20

30

EXAMPLE 3 Immunization of rabbit with formaldehyde killed whole GBS cells and passive protection in mice

A New Zealand rabbit (2.5 kg, Charles River, St-Constant, Québec, Canada) was immunized with formaldehyde killed cells of GBS strain C388/90 (Ia/c) to obtain hyperimmune serum. This rabbit was injected subcutaneously three times at three weeks interval with approximately 1.5X109 cfu of formaldehyde killed whole cells of GBS strain C388/90 (Ia/c). Freund's complete adjuvant (Gibco BRL 25 Life Technologies, Grand Island, New York) was used as the adjuvant for the first immunization, while Freund's incomplete adjuvant (Gibco BRL) was used for the following two injections. Serum samples were obtained before the beginning of the immunization protocol and two weeks after the last injection. The sera were frozen at -20°C.

The ability of this particular rabbit hyperimmune serum to passively protect mice against a lethal infection with GBS

was also evaluated. Intraperitoneal injection of mice with either 15 or 25 μ L of hyperimmune rabbit serum 18 hours before the challenge protected 4 out of 5 mice (80%) against the infection. Comparatively, survival rates lower than 20% were recorded for mice in the control group injected with PBS or serum obtained from a rabbit immunized with meningococcal outer membrane preparation. This result clearly indicates that the immunization of another animal species with killed GBS cells can induce the production of antibodies that can passively protect mice. This reagent will also be used to characterize clones.

Table 2 Passive protection of CD-1 mice conferred by rabbit serum obtained after immunization with formaldehyde killed group B whole streptococci (strain C388/90 (Ia/c)) antigenic preparation

groups	number of living mice 14 days after the bacterial challenge with GBS strain C388/90 (Ia/c) ²	% survival
rabbit hyperimmune serum² - 25 μl	4/5	80
rabbit hyperimmune serum¹ - 15 μl	4/5	80
control rabbit serum - 25 μl	1/5	20
control PBS	1/10	10

Freund's complete adjuvant was used for first immunization, and Freund's incomplete adjuvant for the following two injections;

15

20

25

² intraperitoneal challenge with 1 ml Todd-Hewitt culture medium containing GBS C388/90 (Ia/c) suspension adjusted to 2X10⁴ cfu.

EXAMPLE 4 Recombinant production of His. Tag-GBS fusion protein

The coding region of a GBS gene was amplified by PCR (DNA Thermal Cycler GeneAmp PCR system 2400 Perkin Elmer, San Jose, CA) from the genomic DNA of GBS strain C388/90 (Ia/c) using the oligos that contained base extensions for the addition of the restriction sites BqlII (AGATCT) and HindIII (AAGCTT), respectively. The PCR product was purified from 10 agarose gel using a Qiaex II gel extraction kit from Oiagen (Chatsworth, CA), digested with the restriction enzymes BglII and HindIII (Pharmacia Canada Inc Baie d'Urfe, Canada), and extracted with phenol:chloroform before ethanol precipitation. The pET-32b(+) vector (Novagen, Madison, WI) 15 containing the thioredoxin-His. Tag sequence was digested with the restriction enzymes BqlII and HindIII, extracted with phenol:chloroform, and then ethanol precipitated. BglII-HindIII genomic DNA fragment was ligated to the BglII-HindIII pET-32b(+) vector to create the coding sequence for 20 thioredoxin-His. Tag-GBS fusion protein whose gene was under control of the T7 promoter. The ligated products were transformed into E. coli strain XLI Blue MRF' $(\Delta (mcrA) 183\Delta$ (mcrCB-hsdSMR-mrr)173 endAl supE44 thi-1 recAl gyrA96 relAl lac [F'proAB lacIqZΔM15Tn10 (Tetr)]c) (Stratagene, La Jolla, CA) according to the method of Simanis (Hanahan, D. DNA 25 Cloning, 1985, D.M. Glover (ed.), pp. 109-135). recombinant pET plasmid was purified using a Qiagen kit (Qiagen, Chatsworth, CA) and the nucleotide sequence of the DNA insert was verified by DNA sequencing (Taq Dye Deoxy 30 Terminator Cycle Sequencing kit, ABI, Foster City, CA). recombinant pET plasmid was transformed by electroporation (Gene Pulser II apparatus, BIO-RAD Labs, Mississauga, Canada) into E. coli strain AD494 (DE3) (Δara leu7697 ΔlacX74 ΔphoA PvuII phoR ΔmalF3 F'[lac*(lacIq) pro] trxB::Kan (DE3)) (Novagen, Madison, WI). In this strain of

35

E. coli, the T7 promoter controlling expression of the fusion protein, is specifically recognized by the T7 RNA polymerase (present on the $\lambda DE3$ prophage) whose gene is under the control of the lac promoter which is inducible by isopropyl- β -D-thio-galactopyranoside (IPTG).

The transformant AD494 (DE3)/rpET was grown at 37°C with agitation at 250 rpm in LB broth (peptone 10g/L, Yeast extract 5g/L, NaCl 10g/L) containing 100µg of ampicillin (Sigma-Aldrich Canada Ltd., Oakville, Canada) per mL until the A₆₀₀ reached a value of 0.6. In order to induce the production of the thioredoxin-His.Tag-GBS fusion protein, the cells were incubated for 2 additional hours in the presence of IPTG at a final concentration of 1mM. The bacterial cells were harvested by centrifugation.

The recombinant fusion protein produced by AD494(DE3)/rpET32 upon IPTG induction for 2h was partially obtained as insoluble inclusion bodies which were purified from 20 endogenous E. coli proteins by the isolation of insoluble aggregates (Gerlach, G.F. et al 1992, Infect. Immun. 60:892). Induced cells from a 500 mL culture were resuspended in 20 mL of 25% sucrose-50mM Tris-HCl buffer (pH8.0) and frozen at -70°C. Lysis of cells in thawed 25 suspension was achieved by the addition of 5mL of a solution of lysozyme (10mg/mL) in 250mM Tris-HCl buffer (pH8.0) followed by an incubation of 10 to 15 min on ice, and the addition of 150mL of detergent mix (5 parts of 20mM Tris-HCl buffer [pH7.4]-300mM NaCl-2% deoxycholic acid-2% Nonidet P-30 40 and 4 parts of 100mM Tris-HCl buffer [pH8]-50mM EDTA-2% Triton X-100) followed by 5 min incubation on ice. sonication, protein aggregates were harvested by centrifugation for 30 min at 35,000 X g and a sample of the soluble cellular fraction was kept. The aggregated proteins 35 were solubilized in 6M guanidine hydrochloride. The

presence of the fusion protein in both the soluble and insoluble fractions was shown by Western Blot analysis using the serum of a mouse injected with formaldehyde killed cells of GBS strain C388/90 (Ia/c) that survived a bacterial challenge with the corresponding GBS strain.

The purification of the fusion protein from the soluble fraction of IPTG-induced AD494 (DE3) / rpET was done by affinity chromatography based on the properties of the His. Tag sequence (6 consecutive histidine residues) to bind to divalent cations (Ni2+) immobilized on the His.Bind metal chelation resin (Novagen, Madison, WI). The purification method used are those described in the pET system Manual, 6th Edition (Novagen, Madison, WI). Briefly, the pelleted cells obtained from a 100mL culture induced with IPTG was resuspended in 4mL of Binding buffer (5mM imidazole-500mM NaCl-20mM Tris-HCl pH7.9), sonicated, and spun at 39,000 X g for 20 min to remove debris. The supernatant was filtered $(0.45\mu\text{m}\text{ pore size membrane})$ and deposited on a column of His.Bind resin equilibrated in Binding buffer. The column was then washed with 10 column volumes of Binding buffer followed by 6 column volumes of Wash buffer (20mM imidazole-500mM NaCl-20mM Tris-HCl pH7.9). The thioredoxin-His.Tag-GBS fusion protein was eluted with Elute buffer (1M imidazole-500mM NaCl-20mM Tris-HCl pH7.9). The removal of the salt and imidazole from the sample was done by dialysis against 3 X 1 liter PBS at 4°C.

The quantities of fusion protein obtained from either the soluble or insoluble cytoplasmic fractions of *E. coli* were estimated by Coomassie staining of a sodium dodecyl sulfate (SDS)-polyacrylamide gel with serial dilutions of these proteins and a bovine serum albumin standard (Pierce Chemical Co. Rockford, Ill.).

5

10

20

25

30

EXAMPLE 5 Recombinant production of GBS protein under control of lambda P_L promoter

The DNA coding region of a GBS protein was inserted downstream of the promoter $\lambda P_{\scriptscriptstyle L}$ into the translation vector pURV22. This plasmid was derived from p629 (George et al, 1987, Bio/Technology 5:600) from which the coding region for a portion of the herpes simplex virus type I (HSV-I) glycoprotein (gD-1) was removed and the ampicillin 10 resistance gene replaced by a kanamycin cassette obtained from the plasmid vector pUC4K (Pharmacia Biotech Canada Inc., Baie D'Urfe, Canada). The vector contained a cassette of the bacteriophage λ cI857 temperature sensitive repressor gene from which the functional $P_{\text{\tiny R}}$ promoter had been deleted. 15 The inactivation of the cI857 repressor by temperature increase from the ranges of 30-37°C to 37-42°C resulted in the induction of the gene under the control of λ $P_{\scriptscriptstyle \rm L}.$ The translation of the gene was controlled by the ribosome binding site cro followed downstream by a BglII restriction 20 site (AGATCT) and the ATG: ACTAAGGAGGTTAGATCTATG.

Restriction enzymes and T4 DNA ligase were used according to suppliers (Pharmacia Biotech Canada Inc., Baie D'Urfe, Canada; and New England Biolabs Ltd., Mississauga, Canada). 25 Agarose gel electrophoresis of DNA fragments was performed as described by Sambrook et al. (Molecular cloning : A laboratory Manual, 1989, Cold Spring Harbor Laboratory Press, N.Y). Chromosomal DNA of the GBS bacteria was prepared according to procedures described in Jayarao et al (J. Clin. Microbiol., 1991, 29:2774). DNA amplification 30 reactions by polymerase chain reaction (PCR) were made using DNA Thermal Cycler GeneAmp PCR system 2400 (Perkin Elmer, San Jose, CA). Plasmids used for DNA sequencing were purified using plasmid kits from Qiagen (Chatsworth, CA). DNA fragments were purified from agarose gels using Qiaex II 35

gel extraction kits from Qiagen (Chatsworth, CA). Plasmid transformations were carried out by the method described by Hanahan (DNA Cloning, Glover (ed.) pp, 109-135, 1985). The sequencing of genomic DNA inserts in plasmids was done using synthetic oligonucleotides which were synthesized by oligonucleotide synthesizer model 394 (the Perkin-Elmer Corp., Applied Biosystems Div. (ABI), Foster City, CA). The sequencing reactions were carried out by PCR using the Tag Dye Deoxy Terminator Cycle Sequencing kit (ABI, Foster City, CA) and DNA electrophoresis was performed on automated DNA sequencer 373A (ABI, Foster City, CA). The assembly of the DNA sequence was performed using the program Sequencer 3.0 (Gene Codes Corporation, Ann Arbor, MI). Analysis of the DNA sequences and their predicted polypeptides was performed with the program Gene Works version 2.45 (Intelligenetics, Inc., Mountain View CA).

10

15

The coding region of the GBS gene was amplified by PCR from GBS strain C388/90 (Ia/c) genomic DNA using oligos that contained base extensions for the addition of restriction 20 sites BglII (AGATCT) and XbaI(TCTAGA), respectively. The PCR product was purified from agarose gel using a Qiaex II gel extraction kit from Qiagen (Chatsworth, CA), digested with the restriction enzymes BglII and XbaI, and extracted with phenol:chloroform before ethanol precipitation. The pURV22 25 vector was digested with the restriction enzymes BglII and XbaI, extracted with phenol:chloroform, and ethanol precipitated. The BglII-XbaI genomic DNA fragment was ligated to the BglII-XbaI pURV22 vector in which the GBS gene was under the control of the λPL promoter. The ligated 30 products were transformed into E. coli strain XLI Blue MRF' $(\Delta (mcrA) 183\Delta (mcrCB-hsdSMR-mrr) 173 endA1 supE44 thi-1 recA1$ gyrA96 relA1 lac[F' proAB lac1qZAM15 Tn10(Tetr)]c) (Stratagene, La Jolla CA) according to the methods described in Hanahan, supra. Transformants harboring plasmids with the 35

insert were identified by analysis of lysed cells submitted to electrophoresis on agarose gel (Sambrook et al, <u>supra</u>). The recombinant pURV22 plasmid was purified using a Qiagen kit (Qiagen, Chatsworth, CA) and the nucleotide sequence of the DNA insert was verified by DNA sequencing.

The transformant XLI Blue MRF'/rpURV22 was grown at 34°C with agitation at 250 rpm in LB broth containing $50\mu g$ of kanamycin per mL until the A_{600} reached a value of 0.6. In order to induce the production of the fusion protein, the cells were incubated for 4 additional hours at 39°C. The bacterial cells were harvested by centrifugation , resuspended in sample buffer, boiled for 10 min and kept at -20°C.

15

20

25

30

35

10

EXAMPLE 6 Subcloning GBS protein gene in CMV plasmid pCMV-GH

The DNA coding region of a GBS protein was inserted in phase downstream of the human growth hormone (hGH) gene which was under the transcriptional control of the cytomegalovirus (CMV) promoter in the plasmid vector pCMV-GH (Tang et al, Nature, 1992, 356:152). The CMV promoter is non functional in E. coli cells but active upon administration of the plasmid in eukaryotic cells. The vector also incorporated the ampicillin resistance gene.

The coding region of the gene was amplified by PCR from genomic DNA of GBS strain C388/90 (Ia/c) using the oligos that contained base extensions for the addition of the restriction sites BglII (AGATCT) and HindIII (AAGCTT). The PCR product was purified from agarose gel using a Qiaex II gel extraction kit from Qiagen (Chatsworth, CA), digested with the restriction enzymes BglII and HindIII, and extracted with phenol:chloroform before ethanol precipitation. The pCMV-GH vector (Laboratory of Dr. Stephen

A. Johnston, Department of Biochemistry, The University of Texas, Dallas, Texas) containing the human growth hormone to create fusion proteins was digested with the restriction enzymes BamHI and HindIII, extracted with phenol:chloroform, and ethanol precipitated. The 1.3-kb BglII-HindIII genomic DNA fragment was ligated to the BamHI -HindIII pCMV-GH vector to create the hGH-GBS fusion protein under the control of the CMV promoter. The ligated products were transformed into E. coli strain DH5 α [ϕ 80 lacZ Δ M15 endA1 recA1 hsdR17 ($^{r}K^{-m}K^{+}$) supE44 $thi-1\lambda^{-}$ gyrA96 relA1 $\Delta(lacZYA-$ 10 argF)U169] (Gibco BRL, Gaithersburg, MD) according to the methods described by Hanahan, supra. Transformants harboring plasmids with the insert were identified by analysis of lysed cells submitted to electrophoresis on agarose gel (Sambrook, J. et al , supra). The recombinant 15 pCMV plasmid was purified using a Qiagen kit (Qiagen, Chatsworth, CA) and the nucleotide sequence of the DNA insert was verified by DNA sequencing.

20

EXAMPLE 7 Immunological activity of GBS protein to GBS challenge

Four groups of 12 female CD-1 mice (Charles River, St
Constant, Quebec, Canada) of 6 to 8 weeks were injected subcutaneously three times at three week intervals with 0.1mL of the following antigenic preparations: formaldehyde killed cells of GBS strain C388/90 (~6X10⁷ cfu), 20µg of thioredoxin-His.Tag-GBS fusion protein obtained from the insoluble (inclusion bodies) or 20µg of the fusion protein, affinity purified (nickel column), from the soluble cytoplasmic fraction in E.coli, or 20µg of affinity purified (nickel column) thioredoxin-His.Tag control polypeptide.

20µg of QuilATM (Cedarlane Laboratories Ltd, Hornby, Canada)

was added to each antigenic preparation as the adjuvant. Serum samples were obtained from each mouse before immunization (PB) and on days 20 (TB1), 41 (TB2) and 54 (TB3) during the immunization protocols. Sera were frozen at -20°C.

5

An increase of the ELISA titers was recorded after each injection of the fusion protein indicating a good primary response and a boost of the specific humoral immune response after each of the second and third administration. At the 10 end of the immunization period, the means of reciprocal ELISA titers was 456,145 for the group immunized with $20\mu g$ of fusion protein obtained from inclusion bodies compared to 290,133 for the group of mice immunized with the protein 15 from soluble fraction in E.coli. The latter result suggests that the protein obtained from inclusion bodies could be more immunogenic than the soluble protein. Analysis of mice sera in ELISA using the affinity purified thioredoxin-His. Tag to coat plates showed that negligible antibody 20 titers are made against the thioredoxin-His. Tag portion of the fusion protein. The reactivity of the sera from mice injected with the recombinant fusion protein was also tested by ELISA against formaldehyde killed whole cells of GBS strain C388/90. The antibodies induced by immunization with 25 recombinant fusion protein also recognized their specific epitopes on GBS cells indicating that their conformation is close enough to the native streptococcal protein to induce cross-reactive antibodies.

To verify whether the immune response induced by immunization could protect against GBS infection, mice were challenged with 3.5X10⁵ cfu of GBS strains C338/90(Ia/c) and 1.2X10⁵ cfu of strain NCS246(II/R) the results of which are illustrated in tables 3 and 4 respectively. Mice immunized with control thioredoxin-His.Tag peptide were not protected against challenge with either GBS strain while those

immunized with formaldehyde killed C388/90 whole cells only provided protection against homologous challenge. The thioredoxin-His.Tag-GBS fusion protein of the invention protected mice from challenge with both GBS strains. Blood and spleen culture of these mice did not reveal the presence of any GBS.

PCT/CA99/00114 WO 99/42588

Table 3 Survival from GBS strain C388/90 (Ia/c) challenge¹

immunizing agent	no. mice surviving challenge	% survival
thioredoxin-His.Tag²	1 / 6	17
formaldehyde killed C388/90 cells ³	6 / 6	100
thioredoxin-His.Tag-GBS fusion (inclusion body preparation)4	6 / 6	100
thioredoxin-His.Tag-GBS fusion (cytoplasmic fraction) ⁴	6 / 6	100

intraperitoneal administration with 1 ml Todd-Hewitt culture medium adjusted to 3.5X10⁵ cfu;

5

 ^{2 20}μg administered; posterior legs paralyzed in surviving mouse; GBS detected in blood and spleen;
 3 6X10⁷ cfu administered;

⁴ 20µg administered.

Table 4 Survival from GBS strain NCS246 (II/R) challenge¹

immunizing agent	no. mice surviving challenge	% survival
thioredoxin-His.Tag²	0 / 6	0
formaldehyde killed C388/90 cells ³	2 / 6	34
thioredoxin-His.Tag-GBS fusion (inclusion body preparation) ²	5 / 5⁴	100
thioredoxin-His.Tag-GBS fusion (cytoplasmic fraction) ²	6 / 6	100

intraperitoneal administration with 1 ml Todd-Hewitt culture medium containing GBS NCS246(II/R) suspension adjusted to 1.2X10⁵ cfu.

15

EXAMPLE 8 Immunization with recombinant GBS protein confers protection against experimental GBS infection

This example illustrates the protection of mice against fatal GBS infection by immunization with the recombinant protein corresponding to the SEQ ID NO:39.

Groups of 10 female CD-1 mice (Charles River) were immunized subcutaneously three times at three-week intervals with 20 μg of recombinant protein purified from <u>E. coli</u> strain BLR (Novagen) harboring the recombinant pURV22 plasmid vector containing the GBS gene corresponding to SEQ ID NO:42 in presence of 20 μg of QuilATM adjuvant (Cedarlane Laboratories Ltd, Hornby, Canada) or, as control, with

² 20µg administered;

³ 6X10⁷ cfu administered;

^{10 4} one mouse died during immunization.

QuilATM adjuvant alone in PBS. Blood samples were collected from the orbital sinus on day 1, 22 and 43 prior to each immunization and fourteen days (day 57) following the third injection. One week later the mice were challenged with approximately 10⁴ to 10⁶ CFU of various virulent GBS strains. Samples of the GBS challenge inoculum were plated on TSA/5% sheep blood agar plates to determine the CFU and to verify the challenge dose. Deaths were recorded for a period of 14 days and on day 14 post-challenge, the surviving mice were sacrificed and blood and spleen were tested for the presence of GBS organisms. The survival data are shown in table 5.

Prechallenge sera were analyzed for the presence of antibodies reactive with GBS by standard immunoassays. Elisa and immunoblot analyses indicated that immunization with recombinant GBS protein produced in *E. coli* elicited antibodies reactive with both, recombinant and native GBS protein. Antibody responses to GBS are described in Example 9.

10

15

Table 5. Ability of recombinant GBS protein corresponding to SEQ ID NO: 39 to elicit protection against 8 diverse GBS challenge strains

5

10

	Challenge	strain		
Immunogen	Designation	Туре	No. alive:	No. dead 1
rGBS protein none	C388/90	Ia/c	8 : 2 0 : 10	(P<0.0001)
rGBS protein none	NCS 246	II/R	10 : 0 3 : 7	(P=0.0012)
rGBS protein none	ATCC12401	Ib	10 : 0 3 : 7	(P=0.001)
rGBS protein none	NCS 535	V	10 : 0 5 : 5	(P=0.01)
rGBS protein none	NCS 9842	VI	10 : 0 0 : 10	(P<0.0001)
rGBS protein NCS 915-F ³ none	NCS 915	III	7 : 3 1 : 9 4 : 6	(P=0.0007) ²
rGBS protein NCS 954-F none	NCS 954	III/R	7 : 3 4 : 6 1 : 9	(P=0.002)
rGBS protein COH1-F none	COH1	III	4 : 6 3 : 7 0 : 10	(P=0.0004)

Groups of 10 mice per group were used, the number of mice surviving to infection and the number of dead mice are indicated. The survival curves corresponding to recombinant GBS protein-immunized animals were compared to the survival curves corresponding to mock-immunized animals using the log-rank test for nonparametric analysis.

 2 Comparison analysis to NCS915-F-immunized animals.

All hemocultures from surviving mice were negative at day 14 20 post-challenge. Spleen cultures from surviving mice were negative except for few mice from experiment MB-11.

^{15 &}lt;sup>3</sup> Animals were immunized with formaldehyde-killed GBS in presence of QuilATM adjuvant.

EXAMPLE 9 Vaccination with the recombinant GBS protein elicits an immune response to GBS

Groups of 10 female CD-1 mice were immunized subcutaneously with recombinant GBS protein corresponding to SEQ ID NO:39 as described in Example 8. In order to assess the antibody response to native GBS protein, sera from blood samples collected prior each immunization and fourteen days after the third immunization were tested for antibody reactive 10 with GBS cells by ELISA using plates coated with formaldehyde-killed GBS cells from type III strain NCS 954, type Ib strain ATCC12401, type V strain NCS 535 or type VI strain NCS 9842. The specificity of the raised antibodies for GBS protein was confirmed by Western blot analyses to 15 GBS cell extracts and purified recombinant antigens. The results shown in Figure 10 clearly demonstrate that animals respond strongly to recombinant GBS protein used as immunogens with median reciprocal antibody titers varying between 12000 and 128000, for sera collected after the third immunization, depending of the coating antigen. All 20 preimmune sera were negative when tested at a dilution of 1 :100. GBS-reactive antibodies were detectable in the sera of each animal after a single injection of recombinant GBS protein.

25

Example 10 Antigenic conservation of the GBS protein of the present invention

Monoclonal antibodies (MAbs) specific to the GBS protein of the present invention were used to demonstrate that this surface antigen is produced by all GBS and that it is also antigenically highly conserved.

5

A collection of 68 GBS isolates was used to evaluate the 10 reactivity of the GBS-specific MAbs. These strains were obtained from the National Center for Streptococcus, Provincial Laboratory of Public Health for Northern Alberta, Canada; Centre Hospitalier Universitaire de Quebec, Pavillon CHUL, Quebec, Canada; American Type Culture Collection, USA; 15 Laboratoire de Sante Publique du Quebec, Canada; and Dept. of Infectious Disease, Children's Hospital and Medical Center, Seattle, USA. All eight Mabs were tested against the following panel of strains: 6 isolates of serotype Ia or Ia/c, 3 isolates of serotype Ib, 4 isolates of serotype II, 20 14 isolates of serotype III, 2 isolates of serotype IV, isolates of serotype V, 2 isolates of serotype VI, 2 isolates of serotype VII, 1 isolate of serotype VIII, 10 isolates that were not serotyped and 3 bovine S. agalactiae strains. MAb 3A2 was also reacted with additional GBS: 9 25 isolates of serotype Ia/c and 10 isolates of serotype V. The strains were grown overnight on blood agar plates at 37°C in an atmosphere of 5% CO_2 . Cultures were stored at - 70°C in heart infusion broth with 20% (v/v) glycerol.

To obtain the GBS protein-specific MAbs, mice were immunized three times at three-week intervals with 20 μ g of purified recombinant GBS protein (SEQ ID NO :44) in the presence of 20% QuilATM adjuvant. Hybridoma cell lines were generated by fusion of spleen cells recovered from immunized mice with the nonsecreting SP2/O myeloma cell line as described

previously (Hamel, J. et al. 1987. J. Med. Microbiol. 23:163-170). Hybrid clone supernatants were tested for specific antibody production by ELISA using formaldehyde inactivated GBS and purified recombinant GBS protein (SEQ ID NO :39 or 44) as coating antigen, as previously described (Hamel, J. et al. 1987. J. Med. Microbiol. 23:163-170). Specific hybrid were cloned by limiting dilutions, expanded, and frozen in liquid nitrogen. Production of recombinant GBS protein was presented in Examples 4 & 5. Purified 10 recombinant GBS protein or formaldehyde inactivated GBS were resolved by electrophoresis by using the discontinuous buffer system of Laemmli as recommended by the manufacturer and then transfer onto nitrocellulose membrane for Western immunoblotting as described previously (Martin et al. 1992. 15 Infect. Immun. 60:2718-2725).

Western immunoblotting experiments clearly indicated that all eight MAbs recognized a protein band that corresponded to the purified recombinant GBS protein (SEQ ID NO :39).

20 These MAbs also reacted with a protein band present in every GBS isolates tested so far. The reactivity of these GBS-specific MAbs are presented in Table 6. Each MAb reacted well with all 46 GBS. In addition, these MAbs also recognized the 3 S. agalactiae strains of bovine origin that were tested. MAb 3A2 also recognized nineteen GBS; 9 isolates of serotype Ia/c and 10 of serotype V. The other MAbs were not tested against these additional strains.

These results demonstrated that the GBS protein (SEQ ID NO :39) was produced by all the 65 GBS and the three 3 S. agalactiae strains of bovine origin that were tested so far. More importantly, these results clearly demonstrated that the epitopes recognized by these eight GBS-specific MAbs were widely distributed and conserved among GBS. These results also indicated that these epitopes were not

restricted to serologically related isolates since representatives of all known GBS serotypes including the major disease causing groups were tested.

In conclusion, the data presented in this example clearly demonstrated that the GBS protein of the present invention is produced by all GBS and that it is antigenically highly conserved.

10

Reactivity of eight GBS protein-specific MAbs with different S. agalactiae strains as evaluated by Western immunoblots. Table 6.

Mabs	Num	Number of	each	serotype	ype of	ω.	agalactiae	tiae st	rains	strains recognized by	cue	ricadis .
	Ta or	Ib	II	III	IV	Λ	VI	VII	VIII	NT(10) ²	TOTAL	Bovine
	(9) J/E	(3)	(4)	(4)	(2)	(2)	(5)	(2)	(1)		(26)	(3)
Long	9	3	4	4	2	2	2	2	,–1	10	46	m
3A2-		,	-	-	2	2	2	2		10	46	e
5A12	٥	7 6	<u>_</u>	۲	3 6	1 0		,	-	10	46	2
6G11	9	ຠ	7	4	7	7	7	7	4		7 7	,
000	2	٣	4	4	7	7	7	7	Н	0.7	4.0	2
000		,	•		0	2	2	2		10	46	<u>ო</u>
8 E.T.T	٥	2	*	۴	1 0	1 0	1 0	C	-	C	46	3
12B12	9	m	4	4	7	7	7	7	4	9		,
1001	2	٦	4	4	7	7	~	7	, - 	10	46	2
1011		, ,	-		,	2	~	2	г	10	46	က
20G2	٥	ຠ	7'	#	7	7	1	,				1

1 Nine additional strains of serotype Ia/c and 10 strains of serotype V were recognized by MAb 3A2. 2 These strains were not serotyped

10

WE CLAIM:

1. An isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide having a sequence selected from the group consisting of:

```
SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:44 or fragments, analogs or derivatives thereof.
```

- 2. A polynucleotide according to claim 1, wherein said polynucleotide encodes a polypeptide having at least 95% identity to the second polypeptide.
- 3. An isolated polynucleotide encoding a polypeptide capable of generating antibodies having binding specificity for a polypeptide having a sequence selected from the group consisting of:

 SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:44 or fragments, analogs or derivatives thereof.

4. An isolated polynucleotide that is complementary to the polynucleotide of claim 1.

- 5. An isolated polynucleotide that is complementary to the polynucleotide of claim 3.
- 6. The polynucleotide of claim 1, wherein said polynucleotide is DNA.
- 7. The polynucleotide of claim 3, wherein said polynucleotide is DNA.
- 8. The polynucleotide of claim 1, wherein said polynucleotide is RNA.
- 9. The polynucleotide of claim 3, wherein said polynucleotide is RNA.
- 10. A polynucleotide which hybridizes under stringent conditions to a second polynucleotide having a sequence selected from the group consisting of:

 SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 13, SEQ ID NO: 22, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 37, SEQ ID NO: 42 and SEQ ID NO: 43 or fragments, analogues or derivatives thereof.
- 11. A polynucleotide which hybridizes under stringent conditions to a second polynucleotide having a sequence selected from the group consisting of:

 SEQ ID NO: 37, SEQ ID NO: 42 and SEQ ID NO: 43.
- 12. A polynucleotide according to claim 11 which hybridizes under stringent conditions to a second polynucleotide having the sequence SEQ ID NO : 37.

13. A polynucleotide according to claim 11 which hybridizes under stringent conditions to a second polynucleotide having the sequence SEQ ID NO : 42.

- 14. A polynucleotide according to claim 11 which hybridizes under stringent conditions to a second polynucleotide having the sequence SEQ ID NO : 43.
- 15. A polynucleotide according to claim 10 wherein said polynucleotide has at least 95% complementarity to the second polynucleotide.
- 16. A polynucleotide according to claim 11 wherein said polynucleotide has at least 95% complementarity to the second polynucleotide.
- 17. A vector comprising the polynucleotide of claim 1, wherein said polynucleotide is operably linked to an expression control region.
- 18. A vector comprising the polynucleotide of claim 3, wherein said polynucleotide is operably linked to an expression control region.
- 19. A host cell transfected with the vector of claim 17.
- 20. A host cell transfected with the vector of claim 18.
- 21. A process for producing a polypeptide comprising culturing a host cell according to claim 19 under conditions suitable for expression of said polypeptide.
- 22. A process for producing a polypeptide comprising culturing a host cell according to claim 20 under condition suitable for expression of said polypeptide.

23. An isolated polypeptide having at least 70% identity to a second polypeptide having a sequence selected from the group consisting of:

```
SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:44 or fragments, analogs or derivatives thereof.
```

- 24. The isolated polypeptide of claim 23 having a sequence according to SEQ ID NO : 39.
- 25. The isolated polypeptide of claim 23 having a sequence according to SEQ ID NO : 44.
- 26. An isolated polypeptide capable of generating antibodies having binding specificity for a second polypeptide having a sequence selected from the group consisting of:

```
SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41 and SEQ ID NO:44 or fragments, analogs or derivatives thereof.
```

27. The isolated polypeptide of claim 26 having a sequence according to SEQ ID NO : 39.

- 28. The isolated polypeptide of claim 26 having a sequence according to SEQ ID NO: 44.
- 29. An isolated polypeptide having an amino acid sequence selected from the group consisting of:

```
SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5,
```

- SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10,
- SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15,
- SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19,
- SEO ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24,
- SEO ID NO:25, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:29,
- SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34,
- SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39,
- SEQ ID NO:40 and SEQ ID NO:41 or fragments, analogs or derivatives thereof.
- 30. The isolated polypeptide of claim 29 having an amino acid sequence according to SEQ ID NO : 39.
- 31. An isolated polypeptide having an amino acid sequence according to SEQ ID NO : 44.
- 32. An isolated polypeptide according to any one of claims 29 to 31, wherein the N-terminal Met residue is deleted.
- 33. An isolated polypeptide according to any one of claims 29 to 30, wherein the secretory amino acid sequence is deleted.
- 34. A vaccine composition comprising a polypeptide according to any one of claims 23 to 31 and a pharmaceutically acceptable carrier, diluent or adjuvant.

35. A vaccine composition comprising a polypeptide according to claim 32 and a pharmaceutically acceptable carrier, diluent or adjuvant.

- 36. A vaccine composition comprising a polypeptide according to claim 33 and a pharmaceutically acceptable carrier, diluent or adjuvant.
- 37. A method for therapeutic or prophylactic treatment of streptococcal bacterial infection in an animal susceptible to streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of a composition according to claim 34.
- 38. A method for therapeutic or prophylactic treatment of streptococcal bacterial infection in an animal susceptible to streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of a composition according to claim 35.
- 39. A method for therapeutic or prophylactic treatment of streptococcal bacterial infection in an animal susceptible to streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of a composition according to claim 36.
- 40. A method according to any one of claims 37 to 39, wherein said animal is a bovine.
- 41. A method according to any one of claims 37 to 39, wherein said animal is a human.

42. A method according to any one of claims 37 to 39, wherein said bacterial infection is selected from the group consisting of group A streptococcus and group B streptococcus.

- 43. A method according to claim 42, wherein said bacterial infection is group B streptococcus.
- 44. Use of a vaccine composition according to claim 34 for the therapeutic or prophylactic treatment of streptococcal bacterial infection in an animal susceptible to or infected with streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of the composition.
- 45. Use of a vaccine composition according to any one of claims 35 to 36 for the therapeutic or prophylactic treatment of streptococcal bacterial infection in an animal susceptible to or infected with streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of the composition.
- 46. Use of a vaccine composition according to any one claims 23 to 31 for the manufacture of a vaccine for the therapeutic or prophylactic treatment of streptococcal bacterial infection in an animal susceptible to streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of the composition.
- 47. Use of a vaccine composition according to claim 32 for the manufacture of a vaccine for the therapeutic or

prophylactic treatment of streptococcal bacterial infection in an animal susceptible to streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of the composition.

48. Use of a vaccine composition according to claim 33 for the manufacture of a vaccine for the therapeutic or prophylactic treatment of streptococcal bacterial infection in an animal susceptible to streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount of the composition.

TATCTGGCAA	AGAGCCAGCT	AATCGTTTTA	GTTGGGCTAA	AAATAAATTA	TTAATCAATG	60
S G K	E P A	N R F S	W A K	N K L	L I N G	
•	AACTCTAGCA T L A	GCAACTATCT A T I L	TATTTTTTGC F F A	AGTTCAATTC V Q F	ATAGGTCTTA I G L K	120
AACCAGATTA	CCCTGGAAAA	ACCTACTTTA	TTATCCTATT	GACAGCATGG	ACTTTGATGG	180
P D Y	P G K	T Y F I	I L L	T A W	T L M A	
CATTAGTAAC	TGCTTTAGTG	GGATGGGATA	ATAGGTATGG	TTCCTTCTTG	TCGTTATTAA	240
L V T	A L V	G W D N	R Y G	S F L	S L L I	
TATTATTATT	CCAGCTTGGT	TCAAGCGCAG	GAACTTACCC	AATAGAATTG	AGTCCTAAGT	300
L L F	Q L G	S S A G	T Y P	I E L	S P K F	
TCTTTCAAAC	AATTCAACCA	TTTTTACCGA	TGACTTACTC	TGTTTCAGGA	TTAAGAGAGA	360
F Q T	I Q P	F L P M	T Y S	V S G	L R E T	
CCATCTCGTT	GACGGGAGAC	GTTAACCATC	AATGGAGAAT	GCTAGTAATC	TTTTTAGTAT	420
I S L	T G D	V N H Q	W R M	L V I	F L V S	
CATCGATGAT S M I	ACTTGCTCTT L A L	CTTATTTATC L I Y R	GTAAACAAGA K Q E	AGATTAATAG D	AAAGTATCTA	480
GTGATAGACT	AACAGTATGA	TATGGTATGT	CAAAGTATTT	AGGAGGAGAA	M S T	540
CTTTAACAAT L T I	AATTATTGCA I I A	ACATTAACTG T L T A	CTTTGGAACA L E H	TTTTTATATT F Y I	> ATGTATTTGG M Y L E	600
AGACGTTAGC	CACCCAGTCA	AATATGACTG	GGAAGATTTT	TAGTATGTCT	AAAGAAGAGT	660
T L A	T Q S	N M T G	K I F	S M S	K E E L	
TGTCATATTT S Y L	ACCCGTTATT P V I	AAACTTTTTA K L F K		TGTATACAAC V Y N	GGCTTGATTG G L I G	720
GCCTATTCCT	CCTTTATGGG	TTATATATTT	CACAGAATCA	AGAAATTGTA	GCTGTTTTTT	780
L F L	L Y G	L Y I S	Q N Q	E I V	A V F L	
TAATCAATGT	ATTGCTAGTT	GCTATTTATG	GTGCTTTGAC	AGTTGATAAA	AAAATCTTAT	840
I N V	L L V	A I Y G	A L T	V D K	K I L L	
TAAAACAGGG K Q G	TGGTTTACCT G L P	ATATTAGCTC I L A L	TTTTAACATT L T F	CTTATTTTAA L F	TACTACTTAG	900
CCGTTCGATT	TAGTTGAACG	GCTTTTAGTA	ATCATTTTT	TCTCATAATA	CAGGTAGTTT	960
AAGTAATTTG	TCTTTAAAAA	TAGTATAATA	TAACTACGAA	TTCAAAGAGA	GGTGACTTTG	1020
м т е		ACATACTAAA H T K	GATGGTTCAG D G S D	ATATTTATTA I Y Y	TCGTGTCGTT R V V	1080
> GGTCAAGGTC G Q G Q		TTTTTTACAT F L H		TAAGTAGTCG S S R	CTATTTTGAT Y F D	1140
AAGCAAATAG	CATATTTTC	TAAGTATTAC	CAAGTTATTG	TTATGGATAG	TAGAGGGCAT	1200
K Q I A	Y F S	K Y Y	Q V I V	M D S	R G H	
GGCAAAAGTC	ATGCAAAGCT	AAATACCATT	AGTTTCAGGC	AAATAGCAGT	TGACTTAAAG	1260
G K S H	A K L	N T I	S F R O	I A V	D L K	

GATATCTTAG D I L V	TTCATTTAGA H L E		GTTATATTGG V I L V	TAGGCCATAG G H S	CGATGGTGCC D G A	1320
AATTTAGCTT N L A L	TAGTTTTTCA V F Q		CCAGGTATGG P G M V		TTTGCTTAAT L L N	1380
TCAGGGAACC S G N L	TGACTATTCA T I H	TGGTCAGCGA G Q R	TGGTGGGATA W W D I	TTCTTTTAGT L L V	AAGGATTGCC R I A	1440
TATAAATTCC Y K F L	TTCACTATTT H Y L		TTTCCGTATA F P Y M	TGAGGCAAAA R Q K	AGCTCAAGTT A Q V	1500
ATTTCGCTTA I S L M	TGTTGGAGGA L E D	TTTGAAGATT L K I	AGTCCAGCTG S P A D	ATTTACAGCA L Q H	TGTGTCAACT V S T	1560
CCTGTAATGG P V M V	TTTTGGTTGG L V G	AAATAAGGAC N K D	ATAATTAAGT I I K L	TAAATCATTC N H S	TAAGAAACTT K K L	1620
GCTTCTTATT A S Y F	TTCCAAGGGG P R G	GGAGTTTTAT E F Y	TCTTTAGTTG S L V G	GCTTTGGGCA F G H	TCACATTATT H I I	1680
AAGCAAGATT K Q D S	CCCATGTTTT H V F	TAATATTATT N I I	GCAAAAAAGT A K K F	TTATCAACGA I N D	TACGTTGAAA T L K	1740
GGAGAAATTG G E I V	TTGAAAAAGC E K A	TAATTGAAAA N	AGTCAAATCA	CTGACTTCTG	TGATTAAAAT	1800
TGTATTTTT	ATATCTGTTT	TAGTGCTTAT	TATTGTTGAA	ATGATTCATT M I H L	TGAAACGAAC K R T	1860
	GAGCAACTAA E Q L K		TGGGCAATTA G Q L	TCTCCAATGA S P M N	ATCTTTTCTT L F L	1920
AATTATCCTT I I L	GTGGGGGTTA V G V I	TCGCTGTCTT A V L	ACCGACAACC P T T	GGATATGACT G Y D F	TTGTACTGAA V L N	1980
TGGACTTTTA G L L F		AAAGCAAAAG S K R		CAGACTAGTT Q T S W	GGTGTATCAA C I N	2040
CACTTTTAAT T F N N			CTTAATCGAT L I D	ATTGGGTTGC I G L R	GCATGGCTTT M A F	2100
TTATGGTAAA Y G K k				GTGACTCGTT V T R F	TTTTACCCTA L P Y	2160
TCTTATTTCT L I S G					ATATTTTTCA I F H	2220
TGCCAAAGCT A K A S	AGTGTTGATT V D Y	ACTATTATTT Y Y L	GGTATTAATT V L I	GGTGCTAGTA G A S M	TGTATTTTCC Y F P	2280
TGTTATTTAT V I Y W		GTCATAAAGG H K G		TTCGGAGATA F G D M		2340
TACTCGTATA T R I F	AAATTAGGTG C L G V	TTGTTTCTTT V S F	TTTTGAATGG F E W	GGATGTGCGG G C A A	CCGCAGCATT A A F	2400
TATAATTATC I I I C			TCTACCAGTT L P V	TATAAAATTT Y K I L		2460

TTG C			TG' C						ATC S		TAT I			rgg <i>i</i> G		∖G G	GAAG'	rtt' F	rga E	2520
			TT'							GGG <i>I</i> G				AGA/ E	AACI T		TGGT: V	rgcz A	ATG W	2580
			TA' Y						TAT I			ATTC F		rgc <i>i</i> A		A' I	TCTA!	rtt(F	CTT F	2640
		TATI Y		AGG1 G				AAA N				rgaa E		rgt(V		SA K	AAGA(E		AGT V	2700
ATC. S		rgti V					TGGT(CCA H		M	GCGT R >	I		AGGI G		CATT(CTTA L		2760
ATT' F	TTC S	AACA T			rtti F				TAC T			M M		GTT(AGCT/ L		CTT L	2820
D	P	L	Q	E	Q	M	L	W	Q	F	P	G	L	L	L	G	GGGT'	С	F	2880
Ι	L	L	A	R	T	Ι	D	Q	K	V	K	N	A	F	P	I	TTGC:	I	I	2940
W	Ι	T	L	Т	L	F	Y	L	N	L	G	H	I.	S	W	R	GACT? L	S	F	3000
W	F	I	L	L	L	L	G	L	L	V	Ι	K	P	T	L	Y	ATAA? K	K	Q	3060
F	I	Y	S	W	E	E	R	I	K	D	G	I	I	I	٧	S	GTTTI L	М	G	3120
V	L	F	Y	I	A	G	L	L	F	P	Ι	R	A	Н	Ι	Т	CAGG'	G	S	3180
Ι	E	R	L	Н	Y	I	I	A	W	E	P	I	A	L	A	Т	CGTT(Ι	L	3240
Т	L	V	Y	L	С	L	V	K	I	L	Q	G	K	S	С	Q	AGAT'	G	D	3300
V	F	N	V	D	R	Y	K	K	L	L	Q	A	Y	G	G	S	CTTC(S	D	S	3360
G	L	A	F.	L	N	D	K	R	L	Y	W	Y	Q	K	N	G	GAGA E	D	С	3420
V	Α	F	Q	F	V	I	V	N	N	K	С	L	I	M	G	E	AACCI P	A	G	3480
D	D	Т	Y	I	R	E	A	Ι	E	S	F	Ι	D	D	A	D		L	D	3540
Y	D	L	V	F	Y	S	Ι	G	Q	K	L	T	L	L	L	Н	ATGAGE	Y	G	3600
F	D	F	M	K	V.	. G	E.	JGA.	Δ Δ	. I I I I	77 70 I.,	MAY	. 117 T	7GAY	カガン	ι ΣΤ			raa r	3660

							TCAG											TTT	CTA	3720
G	N	K	Y	K	Р	F.	R	N	A	L	N	R	V	E	K	D	G	F	Y	
				raca. Q			CACA H			AGA E				rag: s			AAGA E	GAT I	TTC S	3780
TAA N	TAC T	TTG(W	T L	ΓAGA. E	AGG G	AC R	GTCC P		AAA K			CTCA S		AGG <i>I</i> G			TTAA N	TAA K		3840
TTA Y	TTT F	CCA? Q		AAGC A			TAGC A			AAA K		TGCT A		ACA(H				TGC A	TTT F	3900
TGC A	TAA N	TAT1	M A				ATGA E		GAG S			CTCT ·S		rga: D			TGCG R	TCA H	CGA D	3960
TAA K	ACA Q	GAA/ K	A A	P P	GAA' N	TG G	GCGT V	TAT M	GGA D	TTT F		CTTT F		ATC <i>I</i> S		AT F	TCTC	TTA Y		4020
TCA Q	AGA E	GAA(K	G G(GATA Y	CCA(H	CT Y	ATTT F	TGA' D	TTT L	GGG(GAT(GGCA A	CC'	rtt <i>i</i> L	ATC: S	AG G	GAGT'	TGG G		4080
CGT V	TGA E	AACA T	A AC		TGC'		AAGA E			GGC A							TCGG' G	TAG S	TCA H	4140
TTT F	CTA Y	CTC <i>I</i> S	A T	'AAT' N	TGG' G	TT L	TACA H		GTA Y			GAAG K		rac <i>i</i> T	ACCI P	AT L	TGTG W	GTC S	GGA E	4200
ACG R	TTA Y	TAT I	T TO	CTTG' C	TTC' S	TC R	GTTC S			GTT: L			GC:						AAT M	4260
GGA E	AGA D	TAG1 S	r Az K		TAA(K		TTGT V	TAA. K	ATA	AGC'	TTT	TTTA	' GG	CAAT	ATT	AA	AAGA	GCA'	TGT	4320
CAT	GCG	ACA	G	CTCT'	TTT	TA	AATC	ATT'	TAA	TAC	CAT'	rgat	TG	CTTC	GAA!	rc	TACT	TTA	TAA	4380
TAT	GAT	GTG	T	TTA	AAT	TA	TGTT	TAG	CTA	CTG'	TAG	CTGC	TG	TTT	TAT	ЭC	ATTT	CAG	CTA	4440
CTT	GGT	AGT	CZ	TTT	CTT	GC	ATTT	CTT'	TTT	CAG	TGA'	TATG	ACC	CAGO	CAA	ЭT	TTAT	TGA	GAG	4500
CTT	ттт	TTAC	T	rga	(S)	EQ	ID N	0:1)											4514

FIG. 1a [clonel-dna/aa]

SGKEPANRFS	WAKNKLLING	FIATLAATIL	FFAVQFIGLK	PDYPGKTYFI	50
ILLTAWTLMA	LVTALVGWDN	RYGSFLSLLI	LLFQLGSSAG	TYPIELSPKF	100
FQTIQPFLPM	TYSVSGLRET	ISLTGDVNHQ	WRMLVIFLVS	SMILALLIYR	150
KQED (SEQ	ID NO:2)				154
		FIG. 1	b		
		YLETLATQSN			50
LFKNQGVYNG	LIGLFLLYGL	YISQNQEIVA	VFLINVLLVA	IYGALTVDKK	100
ILLKQGGLPI	LALLTFLF	(SEQ ID NO:3	3)		118
		FIG. 1	С		
-					
MTENWLHTKD	GSDIYYRVVG	QGQPIVFLHG	NSLSSRYFDK	QIAYFSKYYQ	50
VIVMDSRGHG	KSHAKLNTIS	FRQIAVDLKD	ILVHLEIDKV	ILVGHSDGAN	100
		GNLTIHGQRW			150
PYMRQKAQVI	SLMLEDLKIS	PADLQHVSTP	VMVLVGNKDI	IKLNHSKKLA	200
SYFPRGEFYS	LVGFGHHIIK	QDSHVFNIIA	KKFINDTLKG	EIVEKAN	247
(SEO TD NO:	4)				

FIG. 1d

MIHLKRTISV	EQLKSVFGQL	SPMNLFLIIL	VGVIAVLPTT	GYDFVLNGLL	50
RTDKSKRYIL	QTSWCINTFN	NLSGFGGLID	IGLRMAFYGK	KGQEKSDLRE	100
VTRFLPYLIS	GLSFISVIAL	IMSHIFHAKA	SVDYYYLVLI	GASMYFPVIY	150
WISGHKGSHY	FGDMPSSTRI	KLGVVSFFEW	GCAAAAFIII	GYLMGIHLPV	200
YKILPLFCIG	CAVGIVSLIP	GGLGSFELVL	FTGFAAEGLP	KETVVAWLLL	250
YRLAYYIIPF	FAGIYFFIHY	LGSQINQRYE	NVPKELVSTV	LQTMVSHLMR	300
ILGAFLIFST	AFFENITYIM	WLQKLGLDPL	QEQMLWQFPG	LLLGVCFILL	350
ARTIDQKVKN	AFPIAIIWIT	LTLFYLNLGH	ISWRLSFWFI	LLLLGLLVIK	400
PTLYKKQFIY	SWEERIKDGI	IIVSLMGVLF	YIAGLLFPIR	AHITGGSIER	450
LHYIIAWEPI	ALATLILTLV	YLCLVKILQG	KSCQIGDVFN	VDRYKKLLQA	500
YGGSSDSGLA	FLNDKRLYWY	QKNGEDCVAF	QFVIVNNKCL	IMGEPAGDDT	550
YIREAIESFI	DDADKLDYDL	VFYSIGQKLT	LLLHEYGFDF	MKVGEDALVN	600
LETFTLKGNK	YKPFRNALNR	VEKDGFYFEV	VQSPHSQELL	NSLEEISNTW	650
LEGRPEKGFS	LGYFNKDYFQ	QAPIALVKNA	EHEVVAFANI	MPNYEKSIIS	700
IDLMRHDKQK	IPNGVMDFLF	LSLFSYYQEK	GYHYFDLGMA	PLSGVGRVET	750
SFAKERMAYL	VYHFGSHFYS	FNGLHKYKKK	FTPLWSERYI	SCSRSSWLIC	800
AICALLMEDS	KIKIVK (SE	EQ ID NO:5)			816
		FIG.	1e		
MRILGAFLIF	STAFFENITY	IMWLQKLGLD	PLQEQMLWQF	PGLLLGVCFI	50
LLARTIDQKV	KNAFPIAIIW	ITLTLFYLNL	GHISWRLSFW	FILLLGLLV	100
IKPTLYKKQF	IYSWEERIKD	GIIIVSLMGV	LFYIAGLLFP	IRAHITGGSI	150
ERLHYIIAWE	PIALATLILT	LVYLCLVKIL	QGKSCQIGDV	FNVDRYKKLL	200
QAYGGSSDSG	LAFLNDKRLY	WYQKNGEDCV	AFQFVIVNNK	CLIMGEPAGD	250
DTYIREAIES	FIDDADKLDY	DLVFYSIGQK	LTLLLHEYGF	DFMKVGEDAL	300
VNLETFTLKG	NKYKPFRNAL	NRVEKDGFYF	EVVQSPHSQE	LLNSLEEISN	350
TWLEGRPEKG	FSLGYFNKDY	FQQAPIALVK	NAEHEVVAFA	NIMPNYEKSI	400
ISIDLMRHDK	QKIPNGVMDF	LFLSLFSYYQ	EKGYHYFDLG	MAPLSGVGRV	450
ETSFAKERMA	YLVYHFGSHF	YSFNGLHKYK	KKFTPLWSER	YISCSRSSWL	500

FIG. 1f

518

ICAICALLME DSKIKIVK (SEQ ID NO:6)

N F	D	I		JAA E	T	T.	T	F	E	A A	M	SAA K	AA K	AGCA H	A.CGC		ATT.	ATT(GGAG E	60
AAAA1 K I	TATC S	TG V			CG: R		TTT'		rgaa E	TTI F	GA: D	ГАА К	AC L		'ATI L			TTA' Y		120
CGTAA R K	AAGG G	AA M	TG(CTG	GC <i>I</i> A	ACT L	AATA I	AGA: D	ragt S	CAT H					TCI L		ATG(CTTA L		180
AATAC N R		AT L		CAA Q		AAG S	CGC(TTTG L	TCC S			A G D	ATAA K		TTT F	TTTZ L	ATT: F	rgag E	240
ACATO T S	CAGA E	AC Q	AAC A	CT A	TG(W	GC A	ATC S	ACTO L	CATC	TTC L		rat M	GG E	AAGT V	TGA E	ACA H	CAC?	AAA(K	GACT T	300
TTTTT F L	'AAA K	AA K	raa V	GG. I	AA(K	SAC T	ATC S		rcac H	TTT F				ATGT V		GCA H	TATA	AGTO V	GAT D	360
GTTT <i>F</i> V Y	TCG R	TA I	TTC	GT {	GA <i>I</i> E	ACA Q	AAT(GG <i>I</i> G	ATTG L	GCT A	'AA/ K	AGA E	AC H	ATCT L	TTA Y	TCG R	TTAT Y	rgg <i>r</i> G	AAAA K	420
ACTAT T I	'AAT. I	AA K		CAA						AAA K					GAT M	GGT V	TGAT D	TTT(F	GAA E	480
AAAAT K I	'AGA E	AC Q	AAC I	CTA	GAI D	rag S	TGAC E	TTA L	AGCA A	ATC I	CAT H	rga D	TA R	GGCA H		GAT I		rgtc V	CAAT N	540
GGTGG G G	CAC T	CT L	TAP I	ATC.	AAC K	GAA K	ATTA L	AGG <i>I</i> G		AAA K					GAT M		AGAT D	TATI I	TATC	600
TCTCA S Q	AAT' I	rg E	raa I		GCC A	CAT I	TGTT V		AGGA G	CAA Q			TA N	ATGA E	AGA E	AGA E	GGC1 A	TATI I	TTA L	660
CATTI H F	TGT' V	ra K	AGC C	AG'	TAC Y	CTT L	GATO M	GA1 D	TTAG	AGA	.GGI	ATT.	AT	ATGA M S	· D	F	TTTT L	ragi V	AGA D	720
TGGAI G I	TGA	CT	AAG K	STC S	GG1 V	TG G	GTG# D	ATA. K	AGAC T		CTT F				TTT	CAT	TTA1	CAT I	CCA H	780
TAGTI S I	TAG. D	AC				GA I			STGT V		TGC G			GGAA G K		CAA T	CAC1	rati L	AGA D	840
TGTTA V I	TTT	CG	GG1 G	'GA. E	ATI L	'AG G	GTT1 F	TGA D	ATGG G		TCC R			CCTT P F				CTA <i>F</i> N	ATGA D	900
TTATA Y K	AGA'	ГТ	GCI A	TA' Y	TT1 L	'AA K	AAC <i>I</i> Q	AAGA E	AACC P	AGA D	CTT F	TG. D	AT	GATT D S	CTC Q	AGA T	CAA1	TTT L	GGA D	960
CACCO T V	TAC' L	гт	TCI S	TC S	TG <i>F</i> D	ACT L	TAAC R	GAG <i>I</i> E	AGAT M	GGC A	TTI L	AA1 I	TT	AAAG K E				rarı L		1020
TAATC N H	ACT.	AC	GA.A E	GA. E	AAC S	STA K	AGCA Q	ATC S	CACG R	TCI L	'AG <i>I</i> E	AGA. K	AA	GTAA V M	TGG A	CAG E	CAAA M	GG <i>F</i> D	ATTC S	1080
TTTAG L C	ATG(CT	TGO W	STC' S	ran I	TG E	AGA0 S	GCG <i>F</i> E	AAGT V	CAA K	AA(T	CAG V	AT	TTAT L S	CCA K	AAT L		TAT I		1140
TGATI D L	TGC	AG	TTO L	TC S	GG1 V	TG G	GTGA E	ATT L	TATC S	AGG G	AG(G	GAT L	TA	CGAA R R	GAC R	GTG V	TTC	AATI L	AGC A	1200

Q V L	L N D A	CAGATTTATT D L L	GCTCTTAGAC L L D	GAACCTACTA E P T N	ACCACTTAGA H L D	1260
TATTGACACT	ATTGCATGGT	TAACGAATTT	TTTGAAAAAT	AGTAAAAAGA	CAGTGCTTTT	1320
I D T	I A W L	T N F	L K N	S K K T	V L F	
TATAACTCAT	GATCGTTATT	TTCTAGACAA	TGTTGCAACA	CGTATTTTTG	AATTAGATAA	1380
I T H	D R Y F	L D N	V A T	R I F E	L D K	
GGCACAGATT	ACAGAATATO	AAGGCAATTA	TCAGGATTAT	GTCCGACTTC	GTGCAGAACA	1440
A Q I	T E Y Q	G N Y	Q D Y	V R L R	A E Q	
AGACGAGCGT	GATGCTGCTA	GTTTACATAA	AAAGAAACAG	CTTTATAAAC	AGGAACTAGC	1500
D E R	D A A S	L H K	K K Q	L Y K Q	E L A	
TTGGATGCGT	ACTCAGCCAC	AAGCTCGTGC	AACGAAACAA	CAGGCTCGTA	TTAATCGTTT	1560
W M R	T Q P Q	A R A	T K Q	Q A R I	N R F	
TCAAAATCTA	AAAAACGATT	TACACCAAAC	AAGCGATACA	AGCGATTTGG	AAATGACATT	1620
Q N L	K N D L	H Q T	S D T	S D L E	M T F	
TGAAACAAGT	CGAATTGGGA	AAAAGGTTAT	TAATTTTGAA	AATGTCTCTT	TTTCTTACCC	1680
E T S	R I G K	K V I	N F E	N V S F	S Y P	
AGATAAATCT	ATCTTGAAAG	ACTTTAATTT	GTTAATTCAA	AATAAAGACC	GTATTGGCAT	1740
D K S	I L K D	F N L	L I Q	N K D R	I G I	
CGTTGGAGAT	AATGGTGTTG	GAAAGTCAAC	CTTACTTAAT	TTAATTGTTC	AAGATTTACA	1800
V G D	N G V G	K S T	L L N	L I V Q	D L Q	
GCCGGATTCG	GGTAATGTCT	CTATTGGTGA	AACGATACGT	GTAGGTTACT	TTTCACAACA	1860
P D S	G N V S	I G E	T I R	V G Y F	S Q Q	
ACTTCATAAT	ATGGATGGCT	CAAAACGTGT	TATTAATTAT	TTGCAAGAGG	TTGCAGATGA	1920
L H N	M D G S	K R V	I N Y	L Q E V	A D E	
GGTTAAAACT	AGTGTCGGTA	CAACAAGTGT	GACAGAACTA	TTGGAACAAT	TTCTCTTTCC	1980
V K T	S V G T	T S V	T E L	L E Q F	L F P	
ACGTTCGACA	CATGGAACAC	AAATTGCAAA	ATTATCAGGT	GGTGAGAAAA	AAAGACTTTA	2040
R S T	H G T Q	I A K	L S Ġ	G E K K	R L Y	
CCTTTTAAAA L L K	ATCCTGATTG	AAAAGCCTAA K P N	TGTGTTACTA V L L	CTTGATGAGC L D E P	CGACAAATGA T N D	2100
CTTAGATATT	GCTACATTAA	CTGTTCTTGA	AAATTTTTTA	CAAGGCTTTG	GTGGTCCTGT	2160
L D I	A T L T	V L E	N F L	Q G F G	G P V	
GATTACAGTT	AGTCACGATC	GTTACTTTTT	AGATAAAGTG	GCTAATAAAA	TTATTGCGTT	2220
I T V	S H D R	Y F L	D K V	A N K I	I A F	
TGAAGATAAC	GATATCCGTG	AATTTTTTGG	TAATTATACT	GATTATTTAG	ATGAAAAAGC	2280
E D N	D I R E	F F G	N Y T	D Y L D	E K A	
ATTTAATGAG	CAAAATAATG	AAGTTATCAG	TAAAAAAGAG	AGTACCAAGA	CAAGTCGTGA	2340
F N E	Q N N E	V I S	K K E	S T K T	S R E	
AAAGCAAAGT	CGTAAAAGAA	TGTCTTACTT	TGAAAAACAA	GAATGGGCGA	CAATTGAAGA	2400
K Q S	R K R M	S Y F	E K Q	E W A T	I E D	
CGATATTATG	ATATTGGAAA	ATACTATCAC	TCGTATAGAA	AATGATATGC	AAACATGTGG	2460

D	I	M	I	L	E	N	T	I	T	R	I	E	:	N	D	М	Q	T	С	G	
TA S		ATTTT F			GT' L	TAT S					AGG E			GAT D		AAA K	AA N	ATG.	AAG A	CACT L	2520
TC' L		AAAAG K	TA Y			GTT Y			ACCT L	TA		AGT L		GAC D		1	AT I >	I	CCG' R		2580
AT' I	TAT: I	raaaa K N	ΑT	GAT D	rga D			AGT' V			ATT. L			GAC Q		GT			CGC(A	CTAT Y	2640
GA' D	TTT/ L	AGATA D K		CCI P	rga: D	TAC T	AGC:		TTCA S	GA(CT L	TAG D			TT L	GAC T	CTC S	ATAC Y	2700
TA Y	CGAI E	AAAAA K I		GAC E		GTC S		ATT(F			CAT I		.GG E	AGA R			GA E	GAT'		rggc G	2760
TG' C	TGG(G	CGGCT G F		GG1 G	rCC(GAA K				TGC. A		GA M	TGC. Q			GT V	GTA Y	CAT'	rgca A	2820
GA. E		ITTCC F R		GG1 G	raa(K		GCT:		TACT T			AGT V		AAA M			GA E	AGT: V	AGA E	AGCT A	2880
CG. R		AATTG I G		TAT Y			ACT:		TTTA L	GA E		AGC A	CA S	GTA T			AG S	TAG R	GGC A	AACT T	2940
		ITATA Y K		CAT H	TAT(M	GGG G		ΓΤG' C			ATC S				TAC		AA N	TGA'		AGGT G	3000
		AGCTA A M		GAI D	'TAT		GAT(GA' D		ATA	AG	TTG	AAI	AGT	GG	ATT	AGT(GAAC	3060
AT	GGA:	TAAT	TA	TT	TG	AGA	TAA	GAG(GAAA	GA	AAA	GGA	.GA	CAT	Ŋ	1		Y	TAT' I	rtgg W	3120
TC S		ITTGA L K		AGC R	GTA(Y			TTG(W		TG W		TGA D			TAC		GC		GCT: L	FTTT F	3180
GT V	GAC(GGTTA V I			AGG: G	AAT M	GCC P	CAC T	AGCC A		AGC A		TA M	TGA I			AA N	TGG(CGT' V	TACA T	3240
AA K		IGATC D R		ACI T		AGT V	TTA Y	TCT(L	GTGG W	AC T	GTT F	CAT I	'CA M	TGT F			TT F	TGT' V		ACTA L	3300
GG G	TAT:	TATTG I G		CGI R		TAC T			TTAC Y								AC T	AAC. T	AAT M	GATT I	3360
AG. R	AGA'	IATGC M R	GT	'AA' N	rga' D	TAT M	GTA' Y	TGC' A	TAAG K	CT' L	TCA Q	AGA E	TA. Y	ACT S	CC(CAT I	CA H		ATA' .Y		3420
CA Q	GATA I	AGGTG G V	TA	TCT S			AGT V				GAC T					TT ?			GAT M		3480
TT F	TGC' A	TGAAA E M	TG	TC1 S	rtt. L	ACG R	TTT.				AAC T				AT.		AT I		TAG S		3540
GT V		GATAC I L	TA	ATT I	rac T	GAG S	TCC. P	ATC S	TTTG L		TTG W					GTT J			GCC' P		3600
TT L	GGT V	AGGAG G V	TC	GT:	TTT. L	ATA Y	TGT. V	AGC A	TATA I	AA K	AAC T	AAA K	AAC P	CTT	TA	rct S	GA E	AAG.	ACA O	ACAG	3660

ACTATGCTTG T M L D	ATAAAATCAA K I N	TCAATATGTT Q Y V	CGTGAAAATT R E N L		ACGCGTTGTT R V V	3720
AGAGCCTTTG	CAAGAGAGAA	TTTTCAATCA	CAAAAATTTC	AAGTCGCTAA	CCAACGTTAC	3780
R A F A	R E N	F Q S	Q K F Q	V A N	Q R Y	
ACAGATACTT	CAACTGGTCT	TTTTAAATTA	ACAGGGCTAA	CAGAACCACT	TTTCGTTCAA	3840
T D T S	T G L	F K L	T G L T	E P L	F V Q	
ATTATTATTG	CAATGATTGT	GGCTATCGTT	TGGTTTGCTT	TGGATCCCTT	ACAAAGAGGT	3900
I I I A	M I V	A I V	W F A L	D P L	Q R G	
GCTATTAAAA	TAGGGGATTT	AGTTGCTTTT	ATCGAATATA	GCTTCCATGC	TCTCTTTTCA	3960
A I K I	G D L	V A F	I E Y S	F H A	L F S	
TTTTTGCTAT	TTGCCAATCT	TTTTACTATG	TATCCTCGTA	TGGTGGTATC	AAGCCATCGT	4020
F L L F	A N L	F T M	Y P R M	V V S	S H R	
ATTAGAGAGG	TGATGGATAT	GCCAATCTCT	ATCAATCCTA	ATGCCGAAGG	TGTTACGGAT	4080
I R E V	M D M	P I S	I N P N	A E G	V T D	
ACGAAACTTA	AAGGGCATTT	AGAATTTGAT	AATGTAACAT	TCGCTTATCC	AGGAGAAACA	4140
T K L K	G H L	E F D	N V T F	A Y P	G E T	
GAGAGTCCCG	TTTTGCATGA	TATTTCTTTT	AAAGCTAAGC	CTGGAGAAAC	AATTGCTTTT	4200
E S P V	L H D	I S F	K A K P	G E T	I A F	
ATTGGTTCAA	CAGGTTCAGG	AAAATCTTCT	CTTGTTAATT	TGATTCCACG	TTTTTATGAT	4260
I G S T	G S G	K S S	L V N L	I P R	F Y D	
GŢGACACTTG	GAAAAATCTT	AGTAGATGGA	GTTGATGTAA	GAGATTATAA	CCTTAAATCA	4320
V T L G	K I L	V D G	V D V R	D Y N	L K S	
CTTCGCCAAA	AGATTGGATT	TATCCCCAA	AAAGCTCTTT	TATTTACAGG	GACAATAGGA	4380
L R Q K	I G F	I P Q	K A L L	F T G	T I G	
GAGAATTTAA	AATATGGAAA	AGCTGATGCT	ACTATTGATG	ATCTTAGACA	AGCGGTTGAT	4440
E N L K	Y G K	A D A	T I D D	L R Q	A V D	
ATTTCTCAAG	CTAAAGAGTT	TATTGAGAGT	CACCAAGAAG	CCTTTGAAAC	GCATTTAGCT	4500
I S Q A	K E F	I E S	H Q E A	F E T	H L A	
GAAGGTGGGA	GCAATCTTTC	TGGGGGTCAA	AAACAACGGT	TATCTATTGC	TAGGGCTGTT	4560
E G G S	N L S	G G Q	K Q R L	S I A	R A V	
GTTAAAGATC	CAGATTTATA	TATTTTTGAT	GATTCATTTT	CTGCTCTCGA	TTATAAGACA	4620
V K D P	D L Y	I F D	D S F S	A L D	Y K T	
GACGCTACTT D A T L	TAAGAGCGCG R A R	TCTAAAAGAA L K E	GTAACCGGTG V T G D		TTTGATAGTT L I V	4680
GCTCAAAGGG	TGGGTACGAT	TATGGATGCT	GATCAGATTA	TTGTCCTTGA	TGAAGGCGAA	4740
A Q R V	G T I	M D A	D Q I I	V L D	E G E	
ATTGTCGGTC	GTGGTACCCA	CGCTCAATTA	ATAGAAAATA	ATGCTATTTA	TCGTGAAATC	4800
I V G R	G T H	A Q L	I E N N	A I Y	R E I	
GCTGAGTCAC A E S Q	AACTGAAGAA L K N	CCAAAACTTA Q N L	TCAGAAGGAG S E G E	М	TGAGAAAAA R K K >	4860

ATCTGTTTTT S V F	TTGAGATTAT GGTCTTACC		AAAGCTACTC K A T L	TTTTCTTAGC 49 F L A	20
GATTTTTTG I F L	AAAGTTTTAT CTAGTTTTA K V L S S F M	T GAGTGTTCTG S V L	GAGCCTTTTA E P F I	TTTTAGGGTT 49 L G L	80
AGCGATAACA A I T	GAGTTGACTG CTAACCTTG		AAGGGAGTTT K G V S	CTGGGGCAGA 50 G A E	40
ATTGAACGTT L N V	CCTTATATTG CTGGTATTT		TTTTTCAGAG F F R G	GTGTTTTCTA 51 V F Y	00
TGAATTAGGT E L G	TCTTATGGCT CAAATT (SYGSN	SEQ ID NO:7)		51	26

FIG. 2a

NFDIETTTFE	AMKKHASLLE	KISVERSFIE	FDKLLLAPYW	RKGMLALIDS	50
HAFNYLPCLK	NRELQLSAFL	SQLDKDFLFE	TSEQAWASLI	LSMEVEHTKT	100
FLKKWKTSTH	FQKDVEHIVD	VYRIREQMGL	AKEHLYRYGK	TIIKQAEGIR	150
KARGLMVDFE	KIEQLDSELA	IHDRHEIVVN	GGTLIKKLGI	KPGPQMGDII	200
SQIELAIVLG	QLINEEEAIL	HFVKQYLMD	(SEQ ID NO	:8)	229
		FIG. 2	b		
MSDFLVDGLT	KSVGDKTVFS	NVSFIIHSLD	RIGIIGVNGT	GKTTLLDVIS	50
GELGFDGDRS	PFSSANDYKI	AYLKQEPDFD	DSQTILDTVL	SSDLREMALI	100
KEYELLLNHY	EESKQSRLEK	VMAEMDSLDA	WSIESEVKTV	LSKLGITDLQ	150
LSVGELSGGL	RRRVQLAQVL	LNDADLLLLD	EPTNHLDIDT	IAWLTNFLKN	200
SKKTVLFITH	DRYFLDNVAT	RIFELDKAQI	TEYQGNYQDY	VRLRAEQDER	250
DAASLHKKKQ	LYKQELAWMR	TQPQARATKQ	QARINRFQNL	KNDLHQTSDT	300
SDLEMTFETS	RIGKKVINFE	NVSFSYPDKS	ILKDFNLLIQ	NKDRIGIVGD	350
NGVGKSTLLN	LIVQDLQPDS	GNVSIGETIR	VGYFSQQLHN	MDGSKRVINY	400
LQEVADEVKT	SVGTTSVTEL	LEQFLFPRST	HGTQIAKLSG	GEKKRLYLLK	450
ILIEKPNVLL	LDEPTNDLDI	ATLTVLENFL	QGFGGPVITV	SHDRYFLDKV	500
ANKIIAFEDN	DIREFFGNYT	DYLDEKAFNE	QNNEVISKKE	STKTSREKQS	550
RKRMSYFEKQ	EWATIEDDIM	ILENTITRIE	NDMQTCGSDF	TRLSDLQKEL	600
DAKNEALLEK	YDRYEYLSEL	DT (SEQ II	NO:9)		622
		FIG. 2	_		
		:1G. Z	C		

FIG. 2d

157

IWMIKDL (SEQ ID NO:10)

MIIRPIIKND DQAVAQLIRQ SLRAYDLDKP DTAYSDPHLD HLTSYYEKIE 50 KSGFFVIEER DEIIGCGGFG PLKNLIAEMQ KVYIAERFRG KGLATDLVKM 100 IEVEARKIGY RQLYLETAST LSRATAVYKH MGYCALSQPI ANDQGHTAMD 150

MAYIWSYLKR	YPNWLWLDLL	GAMLFVTVIL	GMPTALAGMI	DNGVTKGDRT	50
GVYLWTFIMF	IFVVLGIIGR	ITMAYASSRL	TTTMIRDMRN	DMYAKLQEYS	100
HHEYEQIGVS	SLVTRMTSDT	FVLMQFAEMS	LRLGLVTPMV	MIFSVVMILI	150
TSPSLAWLVA	VAMPLLVGVV	LYVAIKTKPL	SERQQTMLDK	INQYVRENLT	200
GLRVVRAFAR	ENFQSQKFQV	ANQRYTDTST	GLFKLTGLTE	PLFVQIIIAM	250
IVAIVWFALD	PLQRGAIKIG	DLVAFIEYSF	HALFSFLLFA	NLFTMYPRMV	300
VSSHRIREVM	DMPISINPNA	EGVTDTKLKG	HLEFDNVTFA	YPGETESPVL	350
HDISFKAKPG	ETIAFIGSTG	SGKSSLVNLI	PRFYDVTLGK	ILVDGVDVRD	400
YNLKSLRQKI	GFIPQKALLF	TGTIGENLKY	GKADATIDDL	RQAVDISQAK	450
EFIESHQEAF	ETHLAEGGSN	LSGGQKQRLS	IARAVVKDPD	LYIFDDSFSA	500
LDYKTDATLR	ARLKEVTGDS	TVLIVAQRVG	TIMDADQIIV	LDEGEIVGRG	550
THAQLIENNA	IYREIAESQL	KNQNLSEGE	(SEQ ID NO:	11)	579
		mra ^			

FIG. 2e

MRKKSVFLRL	WSYLTRYKAT	LFLAIFLKVL	SSFMSVLEPF	ILGLAITELT	50
ANLVDMAKGV	SGAELNVPYI	AGILIIYFFR	GVFYELGSYG	SN	92
(SEQ ID NO:	:12)				

FIG. 2f

AATTTGGAAG F G S	TGCTCTATCA A L S	ACAGTTGAAG T V E V	TAAAGGAGAT K E I	TATTAGTGAA I S E	GAAAACATAT E N I W	60
GGTTATATCG		TGCCATTTTA C H F T		ATATTGGAAG Y W K	TTACCAACTT L P T W	120
GGTAAGCATC	ATATGGGTCT M G L		GACAATCAGA D N Q I	TTGCCTATAT A Y I	TGATGACAGC D D S	180
AAAGGTAAGG K G K A		TAAAACAAAC K T N	AAAACGATGG K T M D	ATCAAATCAG Q I S	TGCTGAAGAA A E E	240
GGCATCTCTG G I S A			ATTACTGACC I T D Q	AAGGCTATGT G Y V	GACCTCACAC T S H	300
GGTGACCATT G D H Y	ATCATTTTTA H F Y		GTTCCTTATG V P Y D	ATGCGATTAT A I I	TAGTGAAGAG S E E	360
TTGTTGATGA L L M T	D P N		AAACAATCAG K Q S D	ACGTTATCAA V I N	TGAAATCTTA E I L	420
•	TTATTAAAGT	CAATGGCAAC N G N	TATTATGTTT Y Y V Y	ACCTCAAGCC L K P	AGGTAGTAAG G S K	480
CGCAAAAACA R K N I	TTCGAACCAA R T K		GCTGAGCAAG A E Q V	TAGCCAAAGG A K G	AACTAAAGAA T K E	540
GCTAAAGAAA A K E K	AAGGTTTAGC G L A	TCAAGTGGCC Q V A	CATCTCAGTA H L S K	AAGAAGAAGT E E V	TGCGGCAGTC A A V	600
AATGAAGCAA N E A K	AAAGACAAGG R Q G	ACGCTATACT R Y T	ACAGACGATG T D D G	GCTATATTTT Y I F	TAGTCCGACA S P T	660
GATATCATTG D I I D	ATGATTTAGG D L G		TTAGTACCTC L V P H	ATGGTAATCA G N H	CTATCATTAT Y H Y	720
ATTCCTAAAA I P K K	AGGATTTGTC D L S		CTAGCTGCTG L A A A	CACAAGCCTA Q A Y	CTGGAGTCAA W S Q	780
AAACAAGGTC K Q G R	GAGGTGCTAG G A R	ACCGTCTGAT P S D	TACCGCCCGA Y R P T	CACCAGCCCC P A P	AGGTCGTAGG G R R	840
AAAGCCCCAA K A P I	TTCCTGATGT P D V	GACGCCTAAC T P N	CCTGGACAAG P G Q G	GTCATCAGCC H Q P	AGATAACGGT D N G	900
GGCTATCATC G Y H P	CAGCGCCTCC A P P	TAGGCCAAAT R P N	GATGCGTCAC D A S Q	AAAACAAACA N K H	CCAAAGAGAT Q R D	960
GAGTTTAAAG E F K G	GAAAAACCTT K T F	TAAGGAACTT K E L	TTAGATCAAC L D Q L	TACACCGTCT H R L	TGATTTGAAA D L K	1020
TACCGTCATG Y R H V	TGGAAGAAGA E E D	TGGGTTGATT G L I	TTTGAACCGA F E P T	CTCAAGTGAT Q V I	CAAATCAAAC K S N	1080
GCTTTTGGGT A F G Y	ATGTGGTGCC V V P	TCATGGAGAT H G D	CATTATCATA H Y H I	TTATCCCAAG I P R	AAGTCAGTTA S Q L	1140
TCACCTCTTG S P L E	AAATGGAATT M E L	AGCAGATCGA A D R	TACTTAGCTG Y L A G	GCCAAACTGA Q T E	GGACAATGAC D N D	1200
TCAGGTTCAG	AGCACTCAAA	ACCATCAGAT	AAAGAAGTGA	CACATACCTT	TCTTGGTCAT	1260

s	G	s	E	Н	s	K	P	s	D	K	Ē	v	Т	Н	т	F	L	G	Н	
CC R	CAT I	CAA K	AG A	CTTA Y	.CGG G	AAA K	AGG G	CTI L	TAGAT D	GG G	TAA K	ACC P	CAT Y	ATGA D	TAC T	GAG S	TGA D	ATGC A	TTAT Y	1320
G1 V	TTT F	TAG S	TA K	AAGA E	ATC S	CAT I	TCA H	TTC S	CAGTG V	GA D	TAA K	ATC S	AG G	GAGT V		AGC A		ACA H	CGGA G	1380
GA D	TCA H	TTT F	'CC H	ACTA Y	TAT. I	AGG G	ATT F	'TGG G	AGAA E	CT L	TGA E		AT Y	ATGA E	GTT L	GGA D		.GGT V		1440
A.P. N	CTG W	GGT V	GA K	AAGC A	AAA K	AGG G	TCA Q	AGC A	TGAT D	GA E	GCT L	TGC A	TG A	CTGC A	TTT L	GGA D	TCA Q	_	ACAA Q	1500
GG G	CAA K	AGA E	AA K	AACC P	ACT L	CTT F	TGA D	CAC T	TAAA K	AA. K	AGT V	GAG S	TC R	GCAA. K	AGT V	AAC T	AAA K		TGGT G	1560
AA K	AGT V	GGG G	CT Y	ATAT M	GAT M	GCC P	AAA K	AGA D	TGGT G	AA(K	GGA D	CTA Y	TT F	TCTA'	rgc A	TCG R	TGA D	TCA Q	ACTT L	1620
GA D	TTT L	GAC T	TC Q	AGAT I	TGC A	CTT F	TGC A	CGA E	ACAA Q	GAZ E	ACT. L	AAT M	GC L	TTAA K	AGA' D	TAA K	GAA K	GCA H	TTAC Y	1680
CG R	TTA Y	TGA D	CA I	TTGT V	TGA(CAC T	AGG G	TAT I	TGAG E	CCI P	ACG. R	ACT L	TG A	CTGTZ V		TGT V	GTC S	AAG S	TCTG L	1740
CC P	GAT M	GCA H	TG A	CTGG	TAA' N	TGC A	TAC	TTA Y	.CGAT D	AC:	rgg. G	AAG S	TT S	CGTT:		TAT I	CCC.	ACA H	TATT I	1800
GA D	TCA' H	TAT I	CC H	ATGT(CGT: V	TCC P	GTA Y	TTC S	ATGG W	TTC L	GAC(GCG R	CG D	ATCA(SAT:	rgc A		AGT V		1860
TA Y	TGT(V	GAT M	GC Q	AACA(CCC(P	CGA E	AGT' V	TCG R	TCCG P	GAT D	rgt: V	ATG W	GT S	CTAA(K	GCZ P	AGG G	GCA'	TGA E	AGAG E	1920
TC S	AGG' G	rtc S	GG V	TCAT'	rcc <i>i</i> P	AAA N	TGT' V	TAC T	GCCT P	CTT L	rga: D	TAA K	AC R	GTGCT A	GG:	TAT M	GCC	AAA N	CTGG W	1980
CA. Q	AAT: I	rate I	CC H	ATTC:	rgc: A	rga E	AGA E	AGT V	TCAA Q	AA. K	AGC(A	CCT.	AG A	CAGAA E	AGGT G	rcg R	TTTT	TGC A	AACA T	2040
CC. P	AGA(D	CGG(G	CT Y	ATAT:	r t to F	CGA D	TCC:	ACG. R	AGAT D	GT1 V	ŢŢŢ(L	GGC A	CA K	AAGAA E	ACT T	TTT F	TGT	ATG(W	GAAA K	2100
GA' D	rgg(G	S	CT F	TTAGO S	CATO	CCC P	AAG R	AGC A	AGAT D	GGC G	CAG:	rtcz S	AT L	TGAGA R	ACC T	CAT	TAA:	raa <i>i</i> K	ATCT S	2160
GA' D	TCT <i>I</i> L	ATC S	CC Q	AAGC1 A	rgac E	GTG W	GCAZ Q	ACA Q	AGCT A	CA <i>P</i> Q	AGA(E	GTT/ L	AT L	TGGCA A	AAC K	SAA K	AAA:			2220
GA' D	rgci A	TAC:	rg D	ATACO T	GAI D	raa K	ACC(CAA K	AGAA E	AAG K	CAA Q	ACA(Q	GG A	CAGAT D	'AAG K	SAG S	CAAT N	rga <i>i</i> E	AAAC N	2280
CAZ Q	ACAC Q	ECC <i>I</i> P	AA S	GTGAZ E	AGCC A	CAG S	TAA.	AGAZ E	AGAA E	AAA K	GAA E	ATC S	AG D	ATGAC D	TTI F	TAT	AGA(TTTA L	2340
CC2 P	AGAC D	TAT Y	rg G	GTCT <i>I</i> L	AGA1 D	TAG R	AGCA A	AAC(T	CCTA L	GAA E	GAT D	CA:	ra I	TCAAT N	CAP Q	L L	AGC <i>I</i> A			2400
GC: A	raat N	ATC I	CG D	ATCCT P	'AAG K	STA Y	TCT(CAT:	TTTC F	CAA Q	CCF P	AGAZ E	AG G	GTGTC V	CAA Q	ATT F	TTAT Y	raat N	TAAA K	2460

AATGGTGAAT TGGTAACTT N G E L V T Y	A TGATATCAAG D I K	ACACTTCAAC T L Q Q		TTAACCAAAA	2520
GAAGATCTCA TTGTTAAAG	C ACTGCTTTGT	CAAAGCAAGT	TACGGTGATT	TTGAAGTCAT	2580
TCTATGTAAC GAGTAGTGA	AAAAGTTGGA	TAATAGCGGT	TTTCTTTTGC	AAAGAAATGG	2640
TATCCATGTT AGAATAGTA					2700
CAGAAAACTG TGTTATTTT .K	A TTGCGTTAAA I A N F		TCTTTCTGAT E K Q	TAGGGGTTAG N P T L	2760
TCCTAGATTA GCCGTATGT G L N A T H	GGTTGTAATT PNYN		TTCTCAATGT N E I	ATTCAAAGCA Y E F C	2820
GTCTAATTGA ACCTGTTTG D L'Q V Q K	A TATTTTGATA I N Q Y		TTGATTTGTC N I Q	TATGCTTTAA R H K L	2880
ATACTTGAAA AATGCTTCA Y K F F A E	TTACGGCATT T V A N		TATCCAGGAT Y G P	TAGAAAAAGA N S F S	2940
ATGCATGATA TTGGCACTG H M <	CACCTAATAG	TGAGACGCAA	GAAAAACACT	TTTAGGCAAT A I	3000
CAGTTTTCTG TACTGTACA L K R Y Q V	G GCGACTGGTC P S Q D	GTTTAATCTC N L R	TGTTGAATTC Q Q I	TAGTTTCATT R T E N	3060
ATAAAATGTA ATGTAATTT Y F T I Y N	TAACAATATT K V I N		TCTTTGTTGT D K N	ATTTTCTCCT Y K R R	3120
ATTATGGAAA TAAAAGGTT N H F Y F T	CAGTCTTTAG E T K L	GACGGTGTGA V T H	AACCATTCAA F W E	TACAGGCATT I C A N	3180
ATCTGCAGGT GTTCCTTTT D A P T G K	GAGACATTGA R S M S	GCGGATAATG R I I	TCTTTTTCCG D K E	TGCAAGCCTG T C A Q	3240
GTAGTAAGCC ATAGAAGTA Y Y A M <	ACACTGAGCC	TTGGTCACTG	TGTAAGATTG	CTCCTTTATT	3300
TAGGCAATTT TAACTGATT. K P L K L Q N	AGGGTGTCTA L T D	GTACAAAATC L V F D	CGTGTCCTGA T D Q	CAATCTGAGA C D S	3360
TAGTGTAAGC TATAATTTC I T Y A I I E	CGGTTATAGA R N Y	GATTCATAAT L N M I	TGATGAGAGA S S L	TACAATTTAC Y L K	3420
AGTTACCGAA ATATAGGTA C N G F Y L Y	GTAATATCTG T I D	TTACGAGCTT T V L K	TTCCTTAGGC E K P	TTATCGGCAT K D A	3480
GGAAATCCCG ACTCAATTT H G D R S L K	N D T	AATAATAAGC L Y Y A	TTTACCCAAA K G L	TTGGGAACTT N P V	3540
TCTTGGTACG TGTCCGACA K K T R T R C		TATTTTTCAT N N K M		ACTTTCTTTG V K K	3600
TATTAACAGT CAATCCGTG T N V T L G H	ATTTTTTGA I K K	GCAATCGTGT L L R T	AATGGTACGA I T R	TAGCCATAAA Y G Y	3660
TAAAGTGATT CTCCATACA I F H N E M <	G AGCTGTTCAA	TTAATTCAAT	AAGGTCATCT	TTTTTTGCGG	3720

CTTCTCATAC	TCCTTTTTC	AACGGTAATA	GGTCGACCGC	TTGACCTTAA	AACAGTCTAG	3780
AATGAAAACT	ATCGGGTAGT	TGTTTTTATA	GTCTTCCACA	AGCTTGATAA		3840
1 5 K	R I L G		K L L	DAÖF	Q L Q	3900
TCCACTTCAG E V E	ACAGATGTTC S L H E	CAAGCCTTTA L G K	CCGTAGGTAT G Y T	ATTGCTTGCC Y Q K G		3960
TGAAAACGAT H F R	AAAGCTCCTC Y L E E	GTTTTCGTAC N E Y	CATTTCATCC W K M	AAGTATAGAT W T Y I	TTGACTATTA Q S N	4020
TTTTTGATGC N K I	CTAAAGTCTC G L T E	CATAATAACT M I V	CTGTTAGACT R N S	TGCCTGCTTT K G A K	CTTCATATCG K M D	4080
ATGCAAGCCA I C A	GCTTAGTTTC L K T E	CCATGAATAT W S Y	A K K	V M	ACATTCCTGT	4140
TTCTAGTTTA	CTAAATTTCA	ACAGGAGTGT	TTTTCTTTTG	 TCTCATTTTA	GGGATTCAGT	4200
GCCTATTGTT	GTCATCAATT	ATTTTTCTAA	ATTCCCCGGA	CTTAAATTGT	GACCCTTGGT	4260
		CCTTCAATCT				4320
TCTGTACAAC	ATTTATAAAG	TGTTTTTCTA	GGCAATTAAT . A I L	CTTTTAGTCA R K T	TTGGTGTTTG M P T Q	4380
GTAGTTGAGA Y N L	CTACCATGAA S G H	TGCGGTGGTA I R H Y	ATTCCACCAA N W W	TGAACATAGT H V Y	CTTTAGTCTT D K T K	4440
AAGAGCTAGT L A L	TCTTCCAGCA E E L	ATTGAAAGGT L Q F T	TTCTTGATAA E Q Y	ACAAATTCAA V F E	TTTTGAAAGC I K F A	4500
ACGATACGTA R Y T	CTTTCAGCTA S E A	CGGCATTGTC V A N D	ATAAGGATAA Y P Y	CCAGCCTGAC G A Q	TAAGCGAACG S L S R	4560
TGTGATTCCA T I G	AAGGCTTCCA F A E	ATATTTCATC L I E D	AATTAACTGA I L Q	TTATCAAACT N D F	CTTTGCCACG E K G R	4620
ATCTGAATGG D S H	AACATCTTGA F M K	CTTTGGTCAG V K T L	GGCGTAAGGG A Y P	ATGCTTTGTA I S Q	TGGCTTGCTT I A Q K	4680
AACGAGTTCA V L E	GCGGTCTTGT A T K	GCCAACCAAG H W G L	AGACAGGCCG S L G	ATGATTTCAC I I E	GGTTGTATAG R N Y L	4740
GTCAATGATG D I I	AGGCAAACAT L C V	AAGCCCAACG Y A W R	ATTGCCTACA N G V	CGAACATAGG R V Y	TTAAGTCAGT T L D T	4800
GACTAAGGCT V L A	TGTAGTGGTC Q L P	TTTCTTGCTT R E Q K	AAATTGCCTG F Q R		TGGGAATAGG N P I P	4860
GGCTTCATTC A E N	TTGCCTCTAG K G R	AATGTGGTTT S H P K	GAAGGTGGCT F T A		CAGAAACCAA V S V L	4920
ATTGAGTCGC N L R	TTCATAATGC K M I	GTCGAATCCG R R I R	ACGACGTGAA R R S		CTTCGTTATT G E N N	4980
CAAGCATATT L C I	TTGATTTTTC K I K	TGGATCCGTA R S G Y	TCTAGACTCG R S E		AAATTCTTTT F I R K	5040

110 99142300				TOTION	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
AATAGTTTCT TCAA I T E E	ACTCCG TTTC F E T E				5100
GTGTGGCATA TTCA H P M N	GCCAGC GACA L W R C	ACATCTT TGAAAT M K S I			5160
GATTATTTCC CTTT I I E R (SEQ ID NO:13	K T G Y		A K P Y		5215
FGSALSTVEV KE (SEQ ID NO:14		LYRLSCCHFT	SYSYWKLPTW		40
		FIG. 3	h		
		rig. 5	D		
MGLATKDNQI AY	/IDDSKGKA	KAPKTNKTMD	QISAEEGISA	EQIVVKITDQ	50
GYVTSHGDHY HE	YNGKVPYD	AIISEELLMT	DPNYRFKQSD	VINEILDGYV	100
IKVNGNYYVY LK	(PGSKRKNI	RTKQQIAEQV	AKGTKEAKEK	GLAQVAHLSK	150
EEVAAVNEAK RÇ)GRYTTDDG	YIFSPTDIID	DLGDAYLVPH	GNHYHYIPKK	200
DLSPSELAAA QA	YWSQKQGR	GARPSDYRPT	PAPGRRKAPI	PDVTPNPGQG	250
HQPDNGGYHP AF	PRPNDASQ	NKHQRDEFKG	KTFKELLDQL	HRLDLKYRHV	300
EEDGLIFEPT QV	'IKSNAFGY	VVPHGDHYHI	IPRSQLSPLE	MELADRYLAG	350
QTEDNDSGSE HS	KPSDKEVT	HTFLGHRIKA	YGKGLDGKPY	DTSDAYVFSK	400
ESIHSVDKSG VT	'AKHGDHFH	YIGFGELEQY	ELDEVANWVK	AKGQADELAA	450
ALDQEQGKEK PL	FDTKKVSR	KVTKDGKVGY	MMPKDGKDYF	YARDQLDLTQ	500
IAFAEQELML KD	KKHYRYDI	VDTGIEPRLA	VDVSSLPMHA	GNATYDTGSS	550
FVIPHIDHIH VV	PYSWLTRD	QIATVKYVMQ	HPEVRPDVWS	KPGHEESGSV	600
IPNVTPLDKR AG					650
ETFVWKDGSF SI					700
TDKPKEKQQA DK	SNENQQPS	EASKEEKESD	DFIDSLPDYG	LDRATLEDHI	750
NQLAQKANID PK	YLIFQPEG	VQFYNKNGEL	VTYDIKTLQQ	INP	793
/000 TD NO TE					

FIG. 3c

(SEQ ID NO:15)

MTDPNYRFKQ	SDVINEILDG	YVIKVNGNYY	VYLKPGSKRK	NIRTKQQIAE	50
QVAKGTKEAK	EKGLAQVAHL	SKEEVAAVNE	AKRQGRYTTD	DGYIFSPTDI	100
IDDLGDAYLV	PHGNHYHYIP	KKDLSPSELA	AAQAYWSQKQ	GRGARPSDYR	150
PTPAPGRRKA	PIPDVTPNPG	QGHQPDNGGY	HPAPPRPNDA	SQNKHQRDEF	200
KGKTFKELLD	QLHRLDLKYR	HVEEDGLIFE	PTQVIKSNAF	GYVVPHGDHY	250
HIIPRSQLSP	LEMELADRYL	AGQTEDNDSG	SEHSKPSDKE	VTHTFLGHRI	300
KAYGKGLDGK	PYDTSDAYVF	SKESIHSVDK	SGVTAKHGDH	FHYIGFGELE	350
QYELDEVANW	VKAKGQADEL	AAALDQEQGK	EKPLFDTKKV	SRKVTKDGKV	400
GYMMPKDGKD	YFYARDQLDL	TQIAFAEQEL	MLKDKKHYRY	DIVDTGIEPR	450
LAVDVSSLPM	HAGNATYDTG	SSFVIPHIDH	IHVVPYSWLT	RDQIATVKYV	500
MQHPEVRPDV	WSKPGHEESG	SVIPNVTPLD	KRAGMPNWQI	IHSAEEVQKA	550
LAEGRFATPD	GYIFDPRDVL	AKETFVWKDG	SFSIPRADGS	SLRTINKSDL	600
SQAEWQQAQE	LLAKKNTGDA	TDTDKPKEKQ	QADKSNENQQ	PSEASKEEKE	650
SDDFIDSLPD	YGLDRATLED	HINQLAQKAN	IDPKYLIFQP	EGVQFYNKNG	700
ELVTYDIKTL	QQINP (SEC	Q ID NO:16)			715
		FIG. 3	d		
MHSFSNPGYP	YDNAVTEAFF	KYLKHROTNR	KHYQNIKQVQ	I.DOFFVIENE	50
			SEQ ID NO:17		77
	~	(2	de ib No.17	,	1 1
		FIG. 3	e		
MAVVOACTEV	DIIDOMODIA				
			FHTVLKTETF		50
DSTINIVANI	TIPINETRIQ	QRLNDQSPVQ	YRKLIA (SE	Q ID NO:18)	86
		FIG. 3	f		
MENUETVOVO					
			RIMKNNGWLC		50
			LYFGNCKLYL	SSIMNLYNRE	100
TIAYTISDCQ	DTDFVLDTLN	QLKLPK (SE	Q ID NO:19)		126

FIG. 3g

MVKKAYSWET KLA	CIDMKKA GKSNR	VIMET LGIKNNS	QIY TWMKWYENEE	50
LYRFHQGVGK QYT	YGKGLEH LSEVE	QLQLQ VDLLKKY	RGL IRKSIK	96
(SEQ ID NO:20)				
	E	IG. 3h		

IRYPKASSGDYGTKREIITANKDKYSISKMCRWLNMPHSSYYYQAVESVS50ETEFEETIKRIFLDSESRYGSRKIKICLNNEGITLSRRRIRRIMKRLNLV100SVYQKATFKPHSRGKNEAPIPNHLDRQFKQERPLQALVTDLTYVRVGNRW150AYVCLIIDLYNREIIGLSLGWHKTAELVKQAIQSIPYALTKVKMFHSDRG200KEFDNQLIDEILEAFGITRSLSQAGYPYDNAVAESTYRAFKIEFVYQETF250QLLEELALKTKDYVHWWNYHRIHGSLNYQTPMTKRLIA(SEQ ID NO:21) 288

FIG. 3i

						_														
N	TTT L >	K	AG A	CAGA E	ATT. L	ATC S	TGT V	AGA E	AGAT D	GA E	.GCA. Q	ATA Y	AT. T	CAGC.	AAC. T	AGT V		TGG G		60
TC S	TGC A	TCA H	TG G	GTTC. S	AAC. T	ACC P	ACA Q	AGA E	AGGT G	GT V	TAA N	TGG G	GG A	CGAC	TTA Y		AGC'		TTAT Y	120
CT. L	AAG S	TCA. Q	AT F	TTGA D	TTT' F	TGA E	AGG G	TCC P	TGCT A	CG R	TGC A	TTT F	CT L	TAGA'	TGT V	TAC T	AGC A		CATT I	180
AT' I	TCA H	CGA. E	AG D	ACTT F	CTC S	AGG G	TGA E	AAA K	ACTT L	GG. G	AGT. V	AGC A	TT Y	ATGA E	AGA D	TGA D	CTG'	TAT M	GGGA G	240
CC. P	ATT L	GAG(S	CA M	TGAA' N	TGC A	AGG G	TGT V	CTT F	CCAG Q	TT F	TGA' D	TGA E	AA T	CTAA' N	TGA' D	TGA D	TAA' N	TAC	TATC I	300
GC' A	ICT' L	TAA' N	TT F	TCCG' R	TTA(Y	CCC P	ACA.	AGG G	GACA T	GA D	TGC' A	ГАА К	AA T		CCA.	AAC T	TAA			360
AA K	ACT'	TAA(N	CG G	GAGT' V	rgaz E	AAA K	AGT V	GAC' T	TCTT L	TC S	TGA D	CCA H	TG E		CAC		ACA(CTA' Y	TGTA V	420
CC' P	rato M	GGA(CG D	ATGA: E	ATTI L	AGT V	ATC:	AAC T	CTTA L	CT. L	AGC' A	TGT V	CT Y	ATGA		GCA Q	AAC'			480
AAZ K	AGGZ G	ACA:	rg E	AACA	GGT'	TAT I	TGG' G	TGG' G	TGGG G	AC. T	ATT' F	IGG G	TC R	GCTT	ACT' L	rga E	ACG(TGTT V	540
GCZ A	ATA Y	CGG! G	ГG А	CCAT(GTT(CCC P	AGG	AGA' D	TGAA E	AA N	CAC'	TAT M	GC H		AGC' A			GTA Y		600
CC:	CTT	AGAZ	A.A	ATAT'	rtt	CCG	TTC	GGC'	TGCT	AT	CTA	CGC.	AG	AAGC'	TAT	CTA	TGA	ATT	AATC	660

P	L	E	N	1	. I	· :	R	S	Α	A	I	Y	A	E	А	I	Y	E	L	I	
A K	AAT.	AAA	ATA	OTA	CTI	CAA.	AC	TAA	AT <i>I</i>	ATGTG	ΑT	'CAF	ATGA	ATA	AAGO	GTC	GTG	AAG	ACA	TGAA	720
A	GTG	TCT	TTG	CCI	'CTI	TTT	CA	TAA	.GGT	TAGA	тт	TGG	SAGA	ACT	M	GAC T	D	CTT L	GGA E	AAAA K	780
A'	TTA I	TTA K	AAG A	CAA	TAF.	AAA (AG S	TGA D	TTC S	ACAG Q	AA N	TCA Q	AAA N	TTA Y	ATAC	AGA E	AAA	TGG G	TAT I	TGAT D	840
C ⁽	CTT L	TGT F	TTG A	CTG A	CTC . I	CCT	AA K	AAC T	AGC A	TAGG R	AT I	CAA N	IATA	TG V		GCCA Q		ACC P	TGG G	TTTA L	900
A. K	AAA T	CTC Q	AAG E	AAG A	CAP F	AGA(CT L	CTA Y	TTG W	GAAA K	GA D	TAA K	ATC S	TG G	GAGA D				CCA Q	.GTGG W	960
C'	TTG G	GAG V	TTG D	ATG E	AAC E	AG	AC T	ATT F	TTA Y	CCAT H	TC S		AA <i>F</i> K			TGI V			TTT L		1020
T'	TTT Y	ATT Y	ACC P	CAG G	GCA F	AA(GG G	AAA K	ATC S	AGGA G	GA D	TTT L	'ACC P	CC P		AAA K		TTT F	TGC A		1080
A <i>I</i> K	TAF W	GGC. H	ACC P	CTC	TTA I	TT:	rt L	AAA K	AGA E	AATG M	CC P	TAA N	TGI V	TC Q	AATT L		CTT L		AGT V		1140
C <i>I</i> Q	AGTZ Y	ATG A	CTC Q	AGA K	raa Y	'AT'	ra Y	TCT' L	TGG G	AAGC S	TC S	CGC A	ACA H	TA K		TCT L	AAC T	AGA. E	AAC T	AGTT V	1200
A <i>I</i> K	AAG(A	CTT. Y	ACA K	AAG D	ACI Y	'ATC	CT L	ACC P	CGA D	TTAT Y	TT. L	ACC P	CCI L	'GG V	TTCA H	.CCC P	ATC S	ACC P		AAAT N	1260
C <i>I</i> Q	AAA: I	TTT W	GGC L	TAA K	AGA K	AGA	AA V	TCC:	ATG W	GTTT F	GA. E	AAA K	AGA D	TC L	TAAT I	CGT V		TTT.		AAAG K	1320
A? I	'AG' V	rag A	CAG D	ATA I	TTT L	TAA	AA <	AGA' D	ΓTΑ •	AGGA	TA	GGA	GTT	'GG	TATG M	R	D			CTAC L H	1380
AC	CAC(T	GTA' Y	TTT F	TTC S	CTA Y	TG <i>I</i> D	AΤ	TGT	CAA Q	ACGG T A	CA	TTT F	GAG E	GA D	CTAT	ATT	AAT N			ACAG T G	1440
G'I	ÉGA <i>I</i> E	ATT' F	rat I	CAC T	GAC T	AG <i>I</i> E	A.A	CAT'	ltt F	GATT D L	AT	TCA S	AAT N	CC P	TTAC Y	ACC T	GGT G	CAA(GATG D V	1500
ТТ	P P	rga: D	TTA Y	TAG S	TGC A	TT <i>F</i> Y	Υ	TGT(CAA O	AAAA K I	TA	GAT D	TAT Y	CT L	TAAT N	CAG Q	AAA K	TATO Y		AATC N R	1560
GP	TTI F	raaz K	AAA K	AGG. G	TAA I	TGF E	AA	ATC(GGT G	TATT Y F	TT.	AAA K	GAT D	AG R		TCA S		ATT			1620
ΙA	TT# L	AAA K	AAA N	TAA. K	AGA E	ATI F	T	GAT'	ΓΤΑ. L	AAAC K L	TA:	TTG L	TCA S	AT I	CCAT H					TATG Y D	1680
ΓA	TAT Y	L L	GCA Q	AGA. E	AGA E	AGC A	T	CTG? L I	AAA K	GTAC V P	CA	ACA T	AAG K	GG G	AGCT A			AGA'			1740
A.P	TC	GTA:	rgg	AAT'	ГТG	CCP	T	AGG	CCG	TGTG	GA	AGC	GCA	CG	TTTT.	AGC	TCA	CTT	rga'	TAT	1800
GG	TTT	TC	GTA	AGT'	TAA	ACI	T	AGA:	rgt.	AGAA	GA'	TTT.	AAA	AC	CGTT	TGA	AAC	GCA	TTA	GAAG	1860
CG	CAI	rTT:	ГСА	TAA	AGA	TGI	T	ATC:	raa'	GGGG	TT	AGC	TTT	TG	AACT.	AAA	TAC	CAA	ATC	CCTT	1920

TATCTATATG	GGAATGAAAA	ACTTTATCGC	TATGCTTTAG	AGATACTCA	ACAGCTTGGT	1980
TGTAAACAAT	ACTCTATAGG	CTCTGACGGT	CATATTCCTG	AACATTTTT	TTATGAATTT	2040
GATAGACTTC	AAGGTCTGCT	AAAGGACTAT	CAAATTGATG	AAAATCATTT	' GATATGAGGA	2100
AATTTTTGAT	AAAAAAGCTA	GGCAATATTG	CTTAGCTTTT	TTGTAATGCT	ATTGATAGTT	2160
TTAGTGAAAA	TTTCAAAAAA	ATAAAGAAAT	CATTTACTTG	TTGCAAGCGC	TTGCGTAAAT	2220
				M K		2280
L I G D	K Q I	QYT	IRKL	TAAGTGTTGG S V G	AGTAGCTTCA V A S	2340
GTTACAACAG V T T G	GGGTATGTAT V C I	TTTTCTTCAT F L H	AGTCCACAGG S P Q V	TATTTGCTGA F A E	AGAAGTAAGT E V S	2400
	IIA	I A L	SNIN	QVD	CAACCAACAA N Q Q	2460
TCTACTAATT S T N L	TAAAAGATGA K D D	CATAAACTCA I N S	AACTCTGAGA N S E T	CGGTTGTGAC V V T	ACCCTCAGAT P S D	2520
ATGCCGGATA M P D T	CCAAGCAATT K Q L	AGTATCAGAT V S D	GAAACTGACA E T D T	CTCAAAAGGG Q K G	AGTGACAGAG V T E	2580
	CGACAAGCCT T S L	r F F	NKGP	V S D	KNT	2640
TTAGATTTAA L D L K	AAGTAGCACC V A P	ATCTACATTG S T L	CAAAATACTC Q N T P	CCGACAAAAC D K T	TTCTCAAGCT S Q A	2700
ATAGGTGCTC I G A P	CAAGCCCTAC S P T	CTTGAAAGTA L K V	GCTAATCAAG A N Q A	CTCCACGGAT P R I	TGAAAATGGT E N G	2760
TACTTTAGGC Y F R L	TACATCTTAA H L K	AGAATTGCCT E L P	CAAGGTCATC Q G H P	CTGTAGAAAG V E S	CACTGGACTT T G L	2820
TGGATATGGG W I W G	GAGATGTTGA D V D	TCAACCGTCT Q P S	AGTAATTGGC S N W P	CAAATGGTGC N G A	TATCCCTATG I P M	2880
ACTGATGCTA T D A K	K D D	I G I	YVDF	KLS	E K Q	2940
CGAAAACAAA R K Q I	TATCTTTTT : S F L	AATTAATAAC I N N	AAAGCAGGGA K A G T	CAAATTTAAG N L S	CGGCGATCAT G D H	3000
CATATTCCAT H I P L	TATTACGACC ' L R P	TGAGATGAAC E M N	CAAGTTTGGA ' Q V W I	TTGATGAAAA D E K	GTACGGTATA Y G I	3060
CATACTTATC A	AACCCCTCAA-	AGAAGGGTAT		ACTATTTCAC		3120
AACTATGACC A	ACTTATCAGC A	ATGGCTCTTT :	AAAGATGTTG (K D V A	CAACCCCYTC T P S	AACAACTTGG T T W	3180
CCAGATGGTA (P D G S	GTAATTTTGT (N F V	GAATCAAGGA (CTATATGGAA (GGTATATTGA	TGTATCACTA	3240

AAAACTAACO K T N A	G CCAAAGAGA' A K E I	TGGTTTTCTA G F L	ATCTTAGATO	AAAGTAAGAC S K T	AGGAGATGCA G D A	3300
GTGAAAGTTO V K V (C AACCCAACGA Q P N D	A CTATGTTTT Y V F	AGAGATTTAG R D L A	CTAACCATAA N H N	CCAAATTTTT Q I F	3360
GTAAAAGATA V K D F	A AGGATCCAA! K D P K	A GGTTTATAAT V Y N	AATCCTTATT N P Y Y	ACATTGATCA I D Q	AGTGCAGCTA V Q L	3420
K D A (Q I D	A TTTAACAAGT L T S	I Q A S	FTT	L D G	3480
V D K 1	EIL	AAAAGAATTG K E L	K V T D	K N Q	N A I	3540
QISL) I T L	CGATACTAGT D T S	KSLL	IIK	G D F	3600
и рк Ç	GHF		YNGN	N V M	T R Q	3660
SWEF	KDQ		YSGN	L G A	A T N	3720
Q D G S	K V E	AGCCAGCCTC A S L	WSPS	A D S	V T M	3780
IIYD	K D N		V V A T	T P L	V K N	3840
N K G V	WQT		T K L G	I K N	Y T G	3900
YYYL	YEI		K D K V	KIL	D P Y	3960
AKSL	A E W		TVND	DIK	T A K	4020
A A F V	N P S		PQNL	S F A	K I A	4080
NEKG	кор	TGCTGTTATA A V I	YEAH	V R D	F T S	4140
DK5L	DGK	ATTAAAAAAT L K N	QFGT	F A A	FSE	4200
K L D I	L Q K	⊥ G V	THIQ	L L P		4260
I F I V	N E M	GGATAAGTCA D K S	RSTA	Y T S	S D N	4320
AATTACAATT N Y N W	GGGGCTATGA G Y D	CCCACAGAGC P Q S	TATTTTGCTC Y F A L	TTTCTGGGAT S G M	GTATTCAGAG Y S E	4380
AAACCAAAAG K P K D	ATCCATCAGC P S A	ACGTATCGCC R I A	GAATTAAAAC E L K Q	AATTAATACA L I H	TGATATTCAT D I H	4440

AAACGTGGCA TGGGGGTTAT ACTTGATGTC GTCTATAATC ACACTGCAAA AACTTATCTC K R G M G V I L D V V Y N H T A K T Y L	4500
TTTGAGGATA TAGAACCTAA TTATTATCAC TTTATGAATG AAGATGGTTC ACCAAGAGAA F E D I E P N Y Y H F M N E D G S P R E	4560
AGTTTTGGAG GGGGACGTTT AGGAACCACT CATGCAATGA GTCGTCGTGT TTTGGTTGAT S F G G G R L G T T H A M S R R V L V D	4620
TCCATTAAAT ATCTTACAAG TGAATTTAAA GTTGATGGTT TCCGTTTTGA TATGATGGGA S I K Y L T S E F K V D G F R F D M M G	4680
GATCATGATG CGGCTGCGAT TGAATTAGCT TATAAAGAAG CTAAAGCTAT TAATCCTAAT D H D A A A I E L A Y K E A K A I N P N	4740
ATGATTATGA TTGGTGAGGG CTGGAGAACA TTCCAAGGCG ATCAAGGTCA GCCGGTTAAA M I M I G E G W R T F Q G D Q G Q P V K	4800
CCAGCTGACC AAGATTGGAT GAAGTCAACC GATACAGTTG GCGTCTTTTC AGATGATATT P A D Q D W M K S T D T V G V F S D D I	4860
CGTAATAGCT TGAAATCTGG TTTTCCAAAT GAAGGTACTC CAGCTTTCAT CACAGGTGGC R N S L K S G F P N E G T P A F I T G G	4920
CCACAATCTT TACAAGGTAT TTTTAAAAAT ATCAAAGCAC AACCTGGGAA TTTTGAAGCA P Q S L Q G I F K N I K A Q P G N F E A	4980
GATTCGCCAG GAGATGTGGT GCAGTATATT GCTGCACATG ATAACCTTAC CTTGCATGAT D S P G D V V Q Y I A A H D N L T L H D	5040
GTGATTGCAA AATCAATT (SEQ ID NO:22) V I A K S I .	5058
FIG. 4a	
NLKAELSVED EQYTATVYGK SAHGSTPQEG VNGATYLALY LSQFDFEGPA	50
RAFLDVTANI IHEDFSGEKL GVAYEDDCMG PLSMNAGVFQ FDETNDDNTI	100
ALNFRYPQGT DAKTIQTKLE KLNGVEKVTL SDHEHTPHYV PMDDELVSTL	150
LAVYEKQTGL KGHEQVIGGG TFGRLLERGV AYGAMFPGDE NTMHQANEYM	200
PLENIFRSAA IYAEAIYELI K (SEQ ID NO:23)	221
FIG. 4b	
MTDIEVITVA IVCDCONONY TENCEDRE	
MTDLEKIIKA IKSDSQNQNY TENGIDPLFA APKTARINIV GQAPGLKTQE	50
ARLYWKDKSG DRLRQWLGVD EETFYHSGKF AVLPLDFYYP GKGKSGDLPP	100
RKGFAEKWHP LILKEMPNVQ LTLLVGQYAQ KYYLGSSAHK NLTETVKAYK	150
DYLPDYLPLV HPSPRNQIWL KKNPWFEKDL IVDLQKIVAD ILKD	194
(SEQ ID NO:24)	

FIG. 4c

MRDNHLHTYF SYDCQTAF	ED YINGFTGEFI TTEHFDLSN	IP YTGQDDVPDY 50
SAYCQKIDYL NQKYGNRF	KK GIEIGYFKDR ESDILDYL	N KEFDLKLLSI 100
HHNGRYDYLQ EEALKVPT	KG AFSRLL (SEQ ID NO:2	(5) 126

FIG. 4d

MKRKDLFGDK	QTQYTIRKLS	VGVASVTTGV	CIFLHSPQVF	AEEVSVSPAT	50
TAIAESNINQ	VDNQQSTNLK	DDINSNSETV	VTPSDMPDTK	QLVSDETDTQ	100
KGVTEPDKAT	SLLEENKGPV	SDKNTLDLKV	APSTLQNTPD	KTSQAIGAPS	150
PTLKVANQAP	RIENGYFRLH	LKELPQGHPV	ESTGLWIWGD	VDQPSSNWPN	200
GAIPMTDAKK	DDYGYYVDFK	LSEKQRKQIS	FLINNKAGTN	LSGDHHIPLL	250
RPEMNQVWID	EKYGIHTYQP.	LKEGYVRINY	LSSSSNYDHL	SAWLFKDVAT	300
PSTTWPDGSN	FVNQGLYGRY	IDVSLKTNAK	EIGFLILDES	KTGDAVKVQP	350
NDYVFRDLAN	HNQIFVKDKD	PKVYNNPYYI	DQVQLKDAQQ	IDLTSIQASF	400
TTLDGVDKTE	ILKELKVTDK	NQNAIQISDI	TLDTSKSLLI	IKGDFNPKQG	450
HFNISYNGNN	VMTRQSWEFK	DQLYAYSGNL	GAVLNQDGSK	VEASLWSPSA	500
DSVTMIIYDK	DNQNRVVATT	PLVKNNKGVW	QTILDTKLGI	KNYTGYYYLY	550
EIKRGKDKVK	ILDPYAKSLA	EWDSNTVNDD	IKTAKAAFVN	PSQLGPQNLS	600
FAKIANFKGR	QDAVIYEAHV	RDFTSDRSLD	GKLKNQFGTF	AAFSEKLDYL	650
QKLGVTHIQL	LPVLSYFYVN	EMDKSRSTAY	TSSDNNYNWG	YDPQSYFALS	700
GMYSEKPKDP	SARIAELKQL	IHDIHKRGMG	VILDVVYNHT	AKTYLFEDIE	750
PNYYHFMNED	GSPRESFGGG	RLGTTHAMSR	RVLVDSIKYL	TSEFKVDGFR	800
FDMMGDHDAA	AIELAYKEAK	AINPNMIMIG	EGWRTFQGDQ	GQPVKPADQD	850
WMKSTDTVGV	FSDDIRNSLK	SGFPNEGTPA	FITGGPQSLQ		900
GNFEADSPGD	VVQYIAAHDN	LTLHDVIAKS	I (SEQ ID		931

FIG. 4e

AATTCAAAG'	F TTGACAGAA L T E	G GTCAACTTC G Q L R	G TTCTGATATO S D I			60
>				PEFF	11 G B	
TACTGTACGT T V R	F GTTCACGCT V H A	A AAGTTGTTG K V V E	A AGGTACTCGC G T R	C GAACGTATTC E R I Q		120
AGGTGTTGTT G V V	F ATCTCACGT. I S R	A AAGGTCAAGG K G Q G	G AATCTCAGAA I S E	ATGTACACAG M Y T V		180
TTCTGGTGGT S G G	ATCGGTGTA I G V	G AGCGTACAT E R T F	CCCAATTCAC P I H	ACTCCTCGTG T P R V		240
CGAAGTTGTT E V V	CGTTATGGT	A AAGTACGTCO	G TGCTAAACTT A K L	TACTACTTAC Y Y L R	GCGCATTGCA A L Q	300
AGGTAAAGCT	GCACGTATT	A AAGAAATCC	G TCGTTAATTT	TGATGATCAG	ATTTTAAAAA	360
TGCTTGGTTG	TTTGAGGAT	GTAACTATGT	TTTAAAACTG	GACAACCAAG	ACGTAAAAAA	420
TCTGCCTGTG	GGCAGTTTT	TTACTAGGTO	CCCTTAGTTC	AATGGATATA . H I Y	ACAACTCCCT C S G	480
CCTAAGGAGT G L S	AATTGCTGGT Y N S T	TCGATTCCGG	CAGGGGACAT C P V	ATTCATTGCA Y E N C	TGTAAATAGC T F L	540
GGTTTAGAGC P K S	TATTTTGCCC	CAAATTTCTC L N R	TGATTAAGTT Q N L	TATCGTTCCT K D N R	ATCTTTTTGT D K Q	600
TCTTGTAATT E Q L	GATGTGCGTA Q H A Y	AACTTCTAAA V E L	GTGATATTTA T I N	AATTCTCGTG L N E H	ATCTAAAACT D L V	660
TGAGAGATGG Q S I	AAATTAGATA S I L Y	GCTTGCAAAT S A F	GTATGCCTGA T H R	GAGAGTGCAC L S H V	TCGTACCTCG R V E	720
CGACCAGTTA R G T	TTTTTCGGAT	AGTTTTATTG T K N	ACTGCATTAT V A N	TTGAAAGTTT N S L K	GTCGAATAAT D F L	780
CTGTCGTTTT R D N	TATTTTTTGT K N K T	AAATTCATGC F E H	AAAAAAAATA L F F	ATGTATCATT L T D N	GTCAATTGGT D I P	840
ATATTTCTGA I N R	TACTACTTTT I S S K	GTTTTTTGTT N K T	GGCAGGTATC P L Y	TTTGGTTGAA R Q N F	ATGATAATCC H Y D	900
CAAGTTTTAT W T K	TAATTGATAA N I S L	ATATTTGTTA Y K N	GTGTAATCAA T Y D	TATCATTAAC I D N V	TGTTAAACCT T L G	960
AAACATTCAG L C E	CGAAGCGCAT A F R M	GCCAGTTTTA	GCGATGAGGT	ATAACGCTGC	ATACGATTGA	1020
TGTTGTGATT		AATTTTTATC	AAGCGTAAGT	ATTCATTGGT	TTCAAGAAAT	1080
			CTTTAACCTT			
			ATACGCAGGC			
GCTTTACTGT	ATCTTGCACA	TGCGTTTGAC	ጥ ልምል አጥር አጥጥ	TATCACTECT	TC A TA T T T T T A	1000

TGGAAGTAAT	ATTGCAAAGT	AATATATTTC	CTATTATATG	TTTATACGAT	ATTCGATATT	1320
CCCACCCGTT	GTCGCGTTTA	CGGAAATACG	CCATTGATAT	ACTCCACATT	AGCTAAAGAA	1380
CAGGGTGTTC	AAGGCTACCT	TGATGGAAAA	GGCTCTCTTA	GAGATATTTG	TAAATGGTAT	1440
GATATCTCAA	GTCGCTCTGT	TCTCCAAAAG	TGGATAAAAC	GGTATACTAG	TGGTGAAGAC	1500
TTGAAAGCCA	CTAGTAGAGG	ATATAGCCGT	ATGAAACAAG	GAAGGCAAGC	CACATTTGAA	1560
GAACGTGTAG	AGATTGTTAA	CTACACCATT	GCCCATGGGA	AAGACTATCA	AGCAGCTATT	1620
GAGAAGTTTG	GTGTTTCCTA	CCAACAAATT	TATTCTTGGG	TGCGTAAGCT	TGAGAAGAAT	1680
GGCTCACAAG	GTTTGGTTGA	TAGACGTGTG	AAAGGGTTGG	AGAGTAGGCC	TGATTTAACC	1740
GAGATTGAGC	AACTTTAACT	CAAGATTAAA	CAATTGGAGG	AACGTAATCG	TCTCTTAGAA	1800
ATCGAGGTTA	GTTTACTAAA	AAAGTTAGAA	GACATCAAAC	GAGGAAACAG	ACGGTAAGAC	1860
TAGGTAAGCA	TTTAGCGGAG	TTCCAAGTAA	TCAAGAATTA	TTACGATGAG	GAATCTAATG	1920
TGCCTATTCA	GGCCTTATGC	CAACTCTTGA	AGGGGTCTCG	TTCAGGCTAT	TACAAGTGGC	1980
TCAATCGTCA	AAAAACAGAT	TTTGAGACAA	AAAATACAAA	GCTAATGGCT	AAAATCAAGG	2040
AACTTCGTAG	ACTCTACAAT	GGTATCTTAG	GTTATCGCCG	TATGACAACA	TTTATTAATC	2100
GTCAACTTGG	GACAACTTAA	AACAAGAAAC	GGATTCGTTG	ATTGATGAAC	ATTCTGGGGA	2160
TTAGTTCAGT	CATTCGTCGT	GTTAGCCATG	CTTGTACAAA	AGCTGGTGAC	AGATTTTACG	2220
AAGAAAATAT	TCTTAATCGT	GAATTTACAG	CCACAGCTCA	TAACCAGAAA	TGGTGCACAG	2280
ATGTCACCTA	TCTTCAATAC	GGTCTGGGAG	CTAAAGCTTA	TCTCAGTGCG	ATTAAAGACC	2340
TGTATAACGG	TTCTATTATC	GCTTATGAGA	TTAGTCACAA	CAATGAAATC	CACTTGTTAT	2400
GAAGACCATT	AAAAAGGGGC	TAGAGCTCAA	TCCAGGAGCC	ACACCTATCA	TCCATAGCGA	2460
TTGAGGTAGT	CAATATACTT	CCAAAGAATA	CCGTTATATC	ATACAACAAG	CTGGTCTGAC	2520
CTTATCCATG	TCCCGGATTG	GCAAATGTAT	TGATAATGCA	CCAACTGAAA	GTTTCTTTGG	2580
GTTTTTCAAG	ACTGAGTCTT	ACCACCTTAA	GAAATACAAC	TCTTATGATG	AGTTGGTCAA	2640
TGATGTGGCA	CGTTATATCG	AATTCTACAA	CACACAACGT	TATCAATCAA	AATTAAACAA	2700
CCTGACTCCT	CTAGAATTCA	GGAATCAGGT	TGCATAACTT	ATCTTTTATT	ATTTGACTGT	2760
CTACTTGACA	GGGAGCCGTT	CAGATTGCTT	AACCTTTCTA	AATTTGCTAA	AATAGCTACA	2820
AGAAAACGAG	CCATTTAATG	CTTATTTCTT	ATACTGTCTT	GCCTCACGCT	CTCCTCGACC	2880
AAAAATTGAG	CGTGAGGCTT	TTTGTTTCAT	TAAACGATGA	TATTTCCATA	TTCATCAGTT	2940
TGTTTTCCGA	GAGCCATCAA	AGCTTCGATA	AGGTCGATAA	TTCCAGGAAT	AAAGGTAATA	3000
СТАААААТАА	TATATAAAAA	AACCTGGCCT	ATTTTTCCTG	CGTAAAATTT	ATGCGCTCCA	3060
ATGCCGCCCA	AAAGAACGTT	AATAAAACAT	AAACTACTAT	GTTAGCATAA	GACTTTATTT	3120

TTACAACTG	A ATTTCATATA	AATGGATTA	G AGTAAGGGA'	r aaaagaaati	AGCATAGCTC	3180
TTTTGAAAA	ATTAAAAAAT	ATATAATATO	GAAAAAATT	TATTTCATAA	ACGTTTCATA	3240
AAAGGTATG:	r aatctagtat	' TTAGGCAAC <i>I</i>	A CTATTTTGT	C ACTGGTGTCT	' AGTAACTTAT	3300
AGATTGATA	A TTTTACTAGT	' AAACGTAATI	CTTCGCTTT	A AGAGTTAAAT	GTCTATTTAT	3360
TGTAAGCTA	ATTGGGAGGT	GAACTTATGT	AAAATTAGA	AGGTACTGTC	AAGTACGGGA	3420
TGATTATTG	AACAGCCAGT	ATGCATCATA	AAATCTGTA	TGCTTAATAA	CTATTTCCTT	3480
AACCAGACAT	CAGTTCATTG	TTTATCATCG	CTACCCTAAC	TCTAGTTTTT	TCAATAGAGC	3540
ATTAGGTAGT	TTTTGATAAT	AAAACTATAT	' AAACATGAG <i>A</i>	ATTAGATTTC	GTATTGCATT	3600
CTTCATAATG	AGTTATTTGA	GATTTTCCTT	' TGAATAAAT <i>A</i>	GATACGAAAT	TCAGTAACTT	3660
CATATATAAA	CGGCTCTATC	ATTGAGATAG	TTTGTCAAA1	GAAGAAATTT	TTAATGGAAA	3720
TAGTTTTAAA	AACATTAGTT	GTAGGCGATG	TTATAAAAT	AATCCAGTGG	ATGCAATAGT	3780
TGCGGAGTAA	AAATAGAGAG	GAGTAATTAG	GAAGTGATAA	AAAATGCTAT	AGCATATATT	3840
ACCAGAAAAA	AAAATAGAAC	ACTTATTATA	TTTGCTATTT	TAACAATTGT	TCTTTCTTGC	3900
TTGTATTCAT	GTTTAACAAT	AATGAAATCA M K S	AGTAATGAAA S N E I		TTTATATGAA L Y E	3960
AGTTCTAATT S S N S	CTTCAATATC S I S		AAAGATGGTA K D G K	AATATTTTAA Y F N	TATTAATCAA I N Q	4020
TTTAAGAATA F K N I	TTGAAAAAAT E K I	AAAAGAGGTT K E V	GAAGAAAAA E E K I		TGATGGATTA D G L	4080
GCAAAATTGA A K L K	AAGATCTTAA D L K	AGTAGTTAGT V V S	GGTGAGCAAA G E Q S	GTATAAATAG I N R	AGAAGATTTA E D L	4140
TCTGACGAAT S D E F	TTAAAAATGT K N V	TGTTTCACTA V S L	GAAGCTACAA E A T S	GTAATACTAA N T K	AAGAAATCTT R N L	4200
TTATTTAGTA L F S S	GTGGAGTATT G V F	TAGTTTTAAA S F K	GAAGGAAAAA E G K N	ATATAGAAGA I E E	AAATGATAAG N D K	4260
AATTCAATTC N S I L	TTGTTCATGA V H E	AGAATTTGCT E F A	AAACAAAACA K Q N K		GGGTGATGAA G D E	4320
ATTGATCTTG I D L E	ÀATTACTAGA L L D	TACGGAAAAA T E K	AGTGGAAAAA S G K I	TAAAAAGTCA K S H	TAAATTTAAA K F K	4380
ATTATAGGAA I I G I	TCTTTTCTGG F S G	TAAAAAACAG K K Q	GAAACATATA E T Y T	CAGGATTATC G L S	ATCTGATTTT S D F	4440
AGCGAAAATA S E N M	TGGTTTTTGT V F V	AGATTATTCA D Y S	ACTAGCCAAG T S Q E	AAATATTAAA I L N	TAAATCAGAG K S E	4500
AATAATAGAA N N R I	TTGCAAATAA A N K	AATTTTAATG I L M	TATTCTGGTA Y S G S	GTTTAGAATC L E S	TACAGAGCTT T E L	4560
GCCTTAAACA	AATTGAAAGA	CTTTAAAATT	GATAAGTCAA	AGTATTCTAT	TAAGAAAGAT	4620

A L N K	L K D F K 1	т ркзк узт ккг)
AATAAAGCAT N K A F		CA GTGAGTGGAA TAAAACATAT AATTAAAA S V S G I K H I I K 1	
ATGACTTATT M T Y S	CGATTATGTT AGGTGGAA	ATA GTTGTTCTTT CATTAATCTT GATTCTAT	
TTAAGAGAAA L R E R		TA TTTTTATCTA TTGGAACAAC TAAGATAC F L S I G T T K I C	
ATTATAAGGC I I R Q	AATTTATATT TGAGTTAF F I F E L I	TTA TTCATATCAA TACCAAGTAT AATATCCT	
TTATTTTAG	GGAATCTACT ATTAAAAG	TA ATTGTAGAAG GATTTATTAA CTCAGAGA	
L F L G	N L L L K V	' I V E G F I N S E N	
TCAATGATTT	TCGGTGGAAG TTTAATAA	AT AAAAGCAGTT TTATGTTAAA CATAACAA	
S M I F	G G S L I N	I K S S F M L N I T T	
CTTGCAGAAA L A E S	GTTATTTAAT ATTAATAA Y L I L I S	GT ATTATTGTTT TATCAGTTGT AATGGCCT	
TCATTAATAT	TATTTAAGAA ACCACAAG	AA ATATTATCAA AAATAAGTTA GGAGCAAA	TA 5100
S L I L	F K K P Q E	I L S K I S .	
ATGGATATAT M D I L >		AT TACAGTTACG CAAATTCTAA AGAAAAAG Y S Y A N S K E K V	
TTGTCAGGAG	TAAATCAAAA ATTTGAAC	TT GGAAAGTTTT ATGCGATAGT AGGGAAGT	
L S G V	N Q K F E L	G K F Y A I V G K S	
GGAACAGGAA	AATCCACACT TCTTTCCT	TA CTTGCAGGAC TTGATAAAGT TCAAACAG	
G T G K	S T L L S L	L A G L D K V Q T G	
AAAATCTTGT	TTAAGAATGA AGATATAG	AA AAGAAAGGAT ATAGTAATCA CAGAAAAA	
K I L F	K N E D I E	K K G Y S N H R K N	
AATATATCTT	TGGTATTTCA AAATTATA	AT TTAATAGATT ATTTATCGCC GATTGAAA	
N I S L	V F Q N Y N	L I D Y L S P I E N	
ATTAGACTAG	TAAATAAATC AGTAGATG	AG AGTATCTTGT TCGAATTAGG TTTAGATA	
I R L V	N K S V D E	S I L F E L G L D K	
AAACAAATAA	AAAGAAATGT TATGAAAT	TA TCTGGTGGTC AGCAACAAAG GGTAGCTA	
K Q I K	R N V M K L	S G G Q Q Q R V A I	
GCTAGGGCAC A R A L	TGGTATCAGA TGCCCCAA V S D A P I	TA ATACTAGCTG ATGAGCCTAC CGGTAACC	
	CTGCTGGAGA AATAATT A G E I I.	(SEQ ID NO:27)	5607

FIG. 5a

IQSLTEGQLR	SDIPEFRAGD	TVRVHAKVVE	GTRERIQIFE	GVVISRKGQG	50
ISEMYTVRKI	SGGIGVERTF	PIHTPRVDKI	EVVRYGKVRR	AKLYYLRALQ	100
GKAARIKEIR	R (SEQ ID	NO:28)			111
		FIG. 5	b b		
		LSINKTWDYH			50
		KLSNNAVNKT			100
		YAHQLQEQKD		GQNSSKPLFT	150
CNEYVPCRNR	TSNYSLGGSC	YIH (SEQ	ID NO:29)		173
		FIG. 5			
		rig. 5	OC .		
MKSSNEIEKA	LYESSNSSIS	ITKKDGKYFN	INOFKNIEKI	KEVEEKTFOY	50
		EDLSDEFKNV			100
		EFAKQNKLKL			150
		SDFSENMVFV			200
		FKIDKSKYSI			250
IKIMTYSIML	GGIVVLSLIL	ILWLRERIYE	IGIFLSIGTT	KIQIIRQFIF	300
		LKVIVEGFIN			350
ITTLAESYLI	LISIIVLSVV	MASSLILFKK	PQEILSKIS		389
(SEQ ID NO:	:30)				
		FIG. 5	d		
		LSGVNQKFEL			50
		KKGYSNHRKN			100
		KQIKRNVMKL	SGGQQQRVAI	ARALVSDAPI	150
ILADEPTGNL	DSVTAGEII	(SEQ ID NO:	31)		169

FIG. 5e

CATATGACAA	TATTTTTCAA	AGTCTACATC	ACTTACTCGC	CTGTCGTGGA	AAATCTGGCA	60
ATACATTAAT	CGACCAATTA	GTTGCTGATG	GTTTACTTCA	TGCAGATAAT	CACTACCATT	120
TTTTCAATGG	GAAGTCTCTG	GCCACTTTCA	ATACTAACCA	ATTGATTCGC	GAAGTTGTCT	180
ATGTTGAAAT	ATCCTTAGAT	ACTATGTCTA	GTGGTGAACA	TGATTTAGTA	AAAGTTAACA	240
TTATCAGACC	CACTACCGAG	CATACTATCC	CCACGATGAT	GACAGCTAGC	CCCTATCATC	300
AAGGTATCAA	TGATCCTGCC	GCAGACCAAA	AAACATACCA	AATGGAGGGT	GCGCTAGCAG	360
TTAAACAGCC	TAAACACATA	CAAGTTGACA	CAAAACCATT	TAAAGAAGAA	GTAAAACATC	420
CTTCAAAATT	ACCCATCAGC	CCTGCAACTG	AAAGCTTCAC	ACACATTGAC	AGTTATAGTC	480
TCAATGACTA	TTTTCTTTCT	CGTGGTTTTG	CTAATATATA	CGTTTCAGGT	GTGGGTACTG	540
CTGGCTCTAC	GGGTTTCATG	ACCAGTGGGG	ATTACCAACA	AATACAAAGC	TTTAAAGCAG	600
TCATTGATTG	GTTAAATGGT	AAGGTTACTG	CATTCACAAG	TCATAAACGA	GATAAACAAG	660
TCAAGGCTGA	TTGGTCAAAC	GGCCTTGTAG	CAACCACAGG	TAAATCTTAT	CTCGGTACCA	720
TGTCAACTGG	TTTAGCAACA	ACTGGCGTTG	AGGGGCTGAA	AGTCATTATC	GCTGAAGCCG	780
CAATCTCCAC	ATGGTATGAT	TATTATCGAG	AAAATGGGCT	TGTGTGTAGT	CCAGGCGGCT	840
ACCCCGGTGA	AGATTTAGAC	GTTTTAACAG	AATTAACATA	CTCACGAAAC	CTCTTAGCTG	900
	CAAAAACAAC					960
TTGACCGTCA	AAGTGGGGAT	TACAACCAAT	ACTGGCATGA	CCGTAATTAC	CTAACTCACG	1020
	CAAAAGTCGA					1080
CAAGACATGT	CTACAAAGTT	TTCAATGCAT	TGCCTCAAAC	CATCAAAAA	CACCTTTTTT	1140
TACATCAAGG	TCAACATGTG	TATATGCATA	ATTGGCAGTC	GATTGATTTT	CGTGAAAGCA	1200
	ACTAAGCCAA					1260
TCATTTGGCA	AGATAATACT	ACTGAGCAAA	CTTGGCAAGT	TTTAGATGCT	TTCGGAGGAA	1320
ACCATCAAGA	GCAAATTGGT	TTAGGTGATA	GTAAAAAACT	TATTGATAAC	CATTATGACA	1380
	TGATACTTAT					1440
GAAATAATAA	AACCAATCAA	ATCACTATTA	ATCTTCCTCT	AAAGAAAAAT	TATCTCCTGA	1500
ATGGACAGTG	CAAACTCCAT	CTACGTGTTA	AAACTAGTGA	CAAAAAGGCC	ATTTTATCAG	1560
CCCAAATCTT	AGACTATGGT	CCTAAAAAAC	GATTCAAAGA	TACACCAACC	ATCAAATTCT	1620
TAAACAGCCT	TGATAATGGT	AAAAATTTTG	CCAGAGAAGC	TTTACGTGAA	CTCCCGTTTA	1680
	TTATCGTGTC					1740
	TGAGGCTATC					1800
	TCAATTGAGT					1860
	CATTCGAGAT					1920
	CCCAACTAAT					1980
	TCAACACTTT					2040
	CCATGATAAT					2100
	CGGAAGTTCG					2160
	TGCTCATTTA					2220
	CAATTTAATA					2280
	CGATACCCTA					2340
AACGCGAGGG	AGACTGATTA	ATGTCATCTT	ATTGGAATAA	CTATCCTGAA	CTTAAAAAAA	2400

ATATTGATGA	AACCAATCAA	CTAATTCAAG	AAAGAATACA	GGTCAGAAAT	AAAGATATTG	2460
				GCTCAGACCA		2520
ACCTTTTTTC	TCAACTTGGT	AATAAGGAGA	ATCAAGATAC	TCAGCAACTA	AAGAAAATCG	2580
	AGAAATCCTT			TGATGATGTC		2640
CACCACTAAG	ACGTGGAAAT	ATGACCATTC	AAAGCAAGTT	TGGCAAAGAC	ATCGCAGTTT	2700
ATACTGGGGA	TTTACTTTTC	ACAGTCTTTT	TCGATCTTAT	TTTAGAATCT	ATGACTGATA	2760
CACCATTTAT	GAGGATTAAT	GCAAAATCTA	TGCGTAAAAT	TCTCATGGGA	GAATTGGACC	2820
AGATGCACCT	TCGTTACAAT	CAACAACAAG	GTATCCATCA	CTATTTACGT	GCGATTTCAG	2880
GTAAGACAGC	CGAACTCTTT	AAATTAGCTA	GCAAAGAAGG	AGCTTACTTT	GGTGGTGCAG	2940
AGAAGGAGGT	TGTTCGTCTA	GCAGGCCATA	TCGGCTTTAA	CATTGGTATG	ACATTCCAAA	3000
TTTTGGATGA	TATCCTGGAT	TATACTGCAG	ATAAAAAAAC	ATTTAATAAG	CCTGTCTTAG	3060
AGGATTTAAC	ACAAGGCGTT	TACAGCCTTC	CTCTACTTCT	TGCCATTGAA	GAAAATCCTG	3120
ATATTTTCAA	ACCTATTTTA	GATAAAAAA	CAGATATGGC	TACTGAAGAC	ATGGAAAAA	3180
TTGCTTATCT	CGTCGTTTCC	CATAGAGGTG	TTGACAAAGC	TCGCCATCTA	GCTCGTAAAT	3240
TTACTGAGAA	AGCTATTAGT	GACATAAATA	AGCTACCCCA	GAACTCTGCA	AAAAAACAGT	3300
				AATAATAAA		3360
CAATGCTAGA	AAAGCAGTTA	GGGAATGTTT	TTTTATTATC	ATTTATTTAT	CGCACCTATC	3420
AATCATCATA	GATCACCATC	ATCAGCGGCT	TTCAGCTGAC	GGTAACGTTG	ACTACTTTGA	3480
GACAATTCTT	GAGGAGAACC	TTCCAACTCT	AATTGCCCAT	TTTCTATAAA	TAAGATACGA	3540
TCAGCATGTT	CAATACCTTT	TAAGTGATGT	GTAATCCAAA	CTAAGGTCTT	ACCTTCCAAT	3600
TCTTTCATAA				GATCAAGTCC		3660
				TAGCCAAAGC		3720
				TTGTATAGAG		3780
				CTTTCCATAC		3840
				TTGTATTAAA		3900
GCTTGTTGTA	TCACTCCAAT	ATAGTTAGAA	ATGCAATCAC	CAACTATTGA	AACATCAGCA	3960
				CACGAAGTAG	ACTAGCTAAG	4020
GTACTCTTGC					TTTAATATCC	4080
	and the second s			ACTGGAAACT	TAAATTCTTG	4140
ACGGAAAAAT	CATATGGCTT	ATTAGGCAAT	T (SEQ ID	NO:32)		4171

FIG. 6a

PCT/CA99/00114 WO 99/42588

YDNIFQSLHH	LLACRGKSGN	TLIDQLVADG	LLHADNHYHF	FNGKSLATFN	50
TNQLIREVVY	VEISLDTMSS	GEHDLVKVNI	IRPTTEHTIP	TMMTASPYHQ	100
GINDPAADQK	TYQMEGALAV	KQPKHIQVDT	KPFKEEVKHP	SKLPISPATE	150
SFTHIDSYSL	NDYFLSRGFA	NIYVSGVGTA	GSTGFMTSGD	YQQIQSFKAV	200
IDWLNGKVTA	FTSHKRDKQV	KADWSNGLVA	TTGKSYLGTM	STGLATTGVE	250
GLKVIIAEAA	ISTWYDYYRE	NGLVCSPGGY	PGEDLDVLTE	LTYSRNLLAG	300
DYIKNNDCYQ	ALLNEQSKAI	DRQSGDYNQY	WHDRNYLTHV	NNVKSRVVYT	350
HGLQDWNVKP	RHVYKVFNAL	PQTIKKHLFL	HQGQHVYMHN	WQSIDFRESM	400
NALLSQELLG	IDNHFQLEEV	IWQDNTTEQT	WQVLDAFGGN	HQEQIGLGDS	450
KKLIDNHYDK	EAFDTYCKDF	NVFKNDLFKG	NNKTNQITIN	LPLKKNYLLN	500
GQCKLHLRVK	TSDKKAILSA	QILDYGPKKR	FKDTPTIKFL	NSLDNGKNFA	550
REALRELPFT	KDHYRVISKG	VLNLQNRTDL	LTIEAIEPEQ	WFDIEFSLQP	600
SIYQLSKGDN	LRIILYTTDF	EHTIRDNASY	SITVDLSQSY	LTIPTNQGN	649
(SEQ ID NO	:33)				
		FIG. 6	b		
MKLLTKERFD	DSQHFWYQIN	LLQESNFGAV	FDHDNKNIPQ	VVATIVDDLO	50
			IQVNLKDFDF		100
		(SEQ ID NO			119
		FIG. 6	С		
			KDIEAALSQL		50
			HVATLIHDDV		100
MTIQSKFGKD	IAVYTGDLLF	TVFFDLILES	MTDTPFMRIN	AKSMRKILMG	150
			KLASKEGAYF		200
AGHIGFNIGM	TFQILDDILD	YTADKKTFNK	PVLEDLTQGV	YSLPLLLAIE	250
ENPDIFKPIL	DKKTDMATED	MEKIAYLVVS	HRGVDKARHL	ARKFTEKAIS	300
DINKLPQNSA	KKQLLQLTNY	LLKRKI (SE	EQ ID NO:35)		326

FIG. 6d

326

LPNKPYDFSV	KNLSFQYKPQ	EKWVLHHLDL	DIKEGEKIAI	LGRSGSGKST	50
LASLLRGDLK	ASQGKITLGG	ADVSIVGDCI	SNYIGVIQQA	PYLFNTTLLN	100
NIRIGNQDAS	EEDVWKVLER	VGLKEMVTDL	SDGLYTMVDE	AGLRFSGGER	150
HRIALARILL	KDVPIVILDE	PTVGLDPITE	QALLRVFMKE	LEGKTLVWIT	200
HHLKGIEHAD	RILFIENGQL	ELEGSPQELS	QSSQRYRQLK	AADDGDL	247
(SEQ ID NO:	:36)				

FIG. 6e

AATTCTATTI	GGAGGTTTTT	CTTGAATAAA	TGGTTAGTTA	AGGCAAGTTC	CTTAGTTGTT	60
TTAGGTGGTA	TGGTTTTATC	TGCGGGTTCC	CGAGTTTTAG	CGGATACTTA	TGTCCGTCCA	120
	GTAGAATTAC					180
TATGCTGTTC	CGACTGGAAC	GATTATTAGG	GCAGTGGCAG	ATGGTACTGT	GAAATTTGCA	240
					CATGATTCAA	300
	GAATGCATAG					360
	AACAAGGAGA					420
CCTCACCTTC	ATTTTGAATT	TTTACCAGCT	AACCCTAATT	TTCAAAATGG	TTTCCATGGA	480
CGTATCAATC	CAACGTCACT	AATTGCTAAC	GTTGCGACCT	TTAGTGGAAA	AACGCAAGCA	540
TCAGCTCCAA	GCATTAAGCC	ATTACAATCA	GCTCCTGTAC	AGAATCAATC	TAGTAAATTA	600
AAAGTGTATC	GAGTAGATGA	ATTACAAAAG	GTTAATGGTG	TTTGGTTAGT	CAAAAATAAC	660
ACCCTAACGC	CGACTGGGTT	TGATTGGAAC	GATAATGGTA	TACCAGCATC	AGAAATTGAT	720
GAGGTTGATG	CTAATGGTAA	TTTGACAGCT	GACCAGGTTC	TTCAAAAAGG	TGGTTACTTT	780
ATCTTTAATC	CTAAAACTCT	TAAGACTGTA	GAAAAACCCA	TCCAAGGAAC	AGCTGGTTTA	840
	AGACACGCTT					900
	TTTACAAATA					960
	GTACAATTTC					1020
	GTCTCGGACT					1080
	ATTGACATCG					1140
	AGATACGACG					1200
	CAATAAATCA					1260
	GTCAATTGAT					1320
	TCCTGAGACA					1380
	AATAGAAACA					1440
	CAATCAAGTT					1500
	ACCAGAAGCA					1560
	GAAATCAAAA					1620
	GGTATCAACA					1680
	TAAACCAACT					1740
	TGAAACACCA					1800
	GGCAAGTGTT					1860
AGCATGTATC	AGCTCCAGCA	GTTCCTGTGA	CTACGACTTC	AACAGCTACA	GACAGTAAGT	1920
	TGAAGTTAAG					1980
TAGCACAACC	AGCTTCAACA	ACAAATGCAG	TAGCTGCACA	TCCTGAAAAT	GCAGGGCTCC	2040
AACCTCATGT	TGCAGCTTAT	AAAGAAAAAG	TAGCGTCAAC	TTATGGAGTT	AATGAATTCA	2100
GTACATACCG	TGCAGGTGAT	CCAGGTGATC	ATGGTAAAGG	TTTAGCAGTC	GACTTTATTG	2160
TAGGTAAAAA	CCAAGCACTT	GGTAATGAAG	TTGCACAGTA	CTCTACACAA	AATATGGCAG	2220
CAAATAACAT	TTCATATGTT	ATCTGGCAAC	AAAAGTTTTA	CTCAAATACA	AATAGTATTT	2280
ATGGACCTGC	TAATACTTGG	AATGCAATGC	CAGATCGTGG	TGGCGTTACT	GCCAACCATT	2340
ATGACCATGT	TCACGTATCA	TTTAACAAAT	AATATAAAAA	AGGAAGCTAT	TTGGCTTCTT	2400

TTTTATATGC CTTGAATAG	A CTTTCAAGGT	TCTTATCTAA	TTTTTATTAA	ATTGAGGAGA	2460
TTAAGCTATA AGTCTGAAA	C TACTTTCACG	TTAACCGTGA	CTAAATCAAA	ACGTTAAAAC	2520
TAAAATCTAA GTCTGTAAA	G ATTATTGAAA	ACGCTTTAAA	AACAGATATA	ATAAGGTTTG	2580
TAGATATCTA AAATTAAAA	A AGATAAGGAA	GTGAGAATAT	GCCACATCTA	AGTAAAGAAG	2640
CTTTTAAAAA GCAAATAAA	A AATGGCATTA	TTGTGTCATG	TCAAGCTTTG	CCTGGGGAGC	2700
CTCTTTATAC TGAAAGTGG	A GGTGTTATGC	CTCTTTTAGC	TTTGGCAGCT	CAAGAAGCAG	2760
GAGCGGTTGG TATAAGAGC	C AATAGTGTCC	GCGACATTAA	GGAAATTCAA	GAAGTTACTA	2820
ATTTACCTAT CATCGGCAT	r attaaacgtg	AATATCCTCC	ACAAGAACCA	TTTATCACTG	2880
CTACGATGAC AGAGGTGGA	CAATTAGCTA	GTTTAGATAT	TGCAGTAATA	GCCTTAGATT	2940
GTACACTTAG AGAGCGTCA	GATGGTTTGA	GTGTAGCTGA	GTTTATTCAA	AAGATAAAAG	3000
GGAAATATCC TGAACAGTT	G CTAATGGCTG	ATATAAGTAC	TTTTGAAGAA	GGTAAAAATG	3060
CTTTTGAAGC AGGAGTTGA	TTTGTGGGTA	CAACTCTATC	TGGATACACA	GATTACAGCC	3120
GCCAAGAAGA AGGACCGGA	T ATAGAACTCC	TTAATAAGCT	TTGTCAAGCC	GGTATAGATG	3180
TGATTGCGGA AGGTAAAAT	CATACTCCTA	AGCAAGCTAA	TGAAATTAAT	CATATAGGTG	3240
TTGCAGGAAT TGTAGTTGG	GGTGCTATCA	CTAGACCAAA	AGAAATAGCG	GAGCGTTTCA	3300
TCTCAGGACT TAGTTAAAA	G TGTTACTCAA	AAATCAAAAT	CAAAATAAAA	AAGGGGAATA	3360
GTTATGAGTA TCAAAAAA	G TGTGATTGGT	TTTTGCCTCG	GAGCTGCAGC	ATTATCAATG	3420
TTTGCTTGTG TAGACAGTA	TCAATCTGTT	ATGGCTGCCG	AGAAGGATAA	AGTCGAAATT	3480
(SEQ ID NO:37)					

FIG. 7a

NSIWRFFLNK	WLVKASSLVV	LGGMVLSAGS	RVLADTYVRP	IDNGRITTGF	50
NGYPGHCGVD	YAVPTGTIIR	AVADGTVKFA	GAGANFSWMT	DLAGNCVMIQ	100
HADGMHSGYA	HMSRVVARTG	EKVKQGDIIG	YVGATGMATG	PHLHFEFLPA	150
NPNFQNGFHG	RINPTSLIAN	VATFSGKTQA	SAPSIKPLQS	APVQNQSSKL	. 200
KVYRVDELQK	VNGVWLVKNN	TLTPTGFDWN	DNGIPASEID	EVDANGNLTA	250
DQVLQKGGYF	IFNPKTLKTV	EKPIQGTAGL	TWAKTRFANG	SSVWLRVDNS	300
QELLYK (S	SEQ ID NO:38	3)			306

FIG. 7b

PCT/CA99/00114 WO 99/42588

MKMNKKVLLT	STMAASLLSV	ASVQAQETDT	TWTARTVSEV	KADLVKQDNK	50
SSYTVKYGDT	LSVISEAMSI	DMNVLAKINN	IADINLIYPE	TTLTVTYDQK	100
SHTATSMKIE	TPATNAAGQT	TATVDLKTNQ	VSVADQKVSL	NTISEGMTPE	150
AATTIVSPMK	TYSSAPALKS	KEVLAQEQAV	SQAAANEQVS	TAPVKSITSE	200
VPAAKEEVKP	TQTSVSQSTT	VSPASVAAET	PAPVAKVAPV	RTVAAPRVAS	250
VKVVTPKVET	GASPEHVSAP	AVPVTTTSTA	TDSKLQATEV	KSVPVAQKAP	300
TATPVAQPAS	TTNAVAAHPE	NAGLQPHVAA	YKEKVASTYG	VNEFSTYRAG	350
DPGDHGKGLA	VDFIVGKNQA	LGNEVAQYST	QNMAANNISY	VIWQQKFYSN	400
TNSIYGPANT	WNAMPDRGGV	TANHYDHVHV	SFNK (SEQ	ID NO:39)	434
		FIG. 7	С		
MPHLSKEAFK	KQIKNGIIVS	CQALPGEPLY	TESGGVMPLL	ALAAQEAGAV	50
GIRANSVRDI	KEIQEVTNLP	IIGIIKREYP	PQEPFITATM	TEVDQLASLD	100
IAVIALDCTL	RERHDGLSVA	EFIQKIKGKY	PEQLLMADIS	TFEEGKNAFE	150
AGVDFVGTTL	SGYTDYXRQE	EGPDIELLNK	LCQAGIDVIA	EGKIHTPKQA	200
NEINHIGVAG	IVVGGAITRP	KEIAERFISG	LS (SEQ ID	NO:40)	232
		FIG. 7	d		
MSIKKSVIGF	CLGAAALSMF	ACVDSSQSVM	AAEKDKVEI		39

FIG. 7e

(SEQ ID NO:41)

39

ATGAAAATGA	ATAAAAAGGT	ACTATTGACA	TTCC3 C3 3 TTCC	G3 G G G G G G G G G G G G G G G G G G	
ATTATCAGTC					50
	GCAAGTGTTC	AAGCACAAGA	AACAGATACG		100
CACGTACTGT	TTCAGAGGTA		TGGTAAAGCA	AGACAATAAA	150
TCATCATATA	CTGTGAAATA	TGGTGATACA	CTAAGCGTTA	TTTCAGAAGC	200
AATGTCAATT	GATATGAATG	TCTTAGCAAA	AATTAATAAC	ATTGCAGATA	250
TCAATCTTAT	TTATCCTGAG	ACAACACTGA	CAGTAACTTA	CGATCAGAAG	300
AGTCATACTG	CCACTTCAAT	GAAAATAGAA	ACACCAGCAA	CAAATGCTGC	350
TGGTCAAACA	ACAGCTACTG	TGGATTTGAA	AACCAATCAA	GTTTCTGTTG	400
CAGACCAAAA	AGTTTCTCTC	AATACAATTT	CGGAAGGTAT	GACACCAGAA	450
GCAGCAACAA	CGATTGTTTC	GCCAATGAAG	ACATATTCTT	CTGCGCCAGC	500
TTTGAAATCA	AAAGAAGTAT	TAGCACAAGA	GCAAGCTGTT	AGTCAAGCAG	550
CAGCTAATGA	ACAGGTATCA	ACAGCTCCTG	TGAAGTCGAT	TACTTCAGAA	600
GTTCCAGCAG	CTAAAGAGGA	AGTTAAACCA	ACTCAGACGT	CAGTCAGTCA	650
GTCAACAACA	GTATCACCAG	CTTCTGTTGC	CGCTGAAACA	CCAGCTCCAG	700
TAGCTAAAGT	AGCACCGGTA	AGAACTGTAG	CAGCCCCTAG	AGTGGCAAGT	750
GTTAAAGTAG	TCACTCCTAA	AGTAGAAACT	GGTGCATCAC	CAGAGCATGT	800
ATCAGCTCCA	GCAGTTCCTG	TGACTACGAC	TTCAACAGCT	ACAGACAGTA	850
AGTTACAAGC	GACTGAAGTT	AAGAGCGTTC	CGGTAGCACA		900
ACAGCAACAC	CGGTAGCACA	ACCAGCTTCA	ACAACAAATG	CAGTAGCTGC	950
ACATCCTGAA	AATGCAGGGC	TCCAACCTCA	TGTTGCAGCT	TATAAAGAAA	1000
AAGTAGCGTC	AACTTATGGA	GTTAATGAAT	TCAGTACATA	CCGTGCAGGT	1050
GATCCAGGTG	ATCATGGTAA	AGGTTTAGCA	GTCGACTTTA	TTGTAGGTAA	1100
AAACCAAGCA	CTTGGTAATG	AAGTTGCACA	GTACTCTACA	CAAAATATGG	1150
CAGCAAATAA	CATTTCATAT	GTTATCTGGC	AACAAAAGTT	TTACTCAAAT	1200
ACAAATAGTA	TTTATGGACC	TGCTAATACT	TGGAATGCAA	TGCCAGATCG	
TGGTGGCGTT	ACTGCCAACC	ATTATGACCA	TGTTCACGTA	TCATTTAACA	1250
AATAA		OACCA	TGIICACGIA	ICALITAACA	1300
					1305

(SEQ ID NO:42)

FIG. 8


CAAGAAACAG		GACAGCACGT	ACTGTTTCAG	AGGTAAAGGC	50
TGATTTGGTA	· · · · · · · · · · · · · · · · · · ·	ATAAATCATC	ATATACTGTG	AAATATGGTG	100
ATACACTAAG		GAAGCAATGT	CAATTGATAT	GAATGTCTTA	150
GCAAAAATTA	ATAACATTGC	AGATATCAAT	CTTATTTATC	CTGAGACAAC	200
ACTGACAGTA	ACTTACGATC	AGAAGAGTCA	TACTGCCACT	TCAATGAAAA	250
TAGAAACACC	AGCAACAAAT	GCTGCTGGTC	AAACAACAGC	TACTGTGGAT	
TTGAAAACCA	ATCAAGTŢTC	TGTTGCAGAC	CAAAAAGTTT	CTCTCAATAC	300
AATTTCGGAA	GGTATGACAC	CAGAAGCAGC	AACAACGATT	GTTTCGCCAA	350
TGAAGACATA	TTCTTCTGCG	CCAGCTTTGA	AATCAAAAGA	AGTATTAGCA	400
CAAGAGCAAG	CTGTTAGTCA	AGCAGCAGCT	AATGAACAGG	TATCAACAGC	450
TCCTGTGAAG	TCGATTACTT	CAGAAGTTCC	AGCAGCTAAA	GAGGAAGTTA	500
AACCAACTCA	GACGTCAGTC	AGTCAGTCAA	CAACAGTATC	ACCAGCTTCT	550
GTTGCCGCTG	AAACACCAGC	TCCAGTAGCT	AAAGTAGCAC	CGGTAAGAAC	600
TGTAGCAGCC	CCTAGAGTGG	CAAGTGTTAA	AGTAGTCACT	CCTAAAGTAG	650
AAACTGGTGC	ATCACCAGAG	CATGTATCAG	CTCCAGCAGT	TCCTGTGACT	700
ACGACTTCAA	CAGCTACAGA	CAGTAAGTTA	CAAGCGACTG	AAGTTAAGAG	750
CGTTCCGGTA	GCACAAAAAG	CTCCAACAGC	AACACCGGTA	GCACAACCAG	800
CTTCAACAAC	AAATGCAGTA	GCTGCACATC	CTGAAAATGC		850
CCTCATGTTG	CAGCTTATAA	AGAAAAAGTA	GCGTCAACTT	AGGGCTCCAA	900
TGAATTCAGT	ACATACCGTG	CAGGTGATCC		ATGGAGTTAA	950
TAGCAGTCGA	CTTTATTGTA	GGTAAAAACC	AGGTGATCAT	GGTAAAGGTT	1000
GCACAGTACT	CTACACAAAA	TATGGCAGCA	AAGCACTTGG	TAATGAAGTT	1050
CTGGCAACAA	AAGTTTTACT	·	AATAACATTT	CATATGTTAT	1100
ATACTTGGAA	TGCAATGCCA	CAAATACAAA	TAGTATTTAT	GGACCTGCTA	1150
GACCATGTTC	ACGTATCATT	GATCGTGGTG	GCGTTACTGC	CAACCATTAT	1200
GACCAIGIIC	ACGIATCATT	TAACAAATAA	(SEQ ID	NO:43)	1230

FIG. 9

QETDTTWTAR	TVSEVKADLV	KQDNKSSYTV	KYGDTLSVIS	EAMSIDMNVL	50
AKINNIADIN	LIYPETTLTV	TYDQKSHTAT	SMKIETPATN	AAGQTTATVD	100
LKTNQVSVAD	QKVSLNTISE	GMTPEAATTI	VSPMKTYSSA	PALKSKEVLA	150
QEQAVSQAAA	NEQVSTAPVK	SITSEVPAAK	EEVKPTQTSV	SQSTTVSPAS	200
VAAETPAPVA	KVAPVRTVAA	PRVASVKVVT	PKVETGASPE	HVSAPAVPVT	250
TTSTATDSKL	QATEVKSVPV	AQKAPTATPV	AQPASTTNAV	AAHPENAGLQ	300
	ASTYGVNEFS				350
AQYSTQNMAA	NNISYVIWQQ	KFYSNTNSIY	GPANTWNAMP	DRGGVTANHY	400
DHVHVSFNK	(SEQ ID NO:	44)			409

FIG. 9a

Fig. 10



1 / 63

SEQUENCE LISTING

```
<110> BioChem Vaccins
            RIOUX, Clément
            DENIS, Martin
            BRODEUR, Bernard R.
            HAMEL, Josée
            CHARLEBOIS, Isabelle
            BOYER, Martine
      <120> NOVEL GROUP B STREPTOCOCCUS ANTIGENS
     <130> 12806-9PCT
     <150> 60/075,425
     <151> 1998-02-20
     <160> 44
     <170> FastSEQ for Windows Version 3.0
     <210> 1
     <211> 4514
     <212> DNA
     <213> Streptococcus
     <220>
     <221> CDS
     <222> (3)...(464)
     <221> CDS
     <222> (534)...(887)
     <223>
     <221> CDS
     <222> (1024)...(1767)
     <221> CDS
     <222> (1841) . . . (4288)
     <221> CDS
     <222> (2735)...(4288)
     <400> 1
ta tot ggc aaa gag coa got aat ogt ttt agt tgg got aaa aat aaa
                                                                     47
  Ser Gly Lys Glu Pro Ala Asn Arg Phe Ser Trp Ala Lys Asn Lys
```

10

15

					ttc Phe											95
					ata Ile											143
					ttg Leu		_			_	_	_		_		191
_		-			gat Asp							_				239
				-	ctt Leu 85				_						_	287
					ttt Phe											335
					tta Leu						_	_		-	_	383
					atg Met						_		_	_		431
					tat Tyr						taat	agaa	aag t	tatct	agtga	484
taga	actaa	aca g	gtat	gatai	cg gt	catgt	caaa	a gta	attta	agga	ggag	gaaga		et Se	ct act er Thr	542
			Ile		gca Ala		Leu	Thr								590
					tta Leu											638
ttt Phe 190	agt Ser	atg Met	tct Ser	aaa Lys	gaa Glu 195	gag Glu	ttg Leu	tca Ser	tat Tyr	tta Leu 200	ccc Pro	gtt Val	att Ile	aaa Lys	ctt Leu 205	686
ttt Phe					gta Val											734

													gtt Val 235			782
			_		_	_				_	_		gtt Val	_		830
													ctt Leu			878
	tta Leu		taat	tacta	act t	cage	egtto	cg at	ttag	gttga	a acg	ggctt	tta			927
										atg	act	gag	aac aac Asn	tgg		987 1041
cat His	act Thr 280	aaa Lys	gat Asp	ggt Gly	tca Ser	gat Asp 285	att Ile	tat Tyr	tat Tyr	cgt Arg	gtc Val 290	gtt Val	ggt Gly	caa Gln	ggt Gly	1089
caa Gln 295	ccg Pro	att Ile	gtt Val	ttt Phe	tta Leu 300	cat His	gly	aat Asn	agc Ser	tta Leu 305	agt Ser	agt Ser	cgc Arg	tat Tyr	ttt Phe 310	1137
													att Ile			1185
													acc Thr 340			1233
													cat His			1281
att Ile	gat Asp 360	aaa Lys	gtt Val	ata Ile	ttg Leu	gta Val 365	ggc Gly	cat His	agc Ser	gat Asp	ggt Gly 370	gcc Ala	aat Asn	tta Leu	gct Ala	1329
tta Leu 375	gtt Val	ttt Phe	caa Gln	acg Thr	atg Met 380	ttt Phe	cca Pro	ggt Gly	atg Met	gtt Val 385	aga Arg	gly aaa	ctt Leu	ttg Leu	ctt Leu 390	1377
aat Asn	tca Ser	gly aaa	aac Asn	ctg Leu 395	act Thr	att Ile	cat His	ggt Gly	cag Gln 400	cga Arg	tgg Trp	tgg Trp	gat Asp	att Ile 405	ctt Leu	1425
													aaa Lys 420			1473

	tat Tyr															1521
	aag Lys 440															1569
	ttg Leu															1617
	gct Ala															1665
	cat His															1713
aaa Lys	aag Lys	ttt Phe 505	atc Ile	aac Asn	gat Asp	acg Thr	ttg Leu 510	aaa Lys	gga Gly	gaa Glu	att Ile	gtt Val 515	gaa Glu	aaa Lys	gct Ala	1761
aat Asn	tga *	aaaa	agtca	aaa t	cact	gact	et et	gtga	attaa	a aat	itgta	attt	ttta	atato	etg	1817
ttt	tagto	gct t	atta	attgt	t ga	Me					_	g Th			ct gtt er Val	1870
gag	caa Gln	cta	aag	agt	gtt	Me 52 ttt	et I] 20 999	le H	is Le	eu Ly tct	/s Ai 52 cca	rg Th 25 atg	nr II aat	le Se	er Val	1870
gag Glu 530 tta	caa	cta Leu atc	aag Lys ctt	agt Ser gtg	gtt Val 535 ggg	Me 52 ttt Phe gtt	ggg Gly	caa Gln gct	tta Leu gtc	tct Ser 540	cca Pro	atg Met	aat Asn	ctt Leu gga	ttc Phe 545	
gag Glu 530 tta Leu	caa Gln att	cta Leu atc Ile	aag Lys ctt Leu	agt Ser gtg Val 550	gtt Val 535 ggg Gly	ttt Phe gtt Val	ggg Gly atc Ile	caa Gln gct Ala	tta Leu gtc Val 555 aca	tct Ser 540 tta Leu	ys Ai 52 cca Pro ccg Pro	atg Met aca Thr	aat Asn acc Thr	ctt Leu gga Gly 560	ttc Phe 545 tat Tyr	1918
gag Glu 530 tta Leu gac Asp	caa Gln att Ile	cta Leu atc Ile gta Val	aag Lys ctt Leu ctg Leu 565	agt Ser gtg Val 550 aat Asn	gtt Val 535 ggg Gly gga Gly	ttt Phe gtt Val ctt Leu tgt	ggg Gly atc Ile tta Leu atc	caa Gln gct Ala cgt Arg 570	tta Leu gtc Val 555 aca Thr	tct Ser 540 tta Leu gat Asp	ys Ai 52 cca Pro ccg Pro aaa Lys	atg Met aca Thr agc Ser	aat Asn acc Thr aaa Lys 575	ctt Leu gga Gly 560 agg Arg	ttc Phe 545 tat Tyr tat Tyr	1918 1966
gag Glu 530 tta Leu gac Asp att Ile	caa Gln att Ile ttt Phe	cta Leu atc Ile gta Val cag Gln 580	aag Lys ctt Leu ctg Leu 565 act Thr	agt Ser gtg Val 550 aat Asn agt Ser	gtt Val 535 ggg Gly gga Gly tgg Trp	ttt Phe gtt Val ctt Leu tgt Cys	ggg Gly atc Ile tta Leu atc Ile 585	caa Gln gct Ala cgt Arg 570 aac Asn	tta Leu gtc Val 555 aca Thr act	tct Ser 540 tta Leu gat Asp	cca Pro ccg Pro aaa Lys aat Asn	aca Thr agc Ser aac Asn 590	aat Asn acc Thr aaa Lys 575 ttg Leu	ctt Leu gga Gly 560 agg Arg tca ser	ttc Phe 545 tat Tyr tat Tyr gga Gly	1918 1966 2014

		att Ile														2206
agc Ser	cat His	att Ile	ttt Phe 645	cat His	gcc Ala	aaa Lys	gct Ala	agt Ser 650	gtt Val	gat Asp	tac Tyr	tat Tyr	tat Tyr 655	ttg Leu	gta Val	2254
		ggt Gly 660														2302
		gga Gly														2350
		ggt Gly														2398
ttt Phe	ata Ile	att Ile	atc Ile	ggt Gly 710	tat Tyr	tta Leu	atg Met	ggc Gly	att Ile 715	cat His	cta Leu	cca Pro	gtt Val	tat Tyr 720	aaa Lys	2446
		cca Pro														2494
		ggt Gly 740														2542
		gag Glu														2590
		tta Leu														2638
		cat His	Tyr		Gly		Gln		Asn							2686
		gag Glu														2734
atg Met	cgt Arg	att Ile 820	tta Leu	ggt Gly	gca Ala	ttc Phe	tta Leu 825	ata Ile	ttt Phe	tca Ser	aca Thr	gca Ala 830	ttt Phe	ttt Phe	gaa Glu	2782
aat Asn	att Ile 835	act Thr	tat Tyr	att Ile	atg Met	tgg Trp 840	ttg Leu	cag Gln	aag Lys	cta Leu	ggc Gly 845	ttg Leu	gac Asp	cca Pro	tta Leu	2830

			atg Met													2878
ttt Phe	att Ile	ctc Leu	tta Leu	gct Ala 870	aga Arg	act Thr	att Ile	gat Asp	caa Gln 875	aaa Lys	gtg Val	aaa Lys	aat Asn	gct Ala 880	ttt Phe	2926
cca Pro	att Ile	gct Ala	att Ile 885	atc Ile	tgg Trp	att Ile	act Thr	ttg Leu 890	aca Thr	ttg Leu	ttt Phe	tat Tyr	ctt Leu 895	aat Asn	tta Leu	2974
ggt Gly	cat His	att Ile 900	agt Ser	tgg Trp	cga Arg	cta Leu	tct Ser 905	ttc Phe	tgg Trp	ttt Phe	att Ile	tta Leu 910	cta Leu	ttg Leu	tta Leu	3022
ggc Gly	tta Leu 915	tta Leu	gtc Val	att Ile	aag Lys	cca Pro 920	act Thr	ctc Leu	tat Tyr	aaa Lys	aaa Lys 925	caa Gln	ttt Phe	att Ile	tat Tyr	3070
agc Ser 930	tgg Trp	gaa Glu	gag Glu	cgt Arg	att Ile 935	aag Lys	gat Asp	gga Gly	atc Ile	att Ile 940	atc Ile	gtt Val	agt Ser	tta Leu	atg Met 945	3118
gga Gly	gtt Val	cta Leu	ttt Phe	tat Tyr 950	att Ile	gca Ala	gga Gly	cta Leu	cta Leu 955	ttc Phe	cct Pro	atc Ile	agg Arg	gct Ala 960	cat His	3166
att Ile	aca Thr	ggt Gly	ggt Gly 965	agt Ser	att Ile	gaa Glu	cgc Arg	ctg Leu 970	cat His	tat Tyr	atc Ile	ata Ile	gca Ala 975	tgg Trp	gag Glu	3214
			ttg Leu													3262
gtt Val	aag Lys 995	Ile	tta Leu	caa Gln	gga Gly	aaa Lys 1000	Ser	tgt Cys	cag Gln	att Ile	ggt Gly 1005	Asp	gtg Val	ttc Phe	aat Asn	3310
gtg Val 1010	Asp	Arg	tat Tyr	Lys	Lys	Leu	ctt Leu	Gln	gct Ala	Tyr	Gly	ggt Gly	tct Ser	tcg Ser	gat Asp 1025	3358
agc Ser	ggt Gly	tta Leu	gcc Ala	ttt Phe 1030	Leu	aat Asn	gat Asp	aaa Lys	agg Arg 1035	Leu	tac Tyr	tgg Trp	tac Tyr	caa Gln 1040	Lys	3406
aat Asn	gga Gly	gaa Glu	gat Asp 1045	Cys	gtt Val	gcg Ala	ttc Phe	caa Gln 1050	Phe	gta Val	att Ile	gtc Val	aat Asn 1055	Asn	aaa Lys	3454
tgt Cys	ctt Leu	att Ile 1060	atg Met	gly ggg	gaa Glu	cca Pro	gcc Ala 1065	Gly	gat Asp	gac Asp	act Thr	tat Tyr 1070	Ile	cgt Arg	gaa Glu	3502

gct att gaa Ala Ile Glu 1075	tcg ttt Ser Phe	att gat Ile Asp 108	Asp Ala	gat aag Asp Lys	cta gac Leu Asp 1085	tat ga Tyr As	c ctt p Leu	3550
gtt ttt tac Val Phe Tyr 1090	agt att Ser Ile	gga cag Gly Gln 1095	aag tto Lys Leu	g aca cta Thr Leu 110	Leu Leu	cat ga His Gl	g tat u Tyr 1105	3598
ggt ttt gad Gly Phe Asp	ttt atg Phe Met 1110	Lys Val	ggt gag Gly Glu	gat gct Asp Ala 1115	tta gtt Leu Val	Asn Le	a gaa u Glu 20	3646
acg ttt act Thr Phe Thr	ctt aaa Leu Lys 1125	ggg aat Gly Asn	aag tac Lys Tyr 113	Lys Pro	ttc aga Phe Arg	aat go Asn Al 1135	c cta a Leu	3694
aat aga gtt Asn Arg Val 114	Glu Lys	gat ggt Asp Gly	ttc tat Phe Tyr 1145	ttc gaa Phe Glu	gtt gta Val Val 115	Gln Se	g cca r Pro	3742
cat agt caa His Ser Gln 1155	gag cta Glu Leu	cta aat Leu Asn 116	Ser Leu	gaa gag Glu Glu	att tct Ile Ser 1165	aat ac Asn Th	t tgg r Trp	3790
tta gaa gga Leu Glu Gly 1170	cgt cct Arg Pro	gaa aaa Glu Lys 1175	ggt ttc Gly Phe	tca cta Ser Leu 118	Gly Tyr	ttt aa Phe As	t aaa n Lys 1185	3838
gat tat ttc Asp Tyr Phe	caa caa Gln Gln 1190	Ala Pro	ata gct Ile Ala	ttg gta Leu Val 1195	aaa aat Lys Asn	Ala Gl	a cac u His 00	3886
gaa gtt gtt Glu Val Val	gct ttt Ala Phe 1205	gct aat Ala Asn	att atg Ile Met 121	Pro Asn	tat gaa Tyr Glu	aag ag Lys Se 1215	t att r Ile	3934
atc tct att Ile Ser Ile 122	Asp Leu	atg cgt Met Arg	cac gat His Asp 1225	aaa cag Lys Gln	aaa att Lys Ile 123	Pro As	t ggc n Gly	3982
gtt atg gat Val Met Asp 1235	Phe Leu	ttt tta Phe Leu 124	Ser Leu	Phe Ser	tat tat Tyr Tyr 1245	caa ga Gln Gl	g aag u Lys	4030
gga tac cac Gly Tyr His 1250	tat ttt Tyr Phe	gat ttg Asp Leu 1255	ggg atg Gly Met	gca cct Ala Pro 126	Leu Ser	gga gt Gly Va	t ggt l Gly 1265	4078
cgc gtt gaa Arg Val Glu	aca agt Thr Ser 1270	Phe Ala	aaa gag Lys Glu	aga atg Arg Met 1275	gcg tat Ala Tyr	ctt gt Leu Va 12	l Tyr	4126
cat ttc ggt His Phe Gly	agt cat Ser His 1285	ttc tac Phe Tyr	tca ttt Ser Phe 129	Asn Gly	tta cac Leu His	aag ta Lys Ty 1295	t aag r Lys	4174

aag Lys	aag Lys	ttt Phe 130	aca Thr 0	cca Pro	ttg Leu	tgg Trp	tcg Ser 130	Glu	cgt Arg	tat Tyr	att Ile	tct Ser 131	Cys	tct Ser	cgt Arg	4222
tcg Ser	tcc Ser 131	Trp	tta Leu	att Ile	tgt Cys	gct Ala 132	Ile	tgt Cys	gcc Ala	cta Leu	tta Leu 132	Met	gaa Glu	gat Asp	agt Ser	4270
	Ile		att Ile				getti	tat '	ttgg	caat	ta a	aaag	agca	t		4318
aata taci	atga ttgg	tgt (gctti	ttaa: tttc:	at a	ttgt	ttag	c ta	ctgt	agct	gct	gatt	tat	gctti	ctttat tacagc attgag	4378 4438 4498 4514
	<: <: <:	213>	154 PRT Str	epto	cocci	ıs										
Ser		400> Lvs	2 Glu	Pro	Ala	Asn	Ara	Phe	Ser	Tro	Δla	Lvs	Asn	Lvs	Len	
1				5					10					15		
Leu	ile	Asn	Gly 20	Phe	Ile	Ala	Thr	Leu 25	Ala	Ala	Thr	Ile	Leu 30	Phe	Phe	
Ala	Val	Gln 35	Phe	Ile	Gly	Leu	Lys 40	Pro	Asp	Tyr	Pro	Gly 45	Lys	Thr	Tyr	
Phe	Ile 50	Ile	Leu	Leu	Thr	Ala 55	Trp	Thr	Leu	Met	Ala 60		Val	Thr	Ala	
Leu 65		Gly	Trp	Asp	Asn 70		Tyr	Gly	Ser			Ser	Leu	Leu		
	Leu	Phe	Gln	Leu 85		Ser	Ser	Ala	Gly 90	75 Thr	Tyr	Pro	Ile		80 Leu	
Ser	Pro	Lys	Phe		Gln	Thr	Ile			Phe	Leu	Pro		95 Thr	Tyr	
Ser	Val		100 Gly	Leu	Arg	Glu		105 Ile	Ser	Leu	Thr	Gly	110 Asp	Val	Asn	
His		115 Trp	Arg	Met	Leu		120 Ile	Phe	Leu	Val		125 Ser	Met	Ile	Leu	
Ala 145	130 Leu	Leu	Ile	Tyr	Arg 150	135 Lys	Gln	Glu	Asp		140					
	<: <:	210> 211> 212> 213>	118	eptod	cocci	ıs										
		400>	-	1								_				
Met 1	ser	Thr	Leu	Thr 5	Ile	Ile	Ile	Ala	Thr 10	Leu	Thr	Ala	Leu	Glu 15	His	
Phe	Tyr	Ile	Met 20	Tyr	Leu	Glu	Thr	Leu 25	Ala	Thr	Gln	Ser	Asn 30	Met	Thr	

9 / 63

```
Gly Lys Ile Phe Ser Met Ser Lys Glu Glu Leu Ser Tyr Leu Pro Val
            40
Ile Lys Leu Phe Lys Asn Gln Gly Val Tyr Asn Gly Leu Ile Gly Leu
Phe Leu Leu Tyr Gly Leu Tyr Ile Ser Gln Asn Gln Glu Ile Val Ala
                                  75
Val Phe Leu Ile Asn Val Leu Leu Val Ala Ile Tyr Gly Ala Leu Thr
             85
                                 90
Val Asp Lys Lys Ile Leu Leu Lys Gln Gly Gly Leu Pro Ile Leu Ala
       100 105
Leu Leu Thr Phe Leu Phe
      115
     <210> 4
     <211> 247
     <212> PRT
     <213> Streptococcus
Met Thr Glu Asn Trp Leu His Thr Lys Asp Gly Ser Asp Ile Tyr Tyr
                                 10
Arg Val Val Gly Gln Gly Gln Pro Ile Val Phe Leu His Gly Asn Ser
                            25
Leu Ser Ser Arg Tyr Phe Asp Lys Gln Ile Ala Tyr Phe Ser Lys Tyr
                  40
Tyr Gln Val Ile Val Met Asp Ser Arg Gly His Gly Lys Ser His Ala
              55
Lys Leu Asn Thr Ile Ser Phe Arg Gln Ile Ala Val Asp Leu Lys Asp
                 70
                                   75
Ile Leu Val His Leu Glu Ile Asp Lys Val Ile Leu Val Gly His Ser
                                90
Asp Gly Ala Asn Leu Ala Leu Val Phe Gln Thr Met Phe Pro Gly Met
          100 105 110
Val Arg Gly Leu Leu Asn Ser Gly Asn Leu Thr Ile His Gly Gln
                                        125
                         120
Arg Trp Trp Asp Ile Leu Leu Val Arg Ile Ala Tyr Lys Phe Leu His
                      135
                                        140
Tyr Leu Gly Lys Leu Phe Pro Tyr Met Arg Gln Lys Ala Gln Val Ile
                  150
                                    155
Ser Leu Met Leu Glu Asp Leu Lys Ile Ser Pro Ala Asp Leu Gln His
             165
                                 170
Val Ser Thr Pro Val Met Val Leu Val Gly Asn Lys Asp Ile Ile Lys
          180
                             185
Leu Asn His Ser Lys Lys Leu Ala Ser Tyr Phe Pro Arg Gly Glu Phe
                         200
Tyr Ser Leu Val Gly Phe Gly His His Ile Ile Lys Gln Asp Ser His
                     215
                                        220
Val Phe Asn Ile Ile Ala Lys Lys Phe Ile Asn Asp Thr Leu Lys Gly
                 230
                                  235
Glu Ile Val Glu Lys Ala Asn
     <210> 5
     <211> 816
     <212> PRT
```

<213> Streptococcus

	<	400>	5												
Met 1	Ile	His	Leu	Lys 5	Arg	Thr	Ile	Ser	Val 10	Glu	Gln	Leu	Lys	Ser 15	Val
Phe	Gly	Gln	Leu 20	Ser	Pro	Met	Asn	Leu 25	Phe	Leu	Ile	Ile	Leu 30	Val	Gly
Val	Ile	Ala 35	Val	Leu	Pro	Thr	Thr 40	Gly	Tyr	Asp	Phe	Val 45	Leu	Asn	Gly
Leu	Leu 50	Arg	Thr	Asp	Lys	Ser 55	Lys	Arg	Tyr	Ile	Leu 60	Gln	Thr	Ser	Trp
65			Thr		70					75					80
			Arg	85					90					95	
			Glu 100					105					110		
		115	Ser				120					125			
	130		Val			135					140				
145			Val		150					155					160
			Met _	165					170					175	
			Trp 180					185					190		
		195	Ile				200					205			
	210		Ala			215					220				_
225			Leu		230					235					240
			Val	245					250					255	
			Phe 260					265					270		_
		275	Asn				280					285			
	290		Gln			295					300				
305			Phe		310					315					320
			Lys	325					330					335	
			Gly 340					345					350		
		355	Gln				360					365			
	370		Thr			375					380				
385			Trp		390					395					400
			Tyr	405					410					415	
пур	vah	Эту	Ile 420	тте	тте	val	ser	Leu 425	мет	чτλ	val	ьeu	Phe 430	Tyr	тте

A	.la	Gly	Leu 435	Leu	Phe	Pro	Ile	Arg 440	Ala	His	Ile	Thr	Gly 445	Gly	Ser	Ile
G	lu	Arg 450	Leu	His	Tyr	Ile	Ile 455	Ala	Trp	Glu	Pro	Ile 460	Ala	Leu	Ala	Thr
	eu 65	Ile	Leu	Thr	Leu	Val 470	Tyr	Leu	Cys	Leu	Val 475	Lys	Ile	Leu	Gln	Gly 480
L	ys	Ser	Cys	Gln	Ile 485	Gly	Asp	Val	Phe	Asn 490	Val	Asp	Arg	Tyr	Lys 495	Lys
L	eu	Leu	Gln	Ala 500	Tyr	Gly	Gly	Ser	Ser 505	Asp	Ser	Gly	Leu	Ala 510	Phe	Leu
A	sn	Asp	Lys 515	Arg	Leu	Tyr	Trp	Tyr 520	Gln	Lys	Asn	Gly	Glu 525	Asp	Cys	Val
A	la	Phe 530	Gln	Phe	Val	Ile	Val 535	Asn	Asn	Lys	Cys	Leu 540	Ile	Met	Gly	Glu
	ro 45	Ala	Gly	Asp	Asp	Thr 550	Tyr	Ile	Arg	Glu	Ala 555	Ile	Glu	Ser	Phe	Ile 560
A	sp	Asp	Ala	Asp	Lys 565	Leu	Asp	Tyr	Asp	Leu 570	Val	Phe	Tyr	Ser	Ile 575	Gly
G	ln	Lys	Leu	Thr 580	Leu	Leu	Leu	His	Glu 585	Tyr	Gly	Phe	Asp	Phe 590	Met	Lys
V	al	Gly	Glu 595	Asp	Ala	Leu	Val	Asn 600	Leu	Glu	Thr	Phe	Thr 605	Leu	Lys	Gly
A	sn	Lys 610	Tyr	Lys	Pro	Phe	Arg 615	Asn	Ala	Leu	Asn	Arg 620	Val	Glu	Lys	Asp
	1y 25	Phe	Tyr	Phe	Glu	Val 630	Val	Gln	Ser	Pro	His 635	Ser	Gln	Glu	Leu	Leu 640
A	sn	Ser	Leu	Glu	Glu 645	Ile	Ser	Asn	Thr	Trp 650	Leu	Glu	Gly	Arg	Pro 655	Glu
L	ys	Gly	Phe	Ser 660	Leu	Gly	Tyr	Phe	Asn 665	Lys	Asp	Tyr	Phe	Gln 670	Gln	Ala
P	ro	Ile	Ala 675	Leu	Val	Lys	Asn	Ala 680	Glu	His	Glu	Val	Val 685	Ala	Phe	Ala
A	sn	Ile 690	Met	Pro	Asn	Tyr	Glu 695	Lys	Ser	Ile	Ile	Ser 700	Ile	Asp	Leu	Met
	rg 05	His	Asp	Lys	Gln	Lys 710	Ile	Pro	Asn	Gly	Val 715	Met	Asp	Phe	Leu	Phe 720
L	eu	Ser	Leu	Phe	Ser 725	Tyr	Tyr	Gln	Glu	Lys 730	Gly	Tyr	His	Tyr	Phe 735	Asp
L	eu	Gly	Met	Ala 740	Pro	Leu	Ser	Gly	Val 745	Gly	Arg	Val	Glu	Thr 750	Ser	Phe
A	la	Lys	Glu 755	Arg	Met	Ala	Tyr	Leu 760	Val	Tyr	His	Phe	Gly 765	Ser	His	Phe
		770					775					780	Phe			
	rp 85	Ser	Glu	Arg	Tyr	Ile 790	Ser	Cys	Ser	Arg	Ser 795	Ser	Trp	Leu	Ile	Cys 800
A	la	Ile	Cys	Ala	Leu 805	Leu	Met	Glu	Asp	Ser 810	Lys	Ile	Lys	Ile	Val 815	Lys

<210> 6

<211> 518

<212> PRT

<213> Streptococcus

<400> 6

Met 1	Arg	Ile	Leu	Gly 5	Ala	Phe	Leu	Ile	Phe 10	Ser	Thr	Ala	Phe	Phe 15	Glu
Asn	Ile	Thr	Tyr 20	Ile	Met	Trp	Leu	Gln 25		Leu	Gly	Leu	Asp 30		Leu
Gln	Glu	Gln 35	Met	Leu	Trp	Gln	Phe 40		Gly	Leu	Leu	Leu 45		Val	Cys
Phe	Ile 50	Leu	Leu	Ala	Arg	Thr 55	Ile	Asp	Gln	Lys	Val 60		Asn	Ala	Phe
Pro 65	Ile	Ala	Ile	Ile	Trp 70	Ile	Thr	Leu	Thr	Leu 75		Tyr	Leu	Asn	Leu 80
Gly	His	Ile	Ser	Trp 85	Arg	Leu	Ser	Phe	Trp 90	Phe	Ile	Leu	Leu	Leu 95	
Gly	Leu	Leu	Val 100	Ile	Lys	Pro	Thr	Leu 105	Tyr	Lys	Lys	Gln	Phe 110	Ile	Tyr
Ser	Trp	Glu 115	Glu	Arg	Ile	Lys	Asp 120	Gly	Ile	Ile	Ile	Val 125	Ser	Leu	Met
	130		Phe			135					140		_		
145			Gly		150					155					160
			Leu	165					170					175	
			Leu 180					185					190		
		195	Tyr				200					205			
	210		Ala			215					220				
225			Asp		230					235					240
			Met	245					250					255	
			Ser 260					265					270		
		275	Ser				280					285			_
	290		Phe			295					300				
305			Leu		310					315		_			320
			Glu	325					330					335	
			Glu 340					345					350		
		355	Arg				360					365			_
	370		Gln			375					380				
385			Ala		390					395					400
			Asp	405					410					415	
			Phe 420					425				_	430		_
Gly	Tyr	His 435	Tyr	Phe	Asp	Leu	Gly 440	Met	Ala	Pro	Leu	Ser 445	Gly	Val	Gly

Arg		Glu	Thr	Ser	Phe	Ala	Lys	Glu	Arg	Met	Ala	Tyr	Leu	Val	Tyr	
His	450 Phe	Gly	Ser	His	Phe	455 Tyr	Ser	Phe	Asn	Gly	460 Leu	His	Lys	Tyr	Lys	
465 Lys	Lys	Phe	Thr	Pro	470 Leu	Trp	Ser	Glu	Arg	475 Tyr	Ile	Ser	Cys	Ser	480 Arg	
				485 Ile					490					495		
			500	Val				505	ma	Dea	nea		510	пор	DCI	
цуз	110	515	110	vai	пуъ											
		210>		_												
	<2	212>														
	<2	213>	Str	epto	cocci	ıs										
		220> 221>	CDS													
	<2	222>	(1)	(6	587)											
		221> 222>		1)	. (25	57)										
		221> 222>		56).	(30	036)										
		221> 222>		06).	(48	342)										
		221> 222>		50).	(5:	L25)										
	<2	222>	(485 7													
aat Asn	<2 <4 ttt	222> 100> gat	(485 7 atc	gaa	aca	aca	act Thr	ttt Phe	gag Glu	gca Ala	atg Met	aaa Lys	aag Lys	cac His	gcg Ala	48
aat Asn 1	<2 <4 ttt	222> 100> gat	(485 7 atc		aca	aca	act Thr	ttt Phe	gag Glu 10	gca Ala	atg Met	aaa Lys	aag Lys	cac His 15	gcg Ala	48
Asn 1 tca	<2 ttt Phe tta	222> 100> gat Asp	(485 7 atc Ile gag	gaa Glu 5 aaa	aca Thr	aca Thr	Thr	Phe gag	Glu 10 cgt	Ala	Met	Lys	Lys gaa	His 15 ttt	Ala	48 96
Asn 1 tca	<2 ttt Phe tta	222> 100> gat Asp	(485 7 atc Ile gag	gaa Glu 5	aca Thr	aca Thr	Thr	Phe gag	Glu 10 cgt	Ala	Met	Lys	Lys gaa	His 15 ttt	Ala	
Asn 1 tca Ser	<2 ttt Phe tta Leu	222> 100> gat Asp ttg Leu	7 atc Ile gag Glu 20 tta	gaa Glu 5 aaa Lys	aca Thr ata Ile	aca Thr tct Ser	Thr gtt Val tgg	Phe gag Glu 25 cgt	Glu 10 cgt Arg	Ala tct Ser	Met ttt Phe atg	Lys att Ile ctg	Lys gaa Glu 30 gca	His 15 ttt Phe cta	Ala gat Asp	
Asn 1 tca Ser	<2 ttt Phe tta Leu	222> 100> gat Asp ttg Leu	7 atc Ile gag Glu 20 tta	gaa Glu 5 aaa Lys	aca Thr ata Ile	aca Thr tct Ser	Thr gtt Val tgg	Phe gag Glu 25 cgt	Glu 10 cgt Arg	Ala tct Ser	Met ttt Phe atg	Lys att Ile ctg	Lys gaa Glu 30 gca	His 15 ttt Phe cta	Ala gat Asp	96
Asn 1 tca Ser aaa Lys	<2 ttt Phe tta Leu ctt Leu	222> 100> gat Asp ttg Leu cta Leu 35	7 atc Ile gag Glu 20 tta Leu gct	gaa Glu 5 aaa Lys gca Ala	aca Thr ata Ile cct Pro	aca Thr tct Ser tat Tyr	Thr gtt Val tgg Trp 40 cta	Phe gag Glu 25 cgt Arg	Glu 10 cgt Arg aaa Lys	tct ser gga Gly	Met ttt Phe atg Met aaa	Lys att Ile ctg Leu 45 aat	gaa Glu 30 gca Ala	His 15 ttt Phe cta Leu	Ala gat Asp ata Ile	96
Asn 1 tca Ser aaa Lys	<2 ttt Phe tta Leu ctt Leu	222> 100> gat Asp ttg Leu cta Leu 35	7 atc Ile gag Glu 20 tta Leu gct	gaa Glu 5 aaa Lys gca Ala	aca Thr ata Ile cct Pro	aca Thr tct Ser tat Tyr	Thr gtt Val tgg Trp 40 cta	Phe gag Glu 25 cgt Arg	Glu 10 cgt Arg aaa Lys	tct ser gga Gly	Met ttt Phe atg Met aaa	Lys att Ile ctg Leu 45 aat	gaa Glu 30 gca Ala	His 15 ttt Phe cta Leu	Ala gat Asp ata Ile	96 144
Asn 1 tca Ser aaa Lys gat Asp	tta Phe tta Leu ctt Leu ser 50	222> 100> gat Asp ttg Leu cta Leu 35 cat His	(485) 7 atc Ile gag Glu 20 tta Leu gct Ala	gaa Glu 5 aaa Lys gca Ala ttt Phe	aca Thr ata Ile cct Pro aat Asn	aca Thr tct Ser tat Tyr tat Tyr 55	Thr gtt Val tgg Trp 40 cta Leu cag	Phe gag Glu 25 cgt Arg cca Pro	Glu 10 cgt Arg aaa Lys tgc Cys	tct Ser gga Gly tta Leu	Met ttt Phe atg Met aaa Lys 60 gat	Lys att Ile ctg Leu 45 aat Asn	Lys gaa Glu 30 gca Ala agg Arg	His 15 ttt Phe cta Leu gaa Glu	gat Asp ata Ile tta Leu	96 144
Asn 1 tca Ser aaa Lys gat Asp	tta Phe tta Leu ctt Leu ser 50	222> 100> gat Asp ttg Leu cta Leu 35 cat His	(485) 7 atc Ile gag Glu 20 tta Leu gct Ala	gaa Glu 5 aaa Lys gca Ala ttt	aca Thr ata Ile cct Pro aat Asn	aca Thr tct Ser tat Tyr tat Tyr 55	Thr gtt Val tgg Trp 40 cta Leu cag	Phe gag Glu 25 cgt Arg cca Pro	Glu 10 cgt Arg aaa Lys tgc Cys	tct Ser gga Gly tta Leu	Met ttt Phe atg Met aaa Lys 60 gat	Lys att Ile ctg Leu 45 aat Asn	Lys gaa Glu 30 gca Ala agg Arg	His 15 ttt Phe cta Leu gaa Glu	gat Asp ata Ile tta Leu	96 144 192
Asn 1 tca Ser aaa Lys gat Asp caa Gln 65	ttt Phe tta Leu ctt Leu agt Ser 50 tta Leu	222> 100> gat Asp ttg Leu cta Leu 35 cat His	7 atc Ile gag Glu 20 tta Leu gct Ala gcc Ala	gaa Glu 5 aaa Lys gca Ala ttt Phe	aca Thr ata Ile cct Pro aat Asn ttg Leu 70	aca Thr tct Ser tat Tyr tat Tyr 55 tcc Ser	Thr gtt Val tgg Trp 40 cta Leu cag Gln	Phe gag Glu 25 cgt Arg cca Pro tta Leu	Glu 10 cgt Arg aaa Lys tgc Cys	tct Ser gga Gly tta Leu aaa Lys 75	Met ttt Phe atg Met aaa Lys 60 gat Asp	Lys att Ile ctg Leu 45 aat Asn	Lys gaa Glu 30 gca Ala agg Arg tta Leu	His 15 ttt Phe cta Leu gaa Glu ttt	gat Asp ata Ile tta Leu gag Glu 80	96 144 192 240
Asn 1 tca Ser aaa Lys gat Asp caa Gln 65 aca	tta Phe tta Leu ctt Leu ser 50 tta Leu	222> 100> gat Asp ttg Leu cta Leu 35 cat His agc Ser	(485) 7 atc Ile gag Glu 20 tta Leu gct Ala gcc Ala caa	gaa Glu 5 aaa Lys gca Ala ttt Phe	aca Thr ata Ile cct Pro aat Asn ttg Leu 70 tgg	aca Thr tct Ser tat Tyr tat Tyr 55 tcc Ser	Thr gtt Val tgg Trp 40 cta Leu cag Gln	Phe gag Glu 25 cgt Arg cca Pro tta Leu ctc	Glu 10 cgt Arg aaa Lys tgc Cys gat Asp	tct Ser gga Gly tta Leu aaa Lys 75	Met ttt Phe atg Met aaa Lys 60 gat Asp	Lys att Ile ctg Leu 45 aat Asn ttt Phe	Lys gaa Glu 30 gca Ala agg Arg tta Leu gaa	His 15 ttt Phe cta Leu gaa Glu ttt Phe	Ala gat Asp ata Ile tta Leu gag Glu 80 gaa	96 144 192

cac His	aca Thr	aag Lys	act Thr 100	ttt Phe	tta Leu	aaa Lys	aaa Lys	tgg Trp 105	aag Lys	aca Thr	tca Ser	act Thr	cac His 110	ttt Phe	caa Gln	336
aaa Lys	gat Asp	gtt Val 115	gag Glu	cat His	ata Ile	gtg Val	gat Asp 120	gtt Val	tat Tyr	cgt Arg	att Ile	cgt Arg 125	gaa Glu	caa Gln	atg Met	384
gga Gly	ttg Leu 130	gct Ala	aaa Lys	gaa Glu	cat His	ctt Leu 135	tat Tyr	cgt Arg	tat Tyr	gga Gly	aaa Lys 140	act Thr	ata Ile	ata Ile	aaa Lys	432
caa Gln 145	gcg Ala	gaa Glu	ggt Gly	att Ile	cgc Arg 150	aaa Lys	gca Ala	aga Arg	ggc Gly	ttg Leu 155	atg Met	gtt Val	gat Asp	ttc Phe	gaa Glu 160	480
									gca Ala 170							528
ata Ile	gtt Val	gtc Val	aat Asn 180	ggt Gly	ggc Gly	acc Thr	tta Leu	atc Ile 185	aag Lys	aaa Lys	tta Leu	gga Gly	ata Ile 190	aaa Lys	cct Pro	576
									caa Gln							624
tta Leu	gga Gly 210	caa Gln	ctg Leu	att Ile	aat Asn	gaa Glu 215	gaa Glu	gag Glu	gct Ala	att Ile	tta Leu 220	cat His	ttt Phe	gtt Val	aag Lys	672
		ttg Leu			taga	agagg	gat t		atg a et Se 80				_	ıl As		721
gga Gly	ttg Leu	act Thr	aag Lys 240	tcg Ser	gtt Val	ggt Gly	gat Asp	aag Lys 245	acg Thr	gtc Val	ttt Phe	agt Ser	aat Asn 250	gtt Val	tca Ser	769
+++													250			
Phe	atc Ile	atc Ile 255	cat His	agt Ser	Leu	gac Asp	Arg	Ile	gly aaa	att Ile	Ile	ggt Gly 265	gtc	aat Asn	gga Gly	817
Phe	Ile gga	Ile 255 aag	His	Ser	Leu	Asp tta	Arg 260 gat	Ile gtt	ggg Gly att Ile	Ile tcg	Ile ggt	Gly 265 gaa	gtc Val tta	Asn ggt	Gly	817
Phe act Thr	gga Gly 270	Ile 255 aag Lys gat	His aca Thr	ser aca Thr	Leu cta Leu cct	Asp tta Leu 275 ttt	Arg 260 gat Asp tca	Ile gtt Val tca	Gly att	Ile tcg Ser	ggt Gly 280	Gly 265 gaa Glu tat	gtc Val tta Leu	Asn ggt Gly att	Gly ttt Phe gct	

acc Thr	gta Val	ctt Leu	tct Ser 320	tct Ser	gac Asp	tta Leu	aga Arg	gag Glu 325	atg Met	gct Ala	tta Leu	att Ile	aaa Lys 330	gaa Glu	tat Tyr	1009
gaa Glu	tta Leu	ttg Leu 335	ctt Leu	aat Asn	cac His	tac Tyr	gaa Glu 340	gaa Glu	agt Ser	aag Lys	caa Gln	tca Ser 345	cgt Arg	cta Leu	gag Glu	1057
aaa Lys	gta Val 350	atg Met	gca Ala	gaa Glu	atg Met	gat Asp 355	tct Ser	tta Leu	gat Asp	gct Ala	tgg Trp 360	tct Ser	att Ile	gag Glu	agc Ser	1105
gaa Glu 365	gtc Val	aaa Lys	aca Thr	gta Val	tta Leu 370	tcc Ser	aaa Lys	tta Leu	ggt Gly	att Ile 375	act Thr	gat Asp	ttg Leu	cag Gln	ttg Leu 380	1153
tcg Ser	gtt Val	ggt Gly	gaa Glu	tta Leu 385	tca Ser	gga Gly	gga Gly	tta Leu	cga Arg 390	aga Arg	cgt Arg	gtt Val	caa Gln	tta Leu 395	gcg Ala	1201
caa Gln	gta Val	tta Leu	tta Leu 400	aat Asn	gat Asp	gca Ala	gat Asp	tta Leu 405	ttg Leu	ctc Leu	tta Leu	gac Asp	gaa Glu 410	cct Pro	act Thr	1249
aac Asn	cac His	tta Leu 415	gat Asp	att Ile	gac Asp	act Thr	att Ile 420	gca Ala	tgg Trp	tta Leu	acg Thr	aat Asn 425	ttt Phe	ttg Leu	aaa Lys	1297
aat Asn	agt Ser 430	aaa Lys	aag Lys	aca Thr	gtg Val	ctt Leu 435	ttt Phe	ata Ile	act Thr	cat His	gat Asp 440	cgt Arg	tat Tyr	ttt Phe	cta Leu	1345
gac Asp 445	aat Asn	gtt Val	gca Ala	aca Thr	cgt Arg 450	att Ile	ttt Phe	gaa Glu	tta Leu	gat Asp 455	aag Lys	gca Ala	cag Gln	att Ile	aca Thr 460	1393
gaa Glu	tat Tyr	caa Gln	ggc Gly	aat Asn 465	tat Tyr	cag Gln	gat Asp	tat Tyr	gtc Val 470	cga Arg	ctt Leu	cgt Arg	gca Ala	gaa Glu 475	caa Gln	1441
gac Asp	gag Glu	cgt Arg	gat Asp 480	gct Ala	gct Ala	agt Ser	Leu	cat His 485	Lys	Lys	Lys	Gln	ctt Leu 490	Tyr	aaa Lys	1489
cag Gln	gaa Glu	cta Leu 495	gct Ala	tgg Trp	atg Met	cgt Arg	act Thr 500	cag Gln	cca Pro	caa Gln	gct Ala	cgt Arg 505	gca Ala	acg Thr	aaa Lys	1537
caa Gln	cag Gln 510	gct Ala	cgt Arg	att Ile	aat Asn	cgt Arg 515	ttt Phe	caa Gln	aat Asn	cta Leu	aaa Lys 520	aac Asn	gat Asp	tta Leu	cac His	1585
caa Gln 525	aca Thr	agc Ser	gat Asp	aca Thr	agc Ser 530	gat Asp	ttg Leu	gaa Glu	atg Met	aca Thr 535	ttt Phe	gaa Glu	aca Thr	agt Ser	cga Arg 540	1633

											tct Ser					1681
											att Ile					1729
											aag Lys					1777
											ggt Gly 600					1825
											caa Gln					1873
											gag Glu					1921
											gaa Glu					1969
											att Ile					2017
											atc Ile 680					2065
											gac Asp					2113
										Gly	ttt Phe					2161
att Ile	aca Thr	gtt Val	agt Ser 720	cac His	gat Asp	cgt Arg	tac Tyr	ttt Phe 725	tta Leu	gat Asp	aaa Lys	gtg Val	gct Ala 730	aat Asn	aaa Lys	2209
											ttt Phe					2257
act Thr	gat Asp 750	tat Tyr	tta Leu	gat Asp	gaa Glu	aaa Lys 755	gca Ala	ttt Phe	aat Asn	gag Glu	caa Gln 760	aat Asn	aat Asn	gaa Glu	gtt Val	2305

atc Ile 765	agt Ser	aaa Lys	aaa Lys	gag Glu	agt Ser 770	acc Thr	aag Lys	aca Thr	agt Ser	cgt Arg 775	gaa Glu	aag Lys	caa Gln	agt Ser	cgt Arg 780	2353
aaa Lys	aga Arg	atg Met	tct Ser	tac Tyr 785	ttt Phe	gaa Glu	aaa Lys	caa Gln	gaa Glu 790	tgg Trp	gcg Ala	aca Thr	att Ile	gaa Glu 795	gac Asp	2401
	att Ile															2449
caa Gln	aca Thr	tgt Cys 815	ggt Gly	agt Ser	gat Asp	ttt Phe	aca Thr 820	agg Arg	tta Leu	tct Ser	gat Asp	tta Leu 825	caa Gln	aag Lys	gaa Glu	2497
tta Leu	gat Asp 830	gca Ala	aaa Lys	aat Asn	gaa Glu	gca Ala 835	ctt Leu	cta Leu	gaa Glu	aag Lys	tat Tyr 840	gac Asp	cgt Arg	tat Tyr	gag Glu	2545
tac Tyr 845	ctt Leu	agt Ser	gag Glu	Leu	gacad AspTh 350	atg nrMet	g att	ato E Ile	c cgt e Arg 855	g Pro	g att	atı E Ile	aaa Lys	a aat s Asi 860	gat n Asp	2595
gac Asp	caa Gln	gca Ala	gtt Val 865	gca Ala	caa Gln	tta Leu	att Ile	cga Arg 870	caa Gln	agt Ser	tta Leu	cgc Arg	gcc Ala 875	tat Tyr	gat Asp	2643
tta Leu	gat Asp	aaa Lys 880	cct Pro	gat Asp	aca Thr	gca Ala	tat Tyr 885	tca Ser	gac Asp	cct Pro	cac His	tta Leu 890	gat Asp	cat His	ttg Leu	2691
acc Thr	tca Ser 895	tac Tyr	tac Tyr	gaa Glu	aaa Lys	ata Ile 900	gag Glu	aag Lys	tca Ser	gga Gly	ttc Phe 905	ttt Phe	gtc Val	att Ile	gag Glu	2739
gag Glu 910	aga Arg	gat Asp	gag Glu	att Ile	att Ile 915	Gly	tgt Cys	gly	ggc Gly	ttt Phe 920	ggt Gly	ccg Pro	ctg Leu	aaa Lys	aat Asn 925	2787
cta Leu	att Ile	gca Ala	gag Glu	atg Met 930	cag Gln	aag Lys	Val	tac Tyr	Ile	gca Ala	gaa Glu	cgt Arg	Phe	cgt Arg 940	ggt Gly	2835
aag Lys	gly aaa	ctt Leu	gct Ala 945	act Thr	gat Asp	tta Leu	gtg Val	aaa Lys 950	atg Met	att Ile	gaa Glu	gta Val	gaa Glu 955	gct Ala	cga Arg	2883
aaa Lys	att Ile	960 Gly aaa	tat Tyr	aga Arg	caa Gln	ctt Leu	tat Tyr 965	tta Leu	gag Glu	aca Thr	gcc Ala	agt Ser 970	act Thr	ttg Leu	agt Ser	2931
agg Arg	gca Ala 975	act Thr	gcg Ala	gtt Val	tat Tyr	aag Lys 980	cat His	atg Met	gga Gly	tat Tyr	tgt Cys 985	gcc Ala	tta Leu	tcg Ser	caa Gln	2979

				gat Asp					Ala					Met		3027
	gat Asp		taag	gttga	aaa g	gtgga	attaç	gt ga	aacat	zggat	taa	atta	cttt			3076
gaga	ataa	gag g	gaaaq	gaaaa	ag ga	agaca	atat	Met	_	tat Tyr		-	Ser		_	3129
aaa Lys	agg Arg	Tyr	ccc Pro 1020	aat Asn	tgg Trp	tta Leu	${\tt Trp}$	ctt Leu L025	gat Asp	tta Leu	cta Leu	Gly	gct Ala 1030	atg Met	ctt Leu	3177
Phe	Val	Thr 1035	Val	atc Ile	Leu	Gly	Met L040	Pro	Thr	Ala	Leu	Ala 1045	Gly	Met	Ile	3225
Asp	aat Asn 1050	ggc	gtt Val	aca Thr	Lys	ggt Gly L055	gat Asp	cgg Arg	act Thr	Gly	gtt Val 1060	tat Tyr	ctg Leu	tgg Trp	acg Thr	3273
Phe 1065	Ile	Met	Phe		Phe 1070	Val	Val	Leu	Gly	Ile 1075	Ile	Gly	Arg	Ile	Thr 1080	3321
			Ala	tct Ser 1085				Thr					Arg			3369
Arg	Asn	Asp	Met L100	tat Tyr	Āla	Lys	Leu J	Gln 1105	Glu	Tyr	Ser	His	His 1110	Ğlu	Tyr	3417
Glu	Gln	Ile L115	Gly	gta Val	Ser	Ser	Leu L120	Val	Thr	Arg	Met 1	Thr L125	Ser	Asp	Thr	3465
Phe				caa Gln	Phe					Leu						3513
				atg Met					Val					Thr		3561
			Ala	tgg Trp 1165				Val					Leu			3609
gtc Val	gtt Val	Leu	tat Tyr 1180	gta Val	gct Ala	ata Ile	Lys	aca Thr 1185	aaa Lys	cct Pro	tta Leu	Ser	gaa Glu 1190	aga Arg	caa Gln	3657

cag Gln	Thr	atg Met 1195	ctt Leu	gat Asp	aaa Lys	Ile	aat Asn 1200	caa Gln	tat Tyr	gtt Val	Arg	gaa Glu 1205	aat Asn	tta Leu	aca Thr	3705
Gly	tta Leu 1210	cgc Arg	gtt Val	gtt Val	Arg	gcc Ala 1215	ttt Phe	gca Ala	aga Arg	Glu	aat Asn 1220	ttt Phe	caa Gln	tca Ser	caa Gln	3753
aaa Lys 1225	ttt Phe	caa Gln	gtc Val	Ala	aac Asn 1230	caa Gln	cgt Arg	tac Tyr	Thr	gat Asp 1235	act Thr	tca Ser	act Thr	Gly	ctt Leu 1240	3801
ttt Phe	aaa Lys	tta Leu	Thr	999 Gly 1245	cta Leu	aca Thr	gaa Glu	Pro	ctt Leu L250	ttc Phe	gtt Val	caa Gln	Ile	att Ile 1255	att Ile	3849
gca Ala	atg Met	att Ile	gtg Val 1260	gct Ala	atc Ile	gtt Val	Trp	ttt Phe 1265	gct Ala	ttg Leu	gat Asp	Pro	tta Leu 1270	caa Gln	aga Arg	3897
ggt Gly	Ala	att Ile 1275	aaa Lys	ata Ile	Gly aaa	Asp	tta Leu L280	gtt Val	gct Ala	ttt Phe	Ile	gaa Glu L285	tat Tyr	agc Ser	ttc Phe	3945
His	gct Ala 1290	ctc Leu	ttt Phe	tca Ser	Phe	ttg Leu L295	cta Leu	ttt Phe	gcc Ala	Asn	ctt Leu 1300	ttt Phe	act Thr	atg Met	tat Tyr	3993
cct Pro 1305	cgt Arg	atg Met	gtg Val	Val	tca Ser 1310	agc Ser	cat His	cgt Arg	Ile	aga Arg L315	gag Glu	gtg Val	atg Met	Asp	atg Met L320	4041
cca Pro	atc Ile	tct Ser	Ile	aat Asn 1325	cct Pro	aat Asn	gcc Ala	Glu	ggt Gly .330	gtt Val	acg Thr	gat Asp	Thr	aaa Lys 1335	ctt Leu	4089
aaa Lys	Gly aaa	cat His	tta Leu .340	gaa Glu	ttt Phe	gat Asp	Asn	gta Val 1345	aca Thr	ttc Phe	gct Ala	Tyr	cca Pro .350	gga Gly	gaa Glu	4137
aca Thr	Glu	agt Ser L355	ccc Pro	gtt Val	Leu	cat His 1	Asp	Ile	tct Ser	Phe	aaa Lys 1	Ala	Lys	cct Pro	gga Gly	4185
Glu	aca Thr 1370	att Ile	gct Ala	ttt Phe	Ile	ggt Gly .375	tca Ser	aca Thr	ggt Gly	Ser	gga Gly 1380	aaa Lys	tct Ser	tct Ser	ctt Leu	4233
gtt Val 1385	aat Asn	ttg Leu	att Ile	Pro	cgt Arg 1390	ttt Phe	tat Tyr	gat Asp	Val	aca Thr 395	ctt Leu	gga Gly	aaa Lys	Ile	tta Leu 400	4281
gta Val	gat Asp	gga Gly	Val	gat Asp 405	gta Val	aga Arg	gat Asp	Tyr	aac Asn 410	ctt Leu	aaa Lys	tca Ser	Leu	cgc Arg 415	caa Gln	4329

		Gly					Lys		ctt Leu			Thr				4377
	Glu					Gly		_	gat Asp	_	Thr		_	_		4425
Arg					Ile				aaa Lys	Glu						4473
caa Gln 1465	gaa Glu	gcc Ala	ttt Phe	Glu	acg Thr 1470	cat His	tta Leu	gct Ala	gaa Glu	ggt Gly L475	gly aaa	agc Ser	aat Asn	Leu	tct Ser 1480	4521
gl ^y aaa	ggt Gly	caa Gln	Lys	caa Gln L485	cgg Arg	tta Leu	tct Ser	Ile	gct Ala L490	agg Arg	gct Ala	gtt Val	Val	aaa Lys 1495	gat Asp	4569
Pro	Asp	Leu	Tyr 1500	Ile	Phe	Asp	Asp	Ser L505	ttt Phe	Ser	Ala	Leu 1	Asp L510	Tyr	Lys	4617
Thr	Asp :	Ala 1515	Thr	Leu	Arg	Ala	Arg L520	Leu	aaa Lys	Glu	Val	Thr 1525	Gly	Asp	Ser	4665
Thr	gtt Val 1530	ttg Leu	ata Ile	gtt Val	Ala	caa Gln 1535	agg Arg	gtg Val	ggt Gly	Thr	att Ile 1540	atg Met	gat Asp	gct Ala	gat Asp	4713
cag Gln 1545	att Ile	att Ile	gtc Val	Leu	gat Asp 1550	gaa Glu	ggc Gly	gaa Glu	att Ile	gtc Val L555	ggt Gly	cgt Arg	ggt Gly	Thr	cac His 1560	4761
Ala	Gln	Leu	Ile	Glu L565	Asn	Asn	Ala	Ile	tat Tyr L570	Arg	Glu	Ile	Ala	Glu 1575	Ser	4809
caa Gln	ctg Leu	Lys	aac Asn 1580	caa Gln	aac Asn	tta Leu	Ser	gaa Glu L585	gga Gly	gag Glu	tgat			Arg I		4858
aaa																4906
		gtt Val	Phe					Ser	tac Tyr 1600				Tyr			
Lys act	Ser	Val ttc Phe	Phetta	Leu 1595 gcg	Arg att	Leu ttt	Trp ttg Leu	Ser	Tyr	Leu	Thr	Arg agt Ser	Tyr : ttt	Lys 1605 atg	Ala agt	4954

21 / 63

Asn	ctt Leu 1640	gtt Val	gat Asp	atg Met	Ala	aag Lys 1645	gga Gly	gtt Val	tct Ser	Gly	gca Ala 1650	gaa Glu	ttg Leu	aac Asn	gtt Val	5050
cct Pro 1655	tat Tyr	att Ile	gct Ala	Gly	att Ile 1660	ttg Leu	att Ile	att Ile	Tyr	ttt Phe 1665	ttc Phe	aga Arg	ggt Gly	Val	ttc Phe 1670	5098
			Gly			ggc Gly			t							5126
	<2 <2	210> 211> 212> 213>	229 PRT	eptod	cocci	ıs										
		100>														
Asn 1	Phe	Asp	Ile	Glu 5	Thr	Thr	Thr	Phe	Glu 10	Ala	Met	Lys	Lys	His 15	Ala	
	Leu	Leu	Glu 20	_	Ile	Ser	Val	Glu 25		Ser	Phe	Ile	Glu 30		Asp	
Lys	Leu	Leu 35	Leu	Ala	Pro	Tyr	Trp 40	Arg	Lys	Gly	Met	Leu 45	Ala	Leu	Ile	
Asp	Ser 50	His	Ala	Phe	Asn	Tyr 55	Leu	Pro	Cys	Leu	Lys 60	Asn	Arg	Glu	Leu	
	Leu	Ser	Ala	Phe		Ser	Gln	Leu	Asp		Asp	Phe	Leu	Phe		
65 Thr	Ser	Glu	Gln	Ala 85	70 Trp	Ala	Ser	Leu	Ile 90	75 Leu	Ser	Met	Glu	Val 95	80 Glu	
His	Thr	Lys	Thr 100		Leu	Lys	Lys	Trp		Thr	Ser	Thr	His 110		Gln	
Lys	Asp	Val 115		His	Ile	Val	Asp 120		Tyr	Arg	Ile	Arg 125		Gln	Met	
Gly	Leu 130	Ala	Lys	Glu	His	Leu 135	Tyr	Arg	Tyr	Gly	Lys 140		Ile	Ile	Lys	
	Ala	Glu	Gly	Ile		Lys	Ala	Arg	Gly	Leu	Met	Val	Asp	Phe		
145 Lvs	Ile	Glu	Gln	Leu	150 Asp	Ser	Glu	Leu	Ala	155 Ile	His	Asp	Ara	His	160 Glu	
				165					170					175		
Ile	Val		Asn 180			Thr									Pro	
Gly	Pro	Gln 195	Met	Gly		Ile									Val	
Leu	Gly 210	Gln	Leu	Ile	Asn	Glu 215	Glu	Glu	Ala	Ile	Leu 220	His	Phe	Val	Lys	
Gln 225		Leu	Met	Asp												
	7.5	210>	9													
		211>														
	<2	212>	PRT													

<213> Streptococcus

	< 4	400>	9												
Met 1	Ser	Asp	Phe	Leu 5	Val	Asp	Gly	Leu	Thr 10	Lys	Ser	Val	Gly	Asp 15	Lys
Thr	Val	Phe	Ser 20	Asn	Val	Ser	Phe	Ile 25	Ile	His	Ser	Leu	Asp 30	Arg	Ile
Gly	Ile	Ile 35	Gly	Val	Asn	Gly	Thr 40	Gly	Lys	Thr	Thr	Leu 45	Leu	Asp	Val
	50					Phe 55					60				
65					70	Ala				75					80
Asp	Ser	Gln	Thr	Ile 85	Leu	Asp	Thr	Val	Leu 90	Ser	Ser	Asp	Leu	Arg 95	Glu
			100			Tyr		105					110		
		115				Glu	120					125			
	130					Ser 135					140				
145					150	Leu				155					160
				165		Ala			170					175	
			180			Thr		185					190		
		195				Lys	200					205			
	210					Leu 215					220				
225					230	Thr				235					240
				245		Gln			250					255	
			260			Lys		265					270		
		275				Lys	280					285			
	290					His 295					300				
305					310	Arg				315					320
				325		Pro			330					335	
			340			Asp		345				_	350		_
		355				Leu	360					365			
	370					Ile 375					380				
385					390	Met				395					400
				405		Glu			410					415	
Val	Thr	Glu	Leu 420	Leu	Glu	Gln	Phe	Leu 425	Phe	Pro	Arg	Ser	Thr 430	His	Gly

23 / 63

Thr Gln Ile Ala Lys Leu Ser Gly Gly Glu Lys Lys Arg Leu Tyr Leu 440 Leu Lys Ile Leu Ile Glu Lys Pro Asn Val Leu Leu Leu Asp Glu Pro 455 Thr Asn Asp Leu Asp Ile Ala Thr Leu Thr Val Leu Glu Asn Phe Leu 470 475 Gln Gly Phe Gly Gly Pro Val Ile Thr Val Ser His Asp Arg Tyr Phe 485 490 Leu Asp Lys Val Ala Asn Lys Ile Ile Ala Phe Glu Asp Asn Asp Ile 500 505 Arg Glu Phe Phe Gly Asn Tyr Thr Asp Tyr Leu Asp Glu Lys Ala Phe 520 Asn Glu Gln Asn Asn Glu Val Ile Ser Lys Lys Glu Ser Thr Lys Thr 535 Ser Arg Glu Lys Gln Ser Arg Lys Arg Met Ser Tyr Phe Glu Lys Gln 550 555 Glu Trp Ala Thr Ile Glu Asp Asp Ile Met Ile Leu Glu Asn Thr Ile 565 570 Thr Arg Ile Glu Asn Asp Met Gln Thr Cys Gly Ser Asp Phe Thr Arg 580 585 Leu Ser Asp Leu Gln Lys Glu Leu Asp Ala Lys Asn Glu Ala Leu Leu 600 Glu Lys Tyr Asp Arg Tyr Glu Tyr Leu Ser Glu Leu Asp Thr <210> 10 <211> 157 <212> PRT <213> Streptococcus <400> 10 Met Ile Ile Arg Pro Ile Ile Lys Asn Asp Asp Gln Ala Val Ala Gln 10 Leu Ile Arg Gln Ser Leu Arg Ala Tyr Asp Leu Asp Lys Pro Asp Thr 25 Ala Tyr Ser Asp Pro His Leu Asp His Leu Thr Ser Tyr Tyr Glu Lys 40 Ile Glu Lys Ser Gly Phe Phe Val Ile Glu Glu Arg Asp Glu Ile Ile 55 Gly Cys Gly Gly Phe Gly Pro Leu Lys Asn Leu Ile Ala Glu Met Gln

Leu Ile Arg Gln Ser Leu Arg Ala Tyr Asp Leu Asp Lys Pro Asp Thr
20
Ala Tyr Ser Asp Pro His Leu Asp His Leu Thr Ser Tyr Tyr Glu Lys
35
Ala Tyr Ser Gly Phe Phe Val Ile Glu Glu Arg Asp Glu Ile Ile
50
Gly Cys Gly Gly Phe Gly Pro Leu Lys Asn Leu Ile Ala Glu Met Gln
65
Cys Val Tyr Ile Ala Glu Arg Phe Arg Gly Lys Gly Leu Ala Thr Asp
85
Leu Val Lys Met Ile Glu Val Glu Ala Arg Lys Ile Gly Tyr Arg Gln
100
Leu Tyr Leu Glu Thr Ala Ser Thr Leu Ser Arg Ala Thr Ala Val Tyr
115
Lys His Met Gly Tyr Cys Ala Leu Ser Gln Pro Ile Ala Asn Asp Gln
130
Gly His Thr Ala Met Asp Ile Trp Met Ile Lys Asp Leu
155

<210> 11

<211> 579

<212> PRT

<213> Streptococcus

	< 4	100>	11												
Met 1	Ala	Tyr	Ile	Trp 5	Ser	Tyr	Leu	Lys	Arg 10	Tyr	Pro	Asn	Trp	Leu 15	Trp
Leu	Asp	Leu	Leu 20	Gly	Ala	Met	Leu	Phe 25	Val	Thr	Val	Ile	Leu 30	Gly	Met
		35	Leu				40			-		45	-	-	-
	50		Val			55					60				
65			Ile		70					75					80
			Met	85					90					95	
			Ser 100					105					110		
		115	Met				120					125			
	130		Arg			135					140				
145			Ile		150					155					160
			Pro	165					170					175	
			Leu 180					185					190		
		195	Arg				200					205			
	210		Asn			215					220				
225			Thr		230					235					240
			Val	245					250					255	_
			Asp 260					265			-		270	-	
		275	Ile				280					285			
	290		Leu			295					300				
305			Glu		310					315					320
			Thr	325					330					335	
			Ala 340					345					350		
		355	Lys				360					365			
	370		Gly			375					380		_		_
385			Leu		390					395					400
			Lys	405					410					415	
Ala	Leu	Leu	Phe 420	Thr	Gly	Thr	Ile	Gly 425	Glu	Asn	Leu	Lys	Tyr 430	Gly	Lys

```
Ala Asp Ala Thr Ile Asp Asp Leu Arg Gln Ala Val Asp Ile Ser Gln
   435
                          440
Ala Lys Glu Phe Ile Glu Ser His Gln Glu Ala Phe Glu Thr His Leu
                      455
                                          460
Ala Glu Gly Gly Ser Asn Leu Ser Gly Gly Gln Lys Gln Arg Leu Ser
                   470
                                      475
Ile Ala Arg Ala Val Val Lys Asp Pro Asp Leu Tyr Ile Phe Asp Asp
               485
                                  490
Ser Phe Ser Ala Leu Asp Tyr Lys Thr Asp Ala Thr Leu Arg Ala Arg
          500
                       505
Leu Lys Glu Val Thr Gly Asp Ser Thr Val Leu Ile Val Ala Gln Arg
      515
                          520
Val Gly Thr Ile Met Asp Ala Asp Gln Ile Ile Val Leu Asp Glu Gly
                      535
Glu Ile Val Gly Arg Gly Thr His Ala Gln Leu Ile Glu Asn Asn Ala
                  550
                               555
Ile Tyr Arg Glu Ile Ala Glu Ser Gln Leu Lys Asn Gln Asn Leu Ser
                                 570
Glu Gly Glu
     <210> 12
     <211> 92
     <212> PRT
     <213> Streptococcus
     <400> 12
Met Arg Lys Lys Ser Val Phe Leu Arg Leu Trp Ser Tyr Leu Thr Arg
                                 10
Tyr Lys Ala Thr Leu Phe Leu Ala Ile Phe Leu Lys Val Leu Ser Ser
                             25
Phe Met Ser Val Leu Glu Pro Phe Ile Leu Gly Leu Ala Ile Thr Glu
                         40
Leu Thr Ala Asn Leu Val Asp Met Ala Lys Gly Val Ser Gly Ala Glu
                      55
                                         60
Leu Asn Val Pro Tyr Ile Ala Gly Ile Leu Ile Ile Tyr Phe Phe Arg
                                   75
Gly Val Phe Tyr Glu Leu Gly Ser Tyr Gly Ser Asn
     <210> 13
     <211> 5215
     <212> DNA
     <213> Streptococcus
     <220>
     <221> CDS
     <222> (3)...(122)
     <221> CDS
     <222> (133)...(2511)
     <221> CDS
     <222> (367)...(2511)
     <221> CDS
```

```
<222> (2946)...(2716)
      <223> of complementary strand
      <221> CDS
      <222> (3252)...(2995)
      <223> of complementary strand
      <221> CDS
      <222> (3676)...(3299)
      <223> of complementary strand
      <221> CDS
      <222> (4124)...(3837)
      <223> of complementary strand
      <221> CDS
      <222> (5214)...(4351)
      <223> of complementary strand
     <400> 13
aa ttt gga agt gct cta tca aca gtt gaa gta aag gag att att agt
                                                                      47
   Phe Gly Ser Ala Leu Ser Thr Val Glu Val Lys Glu Ile Ile Ser
gaa gaa aac ata tgg tta tat cgg ctc agt tgc tgc cat ttt act agc
                                                                      95
Glu Glu Asn Ile Trp Leu Tyr Arg Leu Ser Cys Cys His Phe Thr Ser
tac tca tat tgg aag tta cca act tgg taagcatcat atg ggt cta gca
                                                                     144
Tyr Ser Tyr Trp Lys Leu Pro Thr Trp
                                              Met Gly Leu Ala
aca aag gac aat cag att gcc tat att gat gac agc aaa ggt aag gca
                                                                     192
Thr Lys Asp Asn Gln Ile Ala Tyr Ile Asp Asp Ser Lys Gly Lys Ala
aaa gcc cct aaa aca aac aaa acg atg gat caa atc agt gct gaa gaa
                                                                     240
Lys Ala Pro Lys Thr Asn Lys Thr Met Asp Gln Ile Ser Ala Glu Glu
ggc atc tct gct gaa cag atc gta gtc aaa att act gac caa ggc tat
                                                                     288
Gly Ile Ser Ala Glu Gln Ile Val Val Lys Ile Thr Asp Gln Gly Tyr
gtg acc tca cac ggt gac cat tat cat ttt tac aat ggg aaa gtt cct
                                                                     336
Val Thr Ser His Gly Asp His Tyr His Phe Tyr Asn Gly Lys Val Pro
                            100
tat gat gcg att att agt gaa gag ttg ttg atg acq qat cct aat tac
                                                                     384
Tyr Asp Ala Ile Ile Ser Glu Glu Leu Leu Met Thr Asp Pro Asn Tyr
    110
                        115
cgt ttt aaa caa tca gac gtt atc aat gaa atc tta gac ggt tac gtt
                                                                     432
Arg Phe Lys Gln Ser Asp Val Ile Asn Glu Ile Leu Asp Gly Tyr Val
125
                    130
                                        135
                                                             140
```

												cca Pro				480
												caa Gln				528
												gtg Val 185				576
												aga Arg				624
												gat Asp				672
												cac His				720
												gct Ala				768
												tct Ser 265				816
												cct Pro				864
												ggc Gly				912
gcg Ala	cct Pro	cct Pro	Arg	cca Pro 305	Asn	gat Asp	Ala	Ser	caa Gln 310	Asn	Lys	cac His	caa Gln	aga Arg 315	gat Asp	960
gag Glu	ttt Phe	aaa Lys	gga Gly 320	aaa Lys	acc Thr	ttt Phe	aag Lys	gaa Glu 325	ctt Leu	tta Leu	gat Asp	caa Gln	cta Leu 330	cac His	cgt Arg	1008
ctt Leu	gat Asp	ttg Leu 335	aaa Lys	tac Tyr	cgt Arg	cat His	gtg Val 340	gaa Glu	gaa Glu	gat Asp	gly	ttg Leu 345	att Ile	ttt Phe	gaa Glu	1056
ccg Pro	act Thr 350	caa Gln	gtg Val	atc Ile	aaa Lys	tca Ser 355	aac Asn	gct Ala	ttt Phe	Gly aaa	tat Tyr 360	gtg Val	gtg Val	cct Pro	cat His	1104

gga Gly 365	gat Asp	cat His	tat Tyr	cat His	att Ile 370	atc Ile	cca Pro	aga Arg	agt Ser	cag Gln 375	tta Leu	tca Ser	cct Pro	ctt Leu	gaa Glu 380	1152
atg Met	gaa Glu	tta Leu	gca Ala	gat Asp 385	cga Arg	tac Tyr	tta Leu	gct Ala	ggc Gly 390	caa Gln	act Thr	gag Glu	gac Asp	aat Asn 395	gac Asp	1200
tca Ser	ggt Gly	tca Ser	gag Glu 400	cac His	tca Ser	aaa Lys	cca Pro	tca Ser 405	gat Asp	aaa Lys	gaa Glu	gtg Val	aca Thr 410	cat His	acc Thr	1248
ttt Phe	ctt Leu	ggt Gly 415	cat His	cgc Arg	atc Ile	aaa Lys	gct Ala 420	tac Tyr	gga Gly	aaa Lys	ggc Gly	tta Leu 425	gat Asp	ggt Gly	aaa Lys	1296
cca Pro	tat Tyr 430	gat Asp	acg Thr	agt Ser	gat Asp	gct Ala 435	tat Tyr	gtt Val	ttt Phe	agt Ser	aaa Lys 440	gaa Glu	tcc Ser	att Ile	cat His	1344
tca Ser 445	gtg Val	gat Asp	aaa Lys	tca Ser	gga Gly 450	gtt Val	aca Thr	gct Ala	aaa Lys	cac His 455	gga Gly	gat Asp	cat His	ttc Phe	cac His 460	1392
tat Tyr	ata Ile	gga Gly	ttt Phe	gga Gly 465	gaa Glu	ctt Leu	gaa Glu	caa Gln	tat Tyr 470	gag Glu	ttg Leu	gat Asp	gag Glu	gtc Val 475	gct Ala	1440
aac Asn	tgg Trp	gtg Val	aaa Lys 480	gca Ala	aaa Lys	ggt Gly	caa Gln	gct Ala 485	gat Asp	gag Glu	ctt Leu	gct Ala	gct Ala 490	gct Ala	ttg Leu	1488
gat Asp	cag Gln	gaa Glu 495	caa Gln	ggc Gly	aaa Lys	gaa Glu	aaa Lys 500	cca Pro	ctc Leu	ttt Phe	gac Asp	act Thr 505	aaa Lys	aaa Lys	gtg Val	1536
agt Ser	cgc Arg 510	aaa Lys	gta Val	aca Thr	aaa Lys	gat Asp 515	ggt Gly	aaa Lys	gtg Val	ggc Gly	tat Tyr 520	atg Met	atg Met	cca Pro	aaa Lys	1584
gat Asp 525	ggt Gly	aag Lys	gac Asp	tat Tyr	ttc Phe 530	Tyr	gct Ala	Arg	gat Asp	Gln	ctt Leu	gat Asp	ttg Leu	act Thr	cag Gln 540	1632
att Ile	gcc Ala	ttt Phe	gcc Ala	gaa Glu 545	caa Gln	gaa Glu	cta Leu	atg Met	ctt Leu 550	aaa Lys	gat Asp	aag Lys	aag Lys	cat His 555	tac Tyr	1680
cgt Arg	tat Tyr	gac Asp	att Ile 560	gtt Val	gac Asp	aca Thr	ggt Gly	att Ile 565	gag Glu	cca Pro	cga Arg	ctt Leu	gct Ala 570	gta Val	gat Asp	1728
gtg Val	tca Ser	agt Ser 575	ctg Leu	ccg Pro	atg Met	cat His	gct Ala 580	ggt Gly	aat Asn	gct Ala	act Thr	tac Tyr 585	gat Asp	act Thr	gga Gly	1776

agt Ser	tcg Ser 590	ttt Phe	gtt Val	atc Ile	cca Pro	cat His 595	att Ile	gat Asp	cat His	atc Ile	cat His 600	gtc Val	gtt Val	ccg Pro	tat Tyr	1824
tca Ser 605	tgg Trp	ttg Leu	acg Thr	cgc Arg	gat Asp 610	cag Gln	att Ile	gca Ala	aca Thr	gtc Val 615	aag Lys	tat Tyr	gtg Val	atg Met	caa Gln 620	1872
cac His	ccc Pro	gaa Glu	gtt Val	cgt Arg 625	ccg Pro	gat Asp	gta Val	tgg Trp	tct Ser 630	aag Lys	cca Pro	gly aaa	cat His	gaa Glu 635	gag Glu	1920
tca Ser	ggt Gly	tcg Ser	gtc Val 640	att Ile	cca Pro	aat Asn	gtt Val	acg Thr 645	cct Pro	ctt Leu	gat Asp	aaa Lys	cgt Arg 650	gct Ala	ggt Gly	1968
atg Met	cca Pro	aac Asn 655	tgg Trp	caa Gln	att Ile	atc Ile	cat His 660	tct Ser	gct Ala	gaa Glu	gaa Glu	gtt Val 665	caa Gln	aaa Lys	gcc Ala	2016
cta Leu	gca Ala 670	gaa Glu	ggt Gly	cgt Arg	ttt Phe	gca Ala 675	aca Thr	cca Pro	gac Asp	ggc Gly	tat Tyr 680	att Ile	ttc Phe	gat Asp	cca Pro	2064
cga Arg 685	gat Asp	gtt Val	ttg Leu	gcc Ala	aaa Lys 690	gaa Glu	act Thr	ttt Phe	gta Val	tgg Trp 695	aaa Lys	gat Asp	ggc Gly	tcc Ser	ttt Phe 700	2112
agc Ser	atc Ile	cca Pro	aga Arg	gca Ala 705	gat Asp	ggc Gly	agt Ser	tca Ser	ttg Leu 710	aga Arg	acc Thr	att Ile	aat Asn	aaa Lys 715	tct Ser	2160
gat Asp	cta Leu	tcc Ser	caa Gln 720	gct Ala	gag Glu	tgg Trp	caa Gln	caa Gln 725	gct Ala	caa Gln	gag Glu	tta Leu	ttg Leu 730	gca Ala	aag Lys	2208
aaa Lys	aat Asn	act Thr 735	ggt Gly	gat Asp	gct Ala	act Thr	gat Asp 740	acg Thr	gat Asp	aaa Lys	ccc Pro	aaa Lys 745	gaa Glu	aag Lys	caa Gln	2256
cag Gln	gca Ala 750	gat Asp	aag Lys	agc Ser	Asn	gaa Glu 755	aac Asn	caa Gln	cag Gln	cca Pro	agt Ser 760	gaa Glu	gcc Ala	agt Ser	aaa Lys	2304
gaa Glu 765	gaa Glu	aaa Lys	gaa Glu	tca Ser	gat Asp 770	gac Asp	ttt Phe	ata Ile	gac Asp	agt Ser 775	tta Leu	cca Pro	gac Asp	tat Tyr	ggt Gly 780	2352
cta Leu	gat Asp	aga Arg	gca Ala	acc Thr 785	cta Leu	gaa Glu	gat Asp	cat His	atc Ile 790	aat Asn	caa Gln	tta Leu	gca Ala	caa Gln 795	aaa Lys	2400
gct Ala	aat Asn	atc Ile	gat Asp 800	cct Pro	aag Lys	tat Tyr	ctc Leu	att Ile 805	ttc Phe	caa Gln	cca Pro	gaa Glu	ggt Gly 810	gtc Val	caa Gln	2448

```
ttt tat aat aaa aat ggt gaa ttg gta act tat gat atc aag aca ctt
                                                                    2496
Phe Tyr Asn Lys Asn Gly Glu Leu Val Thr Tyr Asp Ile Lys Thr Leu
                            820
caa caa ata aac cct taaccaaaag aagatctcat tgttaaagca ctgctttgtc
                                                                    2551
Gln Gln Ile Asn Pro
    830
aaagcaagtt acggtgattt tgaagtcatt ctatgtaacg agtagtgata aaagttggat 2611
aatagcggtt ttcttttgca aagaaatggt atccatgtta gaatagtaaa aaaagaggag 2671
2726
taaaataatt ttcttctttc tgattagggg ttagtcctag attagccgta tgtgggttgt 2786
aattgttata aaaattctca atgtattcaa agcagtctaa ttgaacctgt ttgatatttt 2846
gataatgttt tcggttgatt tgtctatgct ttaaatactt gaaaaatgct tcagttacgg 2906
cattatcata aggatatcca ggattagaaa aagaatgcat gatattggca ctgcacccta 2966
atagtgagac gcaagaaaaa cacttttaggcaatcagtt ttctgtactg tacaggcgac
atatttgtta tactatcttt gttgtatttt ctcctattat ggaaataaaa ggtttcagtc 3145
tttaggacgg tgtgaaacca ttcaatacag gcattatctg caggtgttcc ttttcgagac 3205 attgagcgga taatgtcttt ttccgtgcaa gcctggtagt aagccataga agtatacact 3265
gagccttggt cactgtgtaa gattgctcct ttatttaggcaatt ttaactgatt
aagggtgtct agtacaaaat ccgtgtcctg acaatctqaq ataqtqtaaq ctataatttc 3379
toggttatag agattcataa ttgatgagag atacaattta cagttaccqa aatataqqta 3439
ggtaatatct gttacgagct tttccttagg cttatcggca tggaaatccc gactcaattt 3499
attatctgtt aaataataag ctttacccaa attgggaact ttcttggtac gtgtccgaca 3559
aagccagcca ttattttca tgatacgata gactttcttt gtattaacag tcaatccgtg 3619
gatttttttg agcaatcgtg taatggtacg atagccataa ataaagtgat tctccataca 3679
gagctgttca attaattcaa taaggtcatc tttttttgcg gcttctcata ctcctttttc 3739
caacggtaat aggtcgaccg cttgacctta aaacagtcta gaatgaaaac tatcgggtag 3799
ttgtttttat agtcttccac aagcttgata agacttactttatcgatt tccttatcaa
                                                                    3857
gcctcgatac ttttttaaga ggtcaacctg taattgtaat tgttccactt cagacagatq 3917
ttccaagcct ttaccgtagg tatattgctt gccaacacct tgatgaaaac gataaagctc 3977
ctcgttttcg taccatttca tccaagtata gatttgacta ttatttttga tgcctaaagt 4037
ctccataata actctgttag acttgcctgc tttcttcata tcgatgcaag ccagcttagt 4097
ttcccatgaa tatgcttttt taaccataat aaaacattcc tgtttctagt ttactaaatt 4157
tcaacaggag tgttttctt ttgtctcatt ttagggattc agtgcctatt gttgtcatca 4217
attatttttc taaattcccc ggacttaaat tgtgaccctt ggtcggaatg aaagagaagt 4277
gttccttcaa tctttcttt attaagtgaa aaggcaacac ttttctgtac aacatttata 4337
aagtgttttt ctaggcaattaatc ttttagtcat tggtgtttgg tagttgagac
                                                                    4391
taccatgaat gcggtggtaa ttccaccaat gaacatagtc tttagtctta agagctagtt 4451
cttccagcaa ttgaaaggtt tcttgataaa caaattcaat tttgaaagca cgatacgtac 4511
tttcagctac ggcattgtca taaggataac cagcctgact aagcgaacgt gtgattccaa 4571
aggettecaa tattteatea attaaetgat tateaaaete tttgeeaega tetgaatgga 4631
acatcttgac tttggtcagg gcgtaaggga tgctttgtat ggcttgctta acgagttcag 4691
cggtcttgtg ccaaccaaga gacaggccga tgatttcacg gttgtatagg tcaatgatga 4751 ggcaaacata agcccaacga ttgcctacac gaacataggt taagtcagtg actaaggctt 4811 gtagtggtct ttcttgctta aattgcctgt ctaagtggtt gggaataggg gcttcattct 4871
tgcctctaga atgtggtttg aaggtggctt tctgataaac agaaaccaaa ttgagtcgct 4931
tcataatgcg tcgaatccga cgacgtgaaa gtgtgatacc ttcgttattc aagcatattt
tgatttttct ggatccgtat ctagactcgc tatcgagaaa aattctttta atagtttctt 5051
caaactccgt ttcagatact gactccacgg cttgatagta ataacttgag tgtggcatat 5111
tcagccagcg acacatcttt gaaatgctgt atttatcctt attagcagtg attatttccc 5171
tttttgtgcc ataatcaccg ctgcttgctt taggatatct aatt
                                                                    5215
      <210> 14
      <211> 40
      <212> PRT
```

31 / 63

<213> Streptococcus

<400> 14 Phe Gly Ser Ala Leu Ser Thr Val Glu Val Lys Glu Ile Ile Ser Glu Glu Asn Ile Trp Leu Tyr Arg Leu Ser Cys Cys His Phe Thr Ser Tyr 20 25 Ser Tyr Trp Lys Leu Pro Thr Trp 35

<210> 15

<211> 793

<212> PRT

<213> Streptococcus

<400> 15

Met Gly Leu Ala Thr Lys Asp Asn Gln Ile Ala Tyr Ile Asp Asp Ser 10 Lys Gly Lys Ala Lys Ala Pro Lys Thr Asn Lys Thr Met Asp Gln Ile 25 Ser Ala Glu Glu Gly Ile Ser Ala Glu Gln Ile Val Val Lys Ile Thr 40 Asp Gln Gly Tyr Val Thr Ser His Gly Asp His Tyr His Phe Tyr Asn 55 Gly Lys Val Pro Tyr Asp Ala Ile Ile Ser Glu Glu Leu Leu Met Thr 70 75 Asp Pro Asn Tyr Arg Phe Lys Gln Ser Asp Val Ile Asn Glu Ile Leu 90 Asp Gly Tyr Val Ile Lys Val Asn Gly Asn Tyr Tyr Val Tyr Leu Lys 105 Pro Gly Ser Lys Arg Lys Asn Ile Arg Thr Lys Gln Gln Ile Ala Glu 120 Gln Val Ala Lys Gly Thr Lys Glu Ala Lys Glu Lys Gly Leu Ala Gln Val Ala His Leu Ser Lys Glu Glu Val Ala Ala Val Asn Glu Ala Lys 150 Arg Gln Gly Arg Tyr Thr Thr Asp Asp Gly Tyr Ile Phe Ser Pro Thr 165 170 Asp Ile Ile Asp Asp Leu Gly Asp Ala Tyr Leu Val Pro His Gly Asn 185 190 His Tyr His Tyr Ile Pro Lys Lys Asp Leu Ser Pro Ser Glu Leu Ala 200 Ala Ala Gln Ala Tyr Trp Ser Gln Lys Gln Gly Arg Gly Ala Arg Pro 215 220 Ser Asp Tyr Arg Pro Thr Pro Ala Pro Gly Arg Arg Lys Ala Pro Ile 230 235 Pro Asp Val Thr Pro Asn Pro Gly Gln Gly His Gln Pro Asp Asn Gly 245 250 255 Gly Tyr His Pro Ala Pro Pro Arg Pro Asn Asp Ala Ser Gln Asn Lys 265 His Gln Arg Asp Glu Phe Lys Gly Lys Thr Phe Lys Glu Leu Leu Asp 275 280 Gln Leu His Arg Leu Asp Leu Lys Tyr Arg His Val Glu Glu Asp Gly 300 Leu Ile Phe Glu Pro Thr Gln Val Ile Lys Ser Asn Ala Phe Gly Tyr 310 315

Val	Val	Pro	His	Gly 325	Asp	His	Tyr	His	Ile 330	Ile	Pro	Arg	Ser		Leu
Ser	Pro	Leu	Glu 340		Glu	Leu	Ala	Asp		Tyr	Leu	Ala	Gly 350	335 Gln	Thr
Glu	Asp	Asn 355		Ser	Gly	Ser	Glu 360		Ser	Lys	Pro	Ser 365		Lys	Glu
Val	Thr 370		Thr	Phe	Leu	Gly 375		Arg	Ile	Lys	Ala 380	Tyr	Gly	Lys	Gly
Leu 385	Asp	Gly	Lys	Pro	Tyr 390	Asp	Thr	Ser	Asp	Ala 395		Val	Phe	Ser	Lys 400
Glu	Ser	Ile	His	Ser 405	Val	Asp	Lys	Ser	Gly 410	Val	Thr	Ala	Lys	His 415	Gly
			420					425				Gln	430		
		435					440					Ala 445			
	450					455					460	Pro			
465					470					475		Lys			480
				485					490			Arg		495	
			500					505				Met	510	_	_
		515					520					Ile 525			
	530					535					540	Gly			
545					550					555		Asp			560
				565					570			Ala		575	
			580					585				Trp	590		
		595					600					Thr 605			
	610					615					620	Ser			
625					630					635		Pro			640
				645					650			Phe		655	
			660					665				Ser	670		
		675					680					Gln 685			
	690					695					700	Thr			
705					710					715		Gln			720
				725					730			Ile	-	735	
			740					745				His	750		
Leu		(- I D	LAVS	Ala	Δcn	110	AGD	Dro	1370	Tree	T 023	TIA	Dho	712	Dro

33 / 63

Glu Gly Val Gln Phe Tyr Asn Lys Asn Gly Glu Leu Val Thr Tyr Asp 775 Ile Lys Thr Leu Gln Gln Ile Asn Pro <210> 16 <211> 715 <212> PRT <213> Streptococcus <400> 16 Met Thr Asp Pro Asn Tyr Arg Phe Lys Gln Ser Asp Val Ile Asn Glu 10 Ile Leu Asp Gly Tyr Val Ile Lys Val Asn Gly Asn Tyr Tyr Val Tyr 2.0 25 Leu Lys Pro Gly Ser Lys Arg Lys Asn Ile Arg Thr Lys Gln Gln Ile 40 Ala Glu Gln Val Ala Lys Gly Thr Lys Glu Ala Lys Glu Lys Gly Leu 55 Ala Gln Val Ala His Leu Ser Lys Glu Glu Val Ala Ala Val Asn Glu 75 Ala Lys Arg Gln Gly Arg Tyr Thr Thr Asp Asp Gly Tyr Ile Phe Ser 90 Pro Thr Asp Ile Ile Asp Asp Leu Gly Asp Ala Tyr Leu Val Pro His 105 Gly Asn His Tyr His Tyr Ile Pro Lys Lys Asp Leu Ser Pro Ser Glu 120 Leu Ala Ala Gln Ala Tyr Trp Ser Gln Lys Gln Gly Arg Gly Ala 135 Arg Pro Ser Asp Tyr Arg Pro Thr Pro Ala Pro Gly Arg Arg Lys Ala 150 155 Pro Ile Pro Asp Val Thr Pro Asn Pro Gly Gln Gly His Gln Pro Asp 165 170 Asn Gly Gly Tyr His Pro Ala Pro Pro Arg Pro Asn Asp Ala Ser Gln 185 Asn Lys His Gln Arg Asp Glu Phe Lys Gly Lys Thr Phe Lys Glu Leu 205 200 Leu Asp Gln Leu His Arg Leu Asp Leu Lys Tyr Arg His Val Glu Glu 215 220 Asp Gly Leu Ile Phe Glu Pro Thr Gln Val Ile Lys Ser Asn Ala Phe 230 235 Gly Tyr Val Val Pro His Gly Asp His Tyr His Ile Ile Pro Arg Ser 245 250 Gln Leu Ser Pro Leu Glu Met Glu Leu Ala Asp Arg Tyr Leu Ala Gly 260 265 Gln Thr Glu Asp Asn Asp Ser Gly Ser Glu His Ser Lys Pro Ser Asp 280 Lys Glu Val Thr His Thr Phe Leu Gly His Arg Ile Lys Ala Tyr Gly 295 300 Lys Gly Leu Asp Gly Lys Pro Tyr Asp Thr Ser Asp Ala Tyr Val Phe 310 315 Ser Lys Glu Ser Ile His Ser Val Asp Lys Ser Gly Val Thr Ala Lys 330 His Gly Asp His Phe His Tyr Ile Gly Phe Gly Glu Leu Glu Gln Tyr

345

34 / 63

```
Glu Leu Asp Glu Val Ala Asn Trp Val Lys Ala Lys Gly Gln Ala Asp
              360
Glu Leu Ala Ala Ala Leu Asp Gln Glu Gln Gly Lys Glu Lys Pro Leu
                    375
Phe Asp Thr Lys Lys Val Ser Arg Lys Val Thr Lys Asp Gly Lys Val
    390
                                  395
Gly Tyr Met Met Pro Lys Asp Gly Lys Asp Tyr Phe Tyr Ala Arg Asp
             405
                              410
Gln Leu Asp Leu Thr Gln Ile Ala Phe Ala Glu Gln Glu Leu Met Leu
                           425
Lys Asp Lys Lys His Tyr Arg Tyr Asp Ile Val Asp Thr Gly Ile Glu
                        440
                                        445
Pro Arg Leu Ala Val Asp Val Ser Ser Leu Pro Met His Ala Gly Asn
                    455
                                      460
Ala Thr Tyr Asp Thr Gly Ser Ser Phe Val Ile Pro His Ile Asp His
                470
                                  475
Ile His Val Val Pro Tyr Ser Trp Leu Thr Arg Asp Gln Ile Ala Thr
             485
                               490
Val Lys Tyr Val Met Gln His Pro Glu Val Arg Pro Asp Val Trp Ser
                 505
Lys Pro Gly His Glu Glu Ser Gly Ser Val Ile Pro Asn Val Thr Pro
                       520
Leu Asp Lys Arg Ala Gly Met Pro Asn Trp Gln Ile Ile His Ser Ala
                   535
Glu Glu Val Gln Lys Ala Leu Ala Glu Gly Arg Phe Ala Thr Pro Asp
545 550 555 560
Gly Tyr Ile Phe Asp Pro Arg Asp Val Leu Ala Lys Glu Thr Phe Val
           565
                              570
Trp Lys Asp Gly Ser Phe Ser Ile Pro Arg Ala Asp Gly Ser Ser Leu
    580 585
Arg Thr Ile Asn Lys Ser Asp Leu Ser Gln Ala Glu Trp Gln Gln Ala
595 600
Gln Glu Leu Leu Ala Lys Lys Asn Thr Gly Asp Ala Thr Asp Thr Asp
  610 615 620
Lys Pro Lys Glu Lys Gln Gln Ala Asp Lys Ser Asn Glu Asn Gln Gln
                      635 640
Pro Ser Glu Ala Ser Lys Glu Glu Lys Glu Ser Asp Asp Phe Ile Asp
                  650 655
Ser Leu Pro Asp Tyr Gly Leu Asp Arg Ala Thr Leu Glu Asp His Ile
Asn Gln Leu Ala Gln Lys Ala Asn Ile Asp Pro Lys Tyr Leu Ile Phe
                       680
Gln Pro Glu Gly Val Gln Phe Tyr Asn Lys Asn Gly Glu Leu Val Thr
                    695
Tyr Asp Ile Lys Thr Leu Gln Gln Ile Asn Pro
705
                 710
    <210> 17
     <211> 77
     <212> PRT
     <213> Streptococcus
Met His Ser Phe Ser Asn Pro Gly Tyr Pro Tyr Asp Asn Ala Val Thr
```

10

35 / 63

Glu Ala Phe Phe Lys Tyr Leu Lys His Arg Gln Ile Asn Arg Lys His 25 Tyr Gln Asn Ile Lys Gln Val Gln Leu Asp Cys Phe Glu Tyr Ile Glu 40 Asn Phe Tyr Asn Asn Tyr Asn Pro His Thr Ala Asn Leu Gly Leu Thr 55 Pro Asn Gln Lys Glu Glu Asn Tyr Phe Asn Ala Ile Lys <210> 18 <211> 86 <212> PRT <213> Streptococcus <400> 18 Met Ala Tyr Tyr Gln Ala Cys Thr Glu Lys Asp Ile Ile Arg Ser Met 10 Ser Arg Lys Gly Thr Pro Ala Asp Asn Ala Cys Ile Glu Trp Phe His 25 Thr Val Leu Lys Thr Glu Thr Phe Tyr Phe His Asn Arg Arg Lys Tyr 40 Asn Lys Asp Ser Ile Thr Asn Ile Val Lys Asn Tyr Ile Thr Phe Tyr 55 Asn Glu Thr Arg Ile Gln Gln Arg Leu Asn Asp Gln Ser Pro Val Gln Tyr Arg Lys Leu Ile Ala <210> 19 <211> 126 <212> PRT <213> Streptococcus <400> 19 Met Glu Asn His Phe Ile Tyr Gly Tyr Arg Thr Ile Thr Arg Leu Leu 5 10 Lys Lys Ile His Gly Leu Thr Val Asn Thr Lys Lys Val Tyr Arg Ile Met Lys Asn Asn Gly Trp Leu Cys Arg Thr Arg Thr Lys Lys Val Pro 40 Asn Leu Gly Lys Ala Tyr Tyr Leu Thr Asp Asn Lys Leu Ser Arg Asp 55 Phe His Ala Asp Lys Pro Lys Glu Lys Leu Val Thr Asp Ile Thr Tyr Leu Tyr Phe Gly Asn Cys Lys Leu Tyr Leu Ser Ser Ile Met Asn Leu 90 Tyr Asn Arg Glu Ile Ile Ala Tyr Thr Ile Ser Asp Cys Gln Asp Thr 105 Asp Phe Val Leu Asp Thr Leu Asn Gln Leu Lys Leu Pro Lys <210> 20 <211> 96

<212> PRT

<213> Streptococcus

36 / 63

<400> 20 Met Val Lys Lys Ala Tyr Ser Trp Glu Thr Lys Leu Ala Cys Ile Asp 10 Met Lys Lys Ala Gly Lys Ser Asn Arg Val Ile Met Glu Thr Leu Gly 25 Ile Lys Asn Asn Ser Gln Ile Tyr Thr Trp Met Lys Trp Tyr Glu Asn 40 Glu Glu Leu Tyr Arg Phe His Gln Gly Val Gly Lys Gln Tyr Thr Tyr 55 Gly Lys Gly Leu Glu His Leu Ser Glu Val Glu Gln Leu Gln Leu Gln 70 75 Val Asp Leu Leu Lys Lys Tyr Arg Gly Leu Ile Arg Lys Ser Ile Lys <210> 21 <211> 288 <212> PRT <213> streptococus <400> 21 Ile Arg Tyr Pro Lys Ala Ser Ser Gly Asp Tyr Gly Thr Lys Arg Glu Ile Ile Thr Ala Asn Lys Asp Lys Tyr Ser Ile Ser Lys Met Cys Arg Trp Leu Asn Met Pro His Ser Ser Tyr Tyr Tyr Gln Ala Val Glu Ser 40 Val Ser Glu Thr Glu Phe Glu Glu Thr Ile Lys Arg Ile Phe Leu Asp 50 55 Ser Glu Ser Arg Tyr Gly Ser Arg Lys Ile Lys Ile Cys Leu Asn Asn 70 Glu Gly Ile Thr Leu Ser Arg Arg Ile Arg Arg Ile Met Lys Arg 85 90 Leu Asn Leu Val Ser Val Tyr Gln Lys Ala Thr Phe Lys Pro His Ser 105 110 Arg Gly Lys Asn Glu Ala Pro Ile Pro Asn His Leu Asp Arg Gln Phe 120 125 Lys Gln Glu Arg Pro Leu Gln Ala Leu Val Thr Asp Leu Thr Tyr Val Arg Val Gly Asn Arg Trp Ala Tyr Val Cys Leu Ile Ile Asp Leu Tyr 150 Asn Arg Glu Ile Ile Gly Leu Ser Leu Gly Trp His Lys Thr Ala Glu 170 Leu Val Lys Gln Ala Ile Gln Ser Ile Pro Tyr Ala Leu Thr Lys Val 185 Lys Met Phe His Ser Asp Arg Gly Lys Glu Phe Asp Asn Gln Leu Ile 200 Asp Glu Ile Leu Glu Ala Phe Gly Ile Thr Arg Ser Leu Ser Gln Ala 215 220 Gly Tyr Pro Tyr Asp Asn Ala Val Ala Glu Ser Thr Tyr Arg Ala Phe 230 235 Lys Ile Glu Phe Val Tyr Gln Glu Thr Phe Gln Leu Leu Glu Glu Leu 250 Ala Leu Lys Thr Lys Asp Tyr Val His Trp Trp Asn Tyr His Arg Ile 265 His Gly Ser Leu Asn Tyr Gln Thr Pro Met Thr Lys Arg Leu Ile Ala

	<: <:	212>	22 505 DNA str		cocci	ıs										
	< 2	220> 221> 222>	CDS	((563)											
		221> 222>	CDS (76	3)	. (134	14)										
		221> 222>	CDS (13	52).	(1	739)										
		221> 222>	CDS	56).	(5	058)										
		400	0.0													
		100>		~												
								gaa Glu								48
								tca Ser 25								96
								cta Leu								144
cct Pro	gct Ala 50	cgt Arg	gct Ala	ttc Phe	tta Leu	gat Asp 55	gtt Val	aca Thr	gcc Ala	aac Asn	att Ile 60	att Ile	cac His	gaa Glu	gac Asp	192
								gct Ala								240
cca Pro	ttg Leu	agc Ser	atg Met	aat Asn 85	gca Ala	ggt Gly	gtc Val	ttc Phe	cag Gln 90	ttt Phe	gat Asp	gaa Glu	act Thr	aat Asn 95	gat Asp	288
gat Asp	aat Asn	act Thr	atc Ile 100	gct Ala	ctt Leu	aat Asn	ttc Phe	cgt Arg 105	tac Tyr	cca Pro	caa Gln	Gly aaa	aca Thr 110	gat Asp	gct Ala	336
aaa Lys	act Thr	atc Ile 115	caa Gln	act Thr	aag Lys	ctt Leu	gag Glu 120	aaa Lys	ctt Leu	aac Asn	gga Gly	gtt Val 125	gaa Glu	aaa Lys	gtg Val	384
act Thr	ctt Leu 130	tct Ser	gac Asp	cat His	gaa Glu	cac His 135	aca Thr	cca Pro	cac His	tat Tyr	gta Val 140	cct Pro	atg Met	gac Asp	gat Asp	432

_							_	_			ggt Gly		480
		-	_		 					_	tta Leu 175		528
											aac Asn		576
											cgt Arg		624
			gaa Glu							taaa	aataa	atc	673
		-		_	atg	act	gac	ttg	gaa	aaa	gtctt att Ile		733 786
											aat Asn		834
											att Ile 260		882
	-					_	_	_			tgg Trp		930
											gaa Glu		978
											ttt Phe		1026
											ggt Gly		1074
							_	_			gtt Val 340		1122
											gga Gly		1170

tcc gca cat Ser Ala His 360	Lys Asn	cta aca Leu Thr	gaa aca Glu Thr 365	gtt aaa Val Lys	a gct tac 370	aaa gac Lys Asp	tat 1218 Tyr
cta ccc gat Leu Pro Asp 375	tat tta Tyr Leu	ccc ctg Pro Leu 380	gtt cac Val His	cca tca Pro Ser	ccg cga Pro Arg 385	aat caa Asn Gln	att 1266 Ile
tgg cta aag Trp Leu Lys 390	aag aat Lys Asn	cca tgg Pro Trp 395	ttt gaa Phe Glu	aaa gat Lys Asp 400	Leu Ile	gtt gat Val Asp	tta 1314 Leu 405
caa aag ata Gln Lys Ile		Asp Ile			ıggatagg	agttggt a Me	_
aga gat aat Arg Asp Asr	cat cta His Leu 420	cac acg His Thr	tat ttt Tyr Phe 425	tcc tat Ser Tyr	gat tgt Asp Cys	caa acg Gln Thr 430	gca 1412 Ala
ttt gag gac Phe Glu Asp 435	Tyr Ile	aat ggt Asn Gly	ttt aca Phe Thr 440	ggt gaa Gly Glu	ttt atc Phe Ile 445	acg aca Thr Thr	gaa 1460 Glu
cat ttt gat His Phe Asp 450	tta tca Leu Ser	aat cct Asn Pro 455	tac acc Tyr Thr	ggt caa Gly Gln	gac gat Asp Asp 460	gtt cct Val Pro	gat 1508 Asp
tat agt gct Tyr Ser Ala 465	tat tgt Tyr Cys	caa aaa Gln Lys 470	ata gat Ile Asp	tat ctt Tyr Leu 475	Asn Gln	aaa tat Lys Tyr	gga 1556 Gly 480
aat cga ttt Asn Arg Phe	aaa aaa Lys Lys 485	gga att Gly Ile	gaa atc Glu Ile	ggt tat Gly Tyr 490	ttt aaa Phe Lys	gat agg Asp Arg 495	gaa 1604 Glu
tca gat att Ser Asp Ile							
ttg tca atc Leu Ser Ile 515	His His	aat ggt Asn Gly	agg tat Arg Tyr 520	gat tat Asp Tyr	ctg caa Leu Gln 525	gaa gaa Glu Glu	gct 1700 Ala
ctg aaa gta Leu Lys Val 530	cca aca Pro Thr	aag gga Lys Gly 535	gct ttt Ala Phe	agc aga Ser Arg	tta ctt Leu Leu 540	taatcgta	atg 1749
gaatttgcca aagttaaact ataaagatgt gggaatgaaa tactctatag caaggtctgc taaaaaagct	tagatgta tatctaag aactttat gctctgac taaaggac	ga agatt gg gttag cg ctatg gg tcata ta tcaaa	taaaa co ctttt ga cttta ga ttcct ga ttgat ga	gtttgaaa actaaata gatactca acattttt aaatcatt	cgcaatte ccaaatce aacagcte gttatgaa tgatatga	gaa gogoa cot ttato tgg ttgta att tgata agg aaatt	ttttc 1869 tatat 1929 taacaa 1989 tgactt 2049 ttttga 2109

										atg	aaa	aga	aaa aaa Lys 545	gac		2229 2283
													agt Ser			2331
													agt Ser			2379
													gcg Ala			2427
													aat Asn			2475
													tca Ser 625			2523
													caa Gln			2571
													aat Asn			2619
													cca Pro			2667
										_			gct Ala		_	2715
													aat Asn 705			2763
ttt Phe	agg Arg	cta Leu 710	cat His	ctt Leu	aaa Lys	gaa Glu	ttg Leu 715	cct Pro	caa Gln	ggt Gly	cat His	cct Pro 720	gta Val	gaa Glu	agc Ser	2811
													agt Ser			2859
													gat Asp			2907

						tta Leu										2955
ttt Phe	tta Leu	att Ile	aat Asn 775	aac Asn	aaa Lys	gca Ala	gly aaa	aca Thr 780	aat Asn	tta Leu	agc Ser	ggc Gly	gat Asp 785	cat His	cat His	3003
att Ile	cca Pro	tta Leu 790	tta Leu	cga Arg	cct Pro	gag Glu	atg Met 795	aac Asn	caa Gln	gtt Val	tgg Trp	att Ile 800	gat Asp	gaa Glu	aag Lys	3051
tac Tyr	ggt Gly 805	ata Ile	cat His	act Thr	tat Tyr	caa Gln 810	ccc Pro	ctc Leu	aaa Lys	gaa Glu	ggg Gly 815	tat Tyr	gtc Val	cgt Arg	att Ile	3099
aac Asn 820	tat Tyr	ttg Leu	agt Ser	tcc Ser	tct Ser 825	agt Ser	aac Asn	tat Tyr	gac Asp	cac His 830	tta Leu	tca Ser	gca Ala	tgg Trp	ctc Leu 835	3147
ttt Phe	aaa Lys	gat Asp	gtt Val	gca Ala 840	acc Thr	ссу Хаа	tca Ser	aca Thr	act Thr 845	tgg Trp	cca Pro	gat Asp	ggt Gly	agt Ser 850	aat Asn	3195
ttt Phe	gtg Val	aat Asn	caa Gln 855	gga Gly	cta Leu	tat Tyr	gga Gly	agg Arg 860	tat Tyr	att Ile	gat Asp	gta Val	tca Ser 865	cta Leu	aaa Lys	3243
act Thr	aac Asn	gcc Ala 870	aaa Lys	gag Glu	att Ile	ggt Gly	ttt Phe 875	cta Leu	atc Ile	tta Leu	gat Asp	gaa Glu 880	agt Ser	aag Lys	aca Thr	3291
gga Gly	gat Asp 885	gca Ala	gtg Val	aaa Lys	gtt Val	caa Gln 890	ccc Pro	aac Asn	gac Asp	tat Tyr	gtt Val 895	ttt Phe	aga Arg	gat Asp	tta Leu	3339
gct Ala 900	aac Asn	cat His	aac Asn	caa Gln	att Ile 905	ttt Phe	gta Val	aaa Lys	gat Asp	aag Lys 910	gat Asp	cca Pro	aag Lys	gtt Val	tat Tyr 915	3387
aat Asn	aat Asn	Pro	Tyr	tac Tyr 920	Ile	gat Asp	caa Gln	Val	cag Gln 925	Leu	aag Lys	gat Asp	gcc Ala	caa Gln 930	caa Gln	3435
att Ile	gat Asp	tta Leu	aca Thr 935	agt Ser	att Ile	caa Gln	gca Ala	agt Ser 940	ttt Phe	aca Thr	act Thr	cta Leu	gat Asp 945	gly ggg	gta Val	3483
gat Asp	aaa Lys	act Thr 950	gaa Glu	att Ile	tta Leu	aaa Lys	gaa Glu 955	ttg Leu	aaa Lys	gtg Val	act Thr	gat Asp 960	aaa Lys	aat Asn	caa Gln	3531
aat Asn	gct Ala 965	ata Ile	caa Gln	att Ile	tct Ser	gat Asp 970	atc Ile	act Thr	ctc Leu	gat Asp	act Thr 975	agt Ser	aaa Lys	tct Ser	ctt Leu	3579

	Ile					Phe					Gly		ttc Phe			3627
					Asn					Gln			gaa Glu		Lys	3675
gac Asp	caa Gln	ctt Leu	tat Tyr 101	Ala	tat Tyr	agt Ser	gga Gly	aat Asn 1020	Leu	ggt Gly	gca Ala	gtt Val	ctc Leu 1025	Asn	caa Gln	3723
			Lys					Leu					gct Ala)			3771
		Met					Lys					Arg	gtt Val			3819
	Thr					Asn					Trp		acg Thr			3867
gat Asp	act Thr	aaa Lys	tta Leu	ggt Gly 1080	Ile	aaa Lys	aac Asn	tat Tyr	act Thr 1085	Gly	tac Tyr	tat Tyr	tat Tyr	ctt Leu 1090	Tyr	3915
				Gly					Lys				cct Pro 1105	Tyr		3963
			Ala					Asn					gat Asp)			4011
		Lys					Asn					Gly	cct Pro			4059
	Ser					Ala	Asn	Phe		Gly	Arg	Gln	gat Asp			4107
ata Ile	tac Tyr	gaa Glu	gca Ala	cat His 1160	Val	aga Arg	gac Asp	ttc Phe	act Thr 1165	Ser	gat Asp	cga Arg	tct Ser	ttg Leu 1170	Asp	4155
	222	tta	aaa	aat	caa	ttt							tca			4203
GIY	Lys			Asn		Phe	Gly	Thr 1180		Ala	Ala	Phe	Ser 1185		Lys	

gta ttg agt Val Leu Ser 1205	tat ttt tat Tyr Phe Tyr	gtt aat g Val Asn G 1210	gaa atg gat Glu Met Asp	aag tca cgc Lys Ser Arg 1215	tca aca 4299 Ser Thr	I
	tcc tca gac Ser Ser Asp 122	Asn Asn T		Gly Tyr Asp		
-	gct ctt tct Ala Leu Ser 1240				2	
	atc gcc gaa Ile Ala Glu 1255	Leu Lys G			His Lys	
	ggg gtt ata Gly Val Ile O				~	
	ttt gag gat Phe Glu Asp					
	tca cca aga Ser Pro Arg 130	Glu Ser P		Gly Arg Leu		
	atg agt cgt Met Ser Arg 1320					
	ttt aaa gtt Phe Lys Val 1335	Asp Gly P			Gly Asp	
	gct gcg att Ala Ala Ile O					
aat cct aat Asn Pro Asn 1365	atg att atg Met Ile Met	att ggt g Ile Gly G 1370	gag ggc tgg Glu Gly Trp	Arg Thr Phe	caa ggc 4779 Gln Gly	
	cag ccg gtt Gln Pro Val 138	Lys Pro A		Asp Trp Met		
acc gat aca Thr Asp Thr	gtt ggc gtc Val Gly Val 1400	ttt tca g Phe Ser A	gat gat att Asp Asp Ile 1405	cgt aat agc Arg Asn Ser	ttg aaa 4875 Leu Lys 1410	
tct ggt ttt Ser Gly Phe	cca aat gaa Pro Asn Glu 1415	Gly Thr P	cca gct ttc Pro Ala Phe 1420	atc aca ggt Ile Thr Gly 142	Gly Pro	

44 / 63

caa tot tta caa ggt att ttt aaa aat atc aaa gca caa cot ggg aat 4971 Gln Ser Leu Gln Gly Ile Phe Lys Asn Ile Lys Ala Gln Pro Gly Asn ttt gaa gca gat tcg cca gga gat gtg gtg cag tat att gct gca cat 5019 Phe Glu Ala Asp Ser Pro Gly Asp Val Val Gln Tyr Ile Ala Ala His 1450 gat aac ctt acc ttg cat gat gtg att gca aaa tca att 5058 Asp Asn Leu Thr Leu His Asp Val Ile Ala Lys Ser Ile 1465 <210> 23 <211> 221 <212> PRT <213> streptococcus <400> 23 Asn Leu Lys Ala Glu Leu Ser Val Glu Asp Glu Gln Tyr Thr Ala Thr Val Tyr Gly Lys Ser Ala His Gly Ser Thr Pro Gln Glu Gly Val Asn 20 25 Gly Ala Thr Tyr Leu Ala Leu Tyr Leu Ser Gln Phe Asp Phe Glu Gly 40 Pro Ala Arg Ala Phe Leu Asp Val Thr Ala Asn Ile Ile His Glu Asp 55 Phe Ser Gly Glu Lys Leu Gly Val Ala Tyr Glu Asp Asp Cys Met Gly 75 Pro Leu Ser Met Asn Ala Gly Val Phe Gln Phe Asp Glu Thr Asn Asp 85 90 Asp Asn Thr Ile Ala Leu Asn Phe Arg Tyr Pro Gln Gly Thr Asp Ala 105 Lys Thr Ile Gln Thr Lys Leu Glu Lys Leu Asn Gly Val Glu Lys Val 120 Thr Leu Ser Asp His Glu His Thr Pro His Tyr Val Pro Met Asp Asp 135 Glu Leu Val Ser Thr Leu Leu Ala Val Tyr Glu Lys Gln Thr Gly Leu 150 Lys Gly His Glu Gln Val Ile Gly Gly Gly Thr Phe Gly Arg Leu Leu 165 170 Glu Arg Gly Val Ala Tyr Gly Ala Met Phe Pro Gly Asp Glu Asn Thr 185 Met His Gln Ala Asn Glu Tyr Met Pro Leu Glu Asn Ile Phe Arg Ser 200 Ala Ala Ile Tyr Ala Glu Ala Ile Tyr Glu Leu Ile Lys 215 <210> 24 <211> 194 <212> PRT <213> streptococcus

<400> 24

45 / 63

Met Thr Asp Leu Glu Lys Ile Ile Lys Ala Ile Lys Ser Asp Ser Gln 10 Asn Gln Asn Tyr Thr Glu Asn Gly Ile Asp Pro Leu Phe Ala Ala Pro 25 Lys Thr Ala Arg Ile Asn Ile Val Gly Gln Ala Pro Gly Leu Lys Thr 40 Gln Glu Ala Arg Leu Tyr Trp Lys Asp Lys Ser Gly Asp Arg Leu Arg Gln Trp Leu Gly Val Asp Glu Glu Thr Phe Tyr His Ser Gly Lys Phe Ala Val Leu Pro Leu Asp Phe Tyr Tyr Pro Gly Lys Gly Lys Ser Gly Asp Leu Pro Pro Arg Lys Gly Phe Ala Glu Lys Trp His Pro Leu Ile 100 105 Leu Lys Glu Met Pro Asn Val Gln Leu Thr Leu Leu Val Gly Gln Tyr 120 Ala Gln Lys Tyr Tyr Leu Gly Ser Ser Ala His Lys Asn Leu Thr Glu 135 Thr Val Lys Ala Tyr Lys Asp Tyr Leu Pro Asp Tyr Leu Pro Leu Val 150 155 His Pro Ser Pro Arg Asn Gln Ile Trp Leu Lys Lys Asn Pro Trp Phe 170 Glu Lys Asp Leu Ile Val Asp Leu Gln Lys Ile Val Ala Asp Ile Leu Lys Asp

<210> 25

<211> 126

<212> PRT

<213> streptococcus

<400> 25

 Met
 Arg
 Asp
 Asn
 His
 Leu
 His
 Thr
 Tyr
 Phe
 Ser
 Tyr
 Asp
 Cys
 Gln
 Thr

 Ala
 Phe
 Glu
 Asp
 Tyr
 Ile
 Asn
 Gly
 Phe
 Thr
 Glu
 Phe
 Ile
 Thr
 Thr
 Asp
 Ile
 Thr
 Thr
 Asp
 Ile
 Thr
 Thr
 Ile
 Ile
 Ile
 Thr
 Ile
 Ile

<210> 26

<211> 931

<212> PRT

<213> streptococcus

<400> 26

Met 1	Lys	Arg	Lys	Asp 5	Leu	Phe	Gly	Asp	Lys 10	Gln	Thr	Gln	Tyr	Thr 15	Ile
Arg	Lys	Leu	Ser 20	Val	Gly	Val	Ala	Ser 25	Val	Thr	Thr	Gly	Val 30	Cys	Ile
Phe	Leu	His 35	Ser	Pro	Gln	Val	Phe 40	Ala	Glu	Glu	Val	Ser 45	Val	Ser	Pro
Ala	Thr 50	Thr	Ala	Ile	Ala	Glu 55	Ser	Asn	Ile	Asn	Gln 60	Val	Asp	Asn	Gln
Gln 65	Ser	Thr	Asn	Leu	Lys 70	Asp	Asp	Ile	Asn	Ser 75		Ser	Glu	Thr	Val 80
Val	Thr	Pro	Ser	Asp 85	Met	Pro	Asp	Thr	Lys 90	Gln	Leu	Val	Ser	Asp 95	
Thr	Asp	Thr	Gln 100	Lys	Gly	Val	Thr	Glu 105	Pro	Asp	Lys	Ala	Thr 110	Ser	Leu
Leu	Glu	Glu 115	Asn	Lys	Gly	Pro	Val 120	Ser	Asp	Lys	Asn	Thr 125	Leu	Asp	Leu
Lys	Val 130	Ala	Pro	Ser	Thr	Leu 135	Gln	Asn	Thr	Pro	Asp 140	Lys	Thr	Ser	Gln
Ala	Ile	Gly	Ala	Pro	Ser	Pro	Thr	Leu	Lys	Val	Ala	Asn	Gln	Ala	Pro
145	~ 7	- 1	_	~ 7	150	_,		_		155					160
				165					170			Glu		175	
			180					185				Gly	190		
		195					200					Met 205		_	
	210					215					220	Leu			
225					230					235		Ala			240
				245					250			Glu		255	
			260					265				Gln	270		
		275					280					Ser 285			
	290					295					300	Xaa			
305					310					315		Tyr			320
				325					330			Gly		335	
			340					345				Gln	350		
		355					360					Phe 365		_	
	370					375					380	Asp			
385					390					395		Gln			400
				405					410			Lys		415	
			420					425				Asp	430		
Asp	Thr	Ser 435	Lys	Ser	Leu	Leu	Ile 440	Ile	Lys	Gly	Asp	Phe 445	Asn	Pro	Lys

Gln	Gly 450	His	Phe	Asn	Ile	Ser 455	Tyr	Asn	Gly	Asn	Asn 460	Val	Met	Thr	Arg
Gln 465		Trp	Glu	Phe	Lys 470		Gln	Leu	Tyr			Ser	Gly	Asn	
	Ala	Val	Leu			Asp	Gly	Ser		475 Val	Glu	Ala	Ser		480 Trp
Ser	Pro	Ser	Ala	485 Asp	Ser	Val	Thr		490 Ile	Ile	Tyr	Asp	_	495 Asp	Asn
~ 3	_	_	500		2.7	em1		505	_		_	_	510	_	
		515	Val				520					525			
	530		Thr			535					540				
Gly 545	Tyr	Tyr	Tyr	Leu	Tyr 550	Glu	Ile	Lys	Arg	Gly 555	Lys	Asp	Lys	Val	Lys 560
Ile	Leu	Asp	Pro	Tyr 565	Ala	Lys	Ser	Leu	Ala 570	Glu	Trp	Asp	Ser	Asn 575	Thr
Val	Asn	Asp	Asp 580	Ile	Lys	Thr	Ala	Lys 585	Ala	Ala	Phe	Val	Asn 590		Ser
Gln	Leu	Gly 595	Pro	Gln	Asn	Leu	Ser 600		Ala	Lys	Ile	Ala 605		Phe	Lys
Gly	Arg 610		Asp	Ala	Val	Ile 615		Glu	Ala	His	Val 620		Asp	Phe	Thr
Cor		Λ×α	Ser	Ten	7 cm		Tara	T 011	Trea	7 ~~		Dho	a 1	mh	nh a
625					630				_	635			_		640
			Ser	645					650					655	
His	Ile	Gln	Leu 660	Leu	Pro	Val	Leu	Ser 665	Tyr	Phe	Tyr	Val	Asn 670	Glu	Met
Asp	Lys	Ser 675	Arg	Ser	Thr	Ala	Tyr 680	Thr	Ser	Ser	Asp	Asn 685	Asn	Tyr	Asn
Trp	Gly 690	Tyr	Asp	Pro	Gln	Ser 695	Tyr	Phe	Ala	Leu	Ser 700	Gly	Met	Tyr	Ser
Glu 705	Lys	Pro	Lys	Asp	Pro 710	Ser	Ala	Arg	Ile	Ala 715	Glu	Leu	Lys	Gln	Leu 720
Ile	His	Asp	Ile	His 725	Lys	Arg	Gly	Met	Gly 730	Val	Ile	Leu	Asp	Val 735	Val
Tyr	Asn	His	Thr 740	Ala	Lys	Thr	Tyr	Leu 745	Phe	Glu	Asp	Ile	Glu 750		Asn
Tyr	Tyr	His	Phe	Met	Asn	Glu	Asp 760		Ser	Pro	Arg	Glu 765		Phe	Gly
Gly	Gly 770		Leu	Gly	Thr	Thr 775		Ala	Met	Ser	Arg 780		Val	Leu	Val
Asp 785		Ile	Lys	Tyr	Leu 790		Ser	Glu	Phe			Asp	Gly	Phe	
	Asp	Met	Met			His	Asp	Ala		795 Ala	Ile	Glu	Leu		800 Tyr
T	a1.,	77.	T 1.00	805	T1.	7	D	70	810	71 -	14 - 1-	- 1 -	a 1	815	G1
			Lys 820					825					830		
		835	Phe				840					845			
Gln	Asp 850	Trp	Met	Lys	Ser	Thr 855	Asp	Thr	Val	Gly	Val 860	Phe	Ser	Asp	Asp
Ile 865	Arg	Asn	Ser	Leu	Lys 870	Ser	Gly	Phe	Pro	Asn 875	Glu	Gly	Thr	Pro	Ala 880
Phe	Ile	Thr	Gly	Gly 885	Pro	Gln	Ser	Leu	Gln 890	Gly	Ile	Phe	Lys	Asn 895	

Lys	Ala	Gln	Pro 900	Gly	Asn	Phe	Glu	Ala 905	Asp	Ser	Pro	Gly		Val	Val	
	Ser	915		Ala	His	Asp	Asn 920		Thr	Leu	His	Asp 925	910 Val	Ile	Ala	
	930															
<210:	<2 <2	212>			cocci	ıs										
	<2	220> 221> 222>	CDS	(3	301)											
I	t ca		gt ti	eu Th					eu Ai					ro Gi	ag ttc lu Phe 15	49
									gct Ala							97
									gtt Val							145
					_			-	cgt Arg							193
									act Thr							241
									cgt Arg 90							289
			caa Gln 100		aaago	ctg (cacgt	atta	aa aq	gaaat	ccgt	cgt	taat	ttt		341
acaa atgg ttca atcg attgaa tgaa tgta ttgg	accaa gatat gatte gttea gtgea gtgea gttea gttga	aga o	egtaa gtaaa gtaaa getaa egtaa egtaa egaa eg	aaaaa cccct atago cttgt aaact cctco ataat aatco	at ct cc ct cg gt ct ct cc gc gc gc cc tc cc ac	egect caagg cttag ctgta agaga accag gtcgt attta	egtgggagtaggagtaggagtaggagtaggagtaggagtaggagttattttattgat	g gca a att c att g atc a aat c att c att c act	agttt tgctg tttgc ttaga ttcgc ttttt tactt	gtt gccc gtaa atag gata gata cgta cttg	tact cgat actt ctts gttt aatt tttt	aggt tccs ttct cctaa gcaaa tatt ccatg ttgtt	gge age age age age age age age age age	cctta agggg gatta tgata ctgca aaaaa gcagg	aactgg agttca gacata aagttt atttaa cctgag attatt aaataa gtatct atgagta	401 461 521 581 641 701 761 821 881 941

taacgctgca	tacgattgat	gttgtgattt	ttctttacaa	atttttatca	agcgtaagta	1061
ttcattggtt	tcaagaaatt	ttatctctat	ttacgcccct	tattttttgc	tttaacctta	1121
				cagccatgga		1181
tttacatgta	tgttaaaacg	ctttactgta	tcttgcacat	gcgtttgact	ataatgattt	1241
				atatatttcc		1301
				ggaaatacgc		1361
				gatggaaaag		1421
				ctccaaaagt		1481
				tatagccgta		1541
				tacaccattg		1601
				caacaaattt		1661
				agacgtgtga		1721
				aagattaaac		1781
				aagttagaag		1841
				tccaagtaat		1901
				aactcttgaa		1961
tcaggctatt	acaagtggct	caatcgtcaa	aaaacagatt	ttgagacaaa	aaatacaaag	2021
				gtatcttagg		2081
				acaagaaacg		2141
				ttagccatgc		2201
gctggtgaca	gattttacga	agaaaatatt	cttaatcgtg	aatttacagc	cacageteat	2261
aaccagaaat	ggtgcacaga	tgtcacctat	cttcaatacg	gtctgggagc	taaagcttat	2321
				cttatgagat		2381
aatgaaatcc	actigitatg	aagaccatta	aaaaggggct	agagctcaat	ccaggagcca	2441
				caaagaatac		2501
				caaatgtatt		2561
				ccaccttaag		2621
				attctacaac		2681
				gaatcaggtt		2741
				agattgctta		2801
				ttatttctta		2861
				ttgtttcatt		2921
				gcttcgataa		2981
gtaaaattta	taggitaatac	taaaaataat	acacaaaaa	acctggccta	tttttcctgc	3041
ttaggataag	agtttattt	tagaagtgaa	aagaacgtta	ataaaacata	aactactatg	3101
				atggattaga		3161
atttcataaa	gcatagctct	anggtatgta	addadiidd	tataatatgg	tatttata	3221
				taggcaacac		3281
				aacgtaattc		3341 3401
gagecaaacg	agtacgggat	graageraaa	acaccacta	aacttatgta tgcatcataa	aaactagata	3461
				ttatcatcgc		3521
ctagttttt	caatagagga	ttaggtagtt	tttcataata	aaactatata	accettaage	3581
				attttccttt		3641
				ttgagatagt		3701
aagaaatttt	taatggaaat	acttttaaaa	acattacttc	taggcgatgt	assatatta	3761
atccagtgga	tacaataatt	ageceedada	acaccagecg	agtaattagg	aaaaacacca	3821
				cttattatat		3881
aacaattgtt	ctttcttact	tatattcata	tttaacaata	atgaaatcaa	gtaatgaaat	3941
agaaaaggct	ttatatgaaa	gttctaattc	ttcaatatca	attacaaaaa	aadatddtaa	4001
atattttaat	attaatcaat	ttaagaatat	tgaaaaaaata	aaagaggttg	aagaaaaaa	4061
atttcaatat	gatggattag	caaaattgaa	agatettasa	gtagttagtg	ataaacaaac	4121
				gtttcactag		4181
				agttttaaag		4241
tatagaagaa	aatgataaga	attcaattct	tattcataaa	gaatttgcta	aacaaaacaa	4301
actaaaatto	gatgatgass	ttgatcttga	attactacat	acggaaaaaa	gtggaaaaat	4361
	Jacana			asyguuuuua	Jeggaaaaac	1001

PCT/CA99/00114 WO 99/42588

50 / 63

agga aatta gaatta aatta actta a actta actta actta actta actta actta actta actta actta actta actta a actta actta actta actta actta actta actta actta actta actta actta actta actta actta actta actta a actta actta actta actta a a a	attai	cca final and a second and a se	totga aaata aacaga aattaa aattot aatato aatato aatagga aattagg gaaaa aattagg gaaaa attagg gaaaa attagg aggaaa attagg aggaaa aattagg aattaa aattato aattagg aattaa a	attit cagagett aaagett aaatge cagaac cagaac cagaac aagtt aagtt aagtaa aataa ataat accta	ca go at ga at cata to the cata to the cata at the cat	cgaaa caata cctaaaq gaacat gaacat gaacat catttga gaacat caggtcaa caacat caaggtcaa caacat caaggtcaa caacat ca caacat ca ca ca caacat ca ca ca ca ca ca	aatatatagaatagaatatagagagagataggatatatatatatatatataggagagagagagagagagagagagagagagagagagaga	ggt tgg t tgg t att t cga t att t cga t att t aga t att t aga t ata t aga t agg	ctttt caaat cgaaa aagag cttat cttat atcta atcta atcaa ccaaat atcaa	egta agacta gttaattataagaattaaagaattaaa gtgataattataagaattaaa gtaaaattaaagaattaaa gtaaaattaaagaattaaa	gatt tttag gatag tttag gatag tttag tttag caatt catt gatag tttag atttt gatag tttag atttt gatag tttag atttt caatt caatt gatag atttt atttt gatag tttag atttt attt	catto ctaal gagto gagtal ctaal aaagt aataa gtaaa ccaal	caa de de ca	ctage attention	atatac ccaga gggaat gggaat ccttat atcaat agagttt atcaa cgttaa aggatta	4421 4481 4541 4661 4721 4781 4841 4961 5021 5081 5141 5261 5321 5381 5441 5561 5561 5607
		100>														
Ile 1	Gln	Ser	Leu	Thr 5	Glu	Gly	Gln	Leu	Arg 10	Ser	Asp	Ile	Pro	Glu 15	Phe	
Arg	Ala	Gly	Asp 20	Thr	Val	Arg	Val	His 25	Ala	Lys	Val	Val	Glu 30	Gly	Thr	
Arg	Glu	Arg 35		Gln	Ile	Phe	Glu 40		Val	Val	Ile	Ser 45		Lys	Gly	
Gln	Gly 50	Ile	Ser	Glu	Met	Tyr 55	Thr	Val	Arg	Lys	Ile 60	Ser	Gly	Gly	Ile	
	Val	Glu	Arg	Thr	Phe 70	Pro	Ile	His	Thr			Val	Asp	Lys		
65 Glu	Val	Val	Arg	Tyr 85		Lys	Val	Arg	Arg 90	75 Ala	Lys	Leu	Tyr	Tyr 95	80 Leu	
Arg	Ala	Leu	Gln 100	Gly	Lys	Ala	Ala	Arg 105		Lys	Glu	Ile	Arg 110			
	<2 <2	210> 211> 212> 213>	173	eptod	cocci	ıs										
N/ - 1-		< 0.01		0 3	O	.	a 2	T .	 1		_	_		_	_	
Met 1	Arg	Pne	Ala	GIu 5	Cys	Leu	GTA	Leu	Thr 10	Val	Asn	Asp	Ile	Asp 15	Tyr	
			20					25			_	-	30	Phe		
Gln	Arg	Tyr 35	Leu	Pro	Thr	Lys	Asn 40	Lys	Ser	Ser	Ile	Arg 45	Asn	Ile	Pro	
Ile	Asp		Asp	Thr	Leu	Phe		Leu	His	Glu	Phe		Lys	Asn	Lys	

	50					55					60				
Asn 65		Arg	Leu	Phe	Asp		Leu	Ser	Asn	Asn 75		Val	Asn	Lys	Thr 80
Ile	Arg	Lys	Ile	Thr 85	Gly	Arg	Glu	Val	Arg 90		His	Ser	Leu	Arg 95	
Thr	Phe	Ala	Ser 100	Tyr	Leu	Ile	Ser	Ile 105	Ser	Gln	Val	Leu	Asp 110	His	Glu
Asn	Leu	Asn 115	Ile	Thr	Leu	Glu	Val 120	Tyr	Ala	His	Gln	Leu 125	Gln	Glu	Gln
Lys	Asp 130	Arg	Asn	Asp	Lys	Leu 135	Asn	Gln	Arg	Asn	Leu 140	Gly	Gln	Asn	Ser
145					150					155		Cys	Arg	Asn	Arg 160
Thr	Ser	Asn	Tyr	Ser 165	Leu	Gly	Gly	Ser	Cys 170	Tyr	Ile	His			
	<2	210>	30												
		211>													
		212>													
	< 2	213>	stre	eptod	cocci	ıs									
	< 4	100>	30												
1				5				-	10		-	Glu		15	
			20					25				Phe	30		
		35					40					Glu 45			
	50					55					60	Val			
65					70					75		Phe	_		80
Val	Ser	Leu	Glu	Ala 85	Thr	Ser	Asn	Thr	Lys 90	Arg	Asn	Leu	Leu	Phe 95	Ser
			100					105				Glu	110		
Lys	Asn	Ser 115	Ile	Leu	Val	His	Glu 120	Glu	Phe	Ala	Lys	Gln 125	Asn	Lys	Leu
Lys	Leu 130	Gly	Asp	Glu	Ile	Asp 135	Leu	Glu	Leu	Leu	Asp 140	Thr	Glu	Lys	Ser
Gly 145	Lys	Ile	Lys	Ser	His 150	Lys	Phe	Lys	Ile	Ile 155	Gly	Ile	Phe	Ser	Gly 160
Lys	Lys	Gln	Glu	Thr 165	Tyr	Thr	Gly	Leu	Ser 170	Ser	Asp	Phe	Ser	Glu 175	Asn
Met	Val	Phe	Val 180	Asp	Tyr	Ser	Thr	Ser 185	Gln	Glu	Ile	Leu	Asn 190	Lys	Ser
Glu	Asn	Asn 195	Arg	Ile	Ala	Asn	Lys 200	Ile	Leu	Met	Tyr	Ser 205	Gly	Ser	Leu
Glu	Ser 210	Thr	Glu	Leu	Ala	Leu 215	Asn	Lys	Leu	Lys	Asp 220	Phe	Lys	Ile	Asp
Lys 225	Ser	Lys	Tyr	Ser	Ile 230	Lys	Lys	Asp	Asn	Lys 235	Ala	Phe	Glu	Glu	Ser 240
Leu	Glu	Ser	Val	Ser 245	Gly	Ile	Lys	His	Ile 250	Ile	Lys	Ile	Met	Thr 255	Tyr
Ser	Ile	Met	Leu 260	Gly	Gly	Ile	Val	Val 265	Leu	Ser	Leu	Ile	Leu 270	Ile	Leu

52 / 63

```
Trp Leu Arg Glu Arg Ile Tyr Glu Ile Gly Ile Phe Leu Ser Ile Gly
      275
                           280
Thr Thr Lys Ile Gln Ile Ile Arg Gln Phe Ile Phe Glu Leu Ile Phe
                       295
Ile Ser Ile Pro Ser Ile Ile Ser Ser Leu Phe Leu Gly Asn Leu Leu
                   310
                                      315
Leu Lys Val Ile Val Glu Gly Phe Ile Asn Ser Glu Asn Ser Met Ile
               325
                               330
Phe Gly Gly Ser Leu Ile Asn Lys Ser Ser Phe Met Leu Asn Ile Thr
                        345 350
Thr Leu Ala Glu Ser Tyr Leu Ile Leu Ile Ser Ile Ile Val Leu Ser
                        360
Val Val Met Ala Ser Ser Leu Ile Leu Phe Lys Lys Pro Gln Glu Ile
                       375
                                          380
Leu Ser Lys Ile Ser
385
     <210> 31
     <211> 169
     <212> PRT
     <213> streptococcus
     <400> 31
Met Asp Ile Leu Glu Ile Lys Asn Val Asn Tyr Ser Tyr Ala Asn Ser
Lys Glu Lys Val Leu Ser Gly Val Asn Gln Lys Phe Glu Leu Gly Lys
Phe Tyr Ala Ile Val Gly Lys Ser Gly Thr Gly Lys Ser Thr Leu Leu
Ser Leu Leu Ala Gly Leu Asp Lys Val Gln Thr Gly Lys Ile Leu Phe
Lys Asn Glu Asp Ile Glu Lys Lys Gly Tyr Ser Asn His Arg Lys Asn
                   70
Asn Ile Ser Leu Val Phe Gln Asn Tyr Asn Leu Ile Asp Tyr Leu Ser
               85
                                   90
Pro Ile Glu Asn Ile Arg Leu Val Asn Lys Ser Val Asp Glu Ser Ile
                               105
Leu Phe Glu Leu Gly Leu Asp Lys Lys Gln Ile Lys Arg Asn Val Met
                           120
Lys Leu Ser Gly Gly Gln Gln Gln Arg Val Ala Ile Ala Arg Ala Leu
                       135
                                          140
Val Ser Asp Ala Pro Ile Ile Leu Ala Asp Glu Pro Thr Gly Asn Leu
                   150
                                       155
Asp Ser Val Thr Ala Gly Glu Ile Ile
     <210> 32
     <211> 4171
     <212> DNA
     <213> Streptococcus
     <400> 32
catatgacaa tatttttcaa agtctacatc acttactcgc ctgtcgtgga aaatctggca
atacattaat cgaccaatta gttgctgatg gtttacttca tgcagataat cactaccatt
ttttcaatgg gaagtctctg gccactttca atactaacca attgattcgc gaagttgtct
```

atgttgaaat atccttagat actatgtcta gtggtgaaca tgatttagta aaagttaaca

120

53 / 63

ttatcagacc cactaccgag catactatcc ccacgatgat gacagctagc ccctatcatc 300 aaggtatcaa tgatcctgcc gcagaccaaa aaacatacca aatggagggt gcgctagcag 360 ttaaacagcc taaacacata caagttgaca caaaaccatt taaagaagaa gtaaaacatc 420 cttcaaaatt acccatcagc cctgcaactg aaagcttcac acacattgac agttatagtc 480 tcaatgacta ttttctttct cgtggttttg ctaatatata cgtttcaggt gtgggtactg 540 ctggctctac gggtttcatg accagtgggg attaccaaca aatacaaagc tttaaagcag 600 tcattgattg gttaaatggt aaggttactg cattcacaag tcataaacga gataaacaag 660 tcaaggctga ttggtcaaac ggccttgtag caaccacagg taaatcttat ctcggtacca 720 tgtcaactgg tttagcaaca actggcgttg aggggctgaa agtcattatc gctgaagccg 780 caatctccac atggtatgat tattatcgag aaaatgggct tgtgtgtagt ccaggcggct 840 accoeggtga agatttagac gttttaacag aattaacata ctcacgaaac ctcttagctg 900 gtgattacat caaaaacaac gattgctatc aagcattgtt aaatgaacaa tcaaaagcaa 960 ttgaccgtca aagtggggat tacaaccaat actggcatga ccgtaattac ctaactcacg tcaataatgt caaaagtcga gtagtttaca ctcatggact acaggattgg aatgttaagc caagacatgt ctacaaagtt ttcaatgcat tgcctcaaac catcaaaaaa cacctttttt tacatcaagg tcaacatgtg tatatgcata attggcagtc gattgatttt cgtgaaagca 1200 tgaatgcctt actaagccaa gaactacttg gcattgacaa tcatttccaa ttagaagagg 1260 tcatttggca agataatact actgagcaaa cttggcaagt tttagatgct ttcggaggaa 1320 accatcaaga gcaaattggt ttaggtgata gtaaaaaact tattgataac cattatgaca 1380 aagaagcctt tgatacttat tgtaaagact tcaatgtgtt caaaaatgat cttttcaagg 1440 gaaataataa aaccaatcaa atcactatta atcttcctct aaagaaaaat tatctcctga atggacagtg caaactccat ctacgtgtta aaactagtga caaaaaggcc attttatcag 1560 cccaaatctt agactatggt cctaaaaaac gattcaaaga tacaccaacc atcaaattct taaacagcct tgataatggt aaaaattttg ccagagaagc tttacqtqaa ctcccqttta ctaaagatca ttatcgtgtc atcagtaaag gtgtcttgaa ccttcaaaat cgtacagact tacttacaat tgaggctatc gagccagaac aatggtttga tatcgagttt agcctccaac caagtatata tcaattgagt aaaggtgata atctaaggat tatcctttat acaactgatt ttgaacatac cattcgagat aatgctagtt actctataac agtagatttg agtcaatctt 1920 atttaactat cccaactaat caaggaaatt aacttatgaa acttcttact aaagaacggt 1980 ttgatgattc tcaacacttt tggtaccaga tcaatttatt acaagagagt aacttcggag 2040 cagtttttga ccatgataat aaaaacattc cacaggttgt tgcaactatt gttgatgatt 2100 tacaaggttc cggaagttcg aatcatttct ggtattttgg caatactact gatacttcca 2160 tccttatgat tgctcattta aatcgaaaat tctatattca ggttaattta aaggactttg 2220 actttgcact caatttaata gctataaata attggaagag tctcctccaa actcaacttg 2280 aagctctaaa cgatacccta gcaatatttc aataaataag gtagaatgga gtgacaaagc 2340 aacgcgaggg agactgatta atgtcatctt attggaataa ctatcctgaa cttaaaaaaa 2400 atattgatga aaccaatcaa ctaattcaag aaagaataca ggtcagaaat aaagatattg 2460 aagcggcgct aagccaactc acagctgcgg gaggaaaaca gctcagacca gcattctttt 2520 accttttttc tcaacttggt aataaggaga atcaagatac tcagcaacta aagaaaatcg ctgcttcttt agaaatcctt cacgttgcta cattaatcca tgatgatgtc attgatgact caccactaag acgtggaaat atgaccattc aaagcaagtt tggcaaagac atcgcagttt atactgggga tttacttttc acagtctttt tcgatcttat tttagaatct atgactgata caccatttat gaggattaat gcaaaatcta tgcgtaaaat tctcatggga gaattggacc 2820 agatgcacct tcgttacaat caacaacaag gtatccatca ctatttacgt gcgatttcag 2880 gtaagacagc cgaactcttt aaattagcta gcaaagaagg agcttacttt ggtggtgcag 2940 agaaggaggt tgttcgtcta gcaggccata tcggctttaa cattggtatg acattccaaa 3000 ttttggatga tatcctggat tatactgcag ataaaaaaac atttaataag cctgtcttag 3060 aggatttaac acaaggegtt tacageette etetaettet tgeeattgaa gaaaateetg 3120 atattttcaa acctatttta gataaaaaaa cagatatggc tactgaagac atggaaaaaa 3180 ttgcttatct cgtcgtttcc catagaggtg ttgacaaagc tcgccatcta gctcgtaaat 3240 ttactgagaa agctattagt gacataaata agctacccca gaactctgca aaaaaacagt 3300 tgctacaatt aactaattac cttttaaaac gcaaaattta aataataaaa aaacattcca 3360 caatgctaga aaagcagtta gggaatgttt ttttattatc atttattat cgcacctatc 3420 aatcatcata gatcaccatc atcagcggct ttcagctgac ggtaacgttg actactttga 3480 gacaattett gaggagaace ttecaactet aattgeeeat tttetataaa taagataega tragratgtt caatacettt taagtgatgt gtaateraaa etaaggtett acetteraat 3600 54 / 63

tcat cttt aaat ctag gctt ccg gtag aaat	cctaa ccagt gcato gcttag cctag ctctt	aga to ac constant of the second of the seco	caaca ctgaa ggttt cact caata cagaa gatgo	aatto	gg ga ct aa ct ca at go at at cc tt ct co ac co	acato agteo aateo egaat egaet egaet egeec egatt	etttt caget caact cgtta cagaa ctgct ctaaa	agt to agt to a to a to a to a to a to a	taaga atcaa tcaa tagcaat gcaat caagt	attc acca agaa aggg ccac ccgc	tago ttago cttt ttgt caao caco ttto	ccaaa catag ccat catta ctatt gaagt	agc gag ac aaa aga aga ac	aatto accat atctt aaggt aacat actag tttaa	gttggc ctatgc cctgat cctca caggc ccagca gctaag atatcc ctcttg	3660 3720 3780 3840 3900 3960 4020 4080 4140 4171
	<2 <2	210> 211> 212> 213>	649 PRT	eptod	cocus	5										
	< 4	100>	33													
-	Asp	Asn	Ile		Gln	Ser	Leu	His		Leu	Leu	Ala	Cys	Arg	Gly	
1 Lvs	Ser	Glv	Asn	5 Thr	Len	Tle	Agn	Gln	10 Len	Val	Δla	Asn	Glv	15 Leu	Len	
270		<u></u> 1	20		204		1101	25	204	• • • •			30			
His	Ala	_	Asn	His	Tyr	His		Phe	Asn	Gly	Lys		Leu	Ala	Thr	
Phe	Asn	35 Thr	Asn	Gln	Leu	Ile	40 Arg	Glu	Val	Val	Tyr	45 Val	Glu	Ile	Ser	
	50			_		55	_				60					
Leu 65	Asp	Thr	Met	Ser	Ser 70	Gly	Glu	His	Asp	Leu 75	Val	Lys	Val	Asn	Ile 80	
	Arg	Pro	Thr	Thr 85		His	Thr	Ile	Pro 90		Met	Met	Thr	Ala 95		
Pro	Tyr	His	Gln 100		Ile	Asn	Asp	Pro 105		Ala	Asp	Gln	Lys 110	Thr	Tyr	
Gln	Met	Glu 115		Ala	Leu	Ala	Val 120		Gln	Pro	Lys	His 125		Gln	Val	
Asp	Thr 130		Pro	Phe	Lys	Glu 135		Val	Lys	His	Pro 140		Lys	Leu	Pro	
Ile		Pro	Ala	Thr	Glu		Phe	Thr	His	Ile		Ser	Tyr	Ser	Leu	
145	7		Dl	T	150		a 1.	-1		155	~ J .		**- 7	0	160	
ASN	Asp	TÀL	Pne	165	ser	Arg	GIŸ	Pne	170	Asn	шe	Tyr	vaı	Ser 175	GIY	
Val	Gly	Thr	Ala 180	Gly	Ser	Thr	Gly	Phe 185	Met	Thr	Ser	Gly	Asp 190	Tyr	Gln	
Gln	Ile	Gln 195	Ser	Phe	Lys	Ala	Val 200	Ile	Asp	Trp	Leu	Asn 205	Gly	Lys	Val	
Thr	Ala 210		Thr	Ser	His	Lys 215		Asp	Lys	Gln	Val 220		Ala	Asp	Trp	
		Gly	Leu	Val			Thr	Gly	Lys			Leu	Gly	Thr		
225 Ser	Thr	Glv	Leu	Ala	230 Thr	Thr	Glv	Va]	Glu	235 Glv	Lev	Lvs	Val	Ile	240 Ile	
				245			_		250	_				255		
Ala	Glu	Ala	Ala 260	Ile	Ser	Thr	Trp	Tyr 265	Asp	Tyr	Tyr	Arg	Glu 270	Asn	Gly	
Leu	Val	Cys 275	Ser	Pro	Gly	Gly	Tyr 280	Pro	Gly	Glu	Asp	Leu 285	Asp	Val	Leu	
Thr	Glu 290		Thr	Tyr	Ser	Arg 295		Leu	Leu	Ala	Gly 300		Tyr	Ile	Lys	
70	7	7	O	m	01 -	77 -	т	т	7	~ 1	a1	0	T	77.	т1.	

Asn Asn Asp Cys Tyr Gln Ala Leu Leu Asn Glu Gln Ser Lys Ala Ile

55 / 63

305					310					315					320
	Arg	Gln	Ser	Gly 325	Asp	Tyr	Asn	Gln	Tyr 330		His	Asp	Arg	Asn 335	
Leu	Thr	His	Val 340	Asn	Asn	Val	Lys	Ser 345	Arg	Val	Val	Tyr	Thr 350	His	Gly
Leu	Gln	Asp 355	Trp	Asn	Val	Lys	Pro 360	Arg	His	Val	Tyr	Lys 365	Val	Phe	Asn
	370		Gln			375	_				380			•	
385			Met		390					395					400
			Leu	405					410					415	
			Val 420					425					430		
		435	Ala				440					445			
	450		Lys			455					460				_
465			Lys		470					475				_	480
			Thr	485					490					495	
			Asn 500					505					510		
		515	Ala				520				_	525	_		_
	530		Lys			535					540				
545			Asn		550					555					560
			Tyr	565					570					575	
			Leu 580					585					590	-	
		595	Phe				600					605			
	610		Arg			615					620				
625			Ala		630				vai	635	ьeu	ser	GIn	ser	1yr 640
ьец	IIII	iie	Pro	645	ASII	GIII	GIY	ASI							
	<2	210>	34												
		211>													
		212>	Stre	entor	20011	<u>.</u>									
	~ 2		DCT	-p-00	Jocus	,									
		100>		ml	τ.	a ?	70 -	D)		_	~	~ 7		_,	_
Met 1	гуѕ	ьеи	Leu	Thr 5	ьys	GIU	arg	rne	Asp 10	Asp	ser	GIn	His	Phe 15	Trp
_			Asn 20					25			•		30		_
His	Asp	Asn	Lys	Asn	Ile	Pro	Gln	Val	Val	Ala	Thr	Ile	Val	Asp	Asp

40

56 / 63

Leu Gln Gly Ser Gly Ser Ser Asn His Phe Trp Tyr Phe Gly Asn Thr Thr Asp Thr Ser Ile Leu Met Ile Ala His Leu Asn Arg Lys Phe Tyr Ile Gln Val Asn Leu Lys Asp Phe Asp Phe Ala Leu Asn Leu Ile Ala 90 Ile Asn Asn Trp Lys Ser Leu Leu Gln Thr Gln Leu Glu Ala Leu Asn 100 105 Asp Thr Leu Ala Ile Phe Gln 115 <210> 35 <211> 326 <212> PRT <213> Streptococus <400> 35 Met Ser Ser Tyr Trp Asn Asn Tyr Pro Glu Leu Lys Lys Asn Ile Asp 10 Glu Thr Asn Gln Leu Ile Gln Glu Arg Ile Gln Val Arg Asn Lys Asp Ile Glu Ala Ala Leu Ser Gln Leu Thr Ala Ala Gly Gly Lys Gln Leu 40 Arg Pro Ala Phe Phe Tyr Leu Phe Ser Gln Leu Gly Asn Lys Glu Asn 55 60 Gln Asp Thr Gln Gln Leu Lys Lys Ile Ala Ala Ser Leu Glu Ile Leu 70 75 His Val Ala Thr Leu Ile His Asp Asp Val Ile Asp Asp Ser Pro Leu 90 Arg Arg Gly Asn Met Thr Ile Gln Ser Lys Phe Gly Lys Asp Ile Ala 105 Val Tyr Thr Gly Asp Leu Leu Phe Thr Val Phe Phe Asp Leu Ile Leu 120 Glu Ser Met Thr Asp Thr Pro Phe Met Arg Ile Asn Ala Lys Ser Met 135 Arg Lys Ile Leu Met Gly Glu Leu Asp Gln Met His Leu Arg Tyr Asn 150 155 Gln Gln Gln Gly Ile His His Tyr Leu Arg Ala Ile Ser Gly Lys Thr 165 170 Ala Glu Leu Phe Lys Leu Ala Ser Lys Glu Gly Ala Tyr Phe Gly Gly 185 Ala Glu Lys Glu Val Val Arg Leu Ala Gly His Ile Gly Phe Asn Ile 200 Gly Met Thr Phe Gln Ile Leu Asp Asp Ile Leu Asp Tyr Thr Ala Asp 215 220 Lys Lys Thr Phe Asn Lys Pro Val Leu Glu Asp Leu Thr Gln Gly Val 230 235 Tyr Ser Leu Pro Leu Leu Leu Ala Ile Glu Glu Asn Pro Asp Ile Phe 245 250 Lys Pro Ile Leu Asp Lys Lys Thr Asp Met Ala Thr Glu Asp Met Glu 260 265 Lys Ile Ala Tyr Leu Val Val Ser His Arg Gly Val Asp Lys Ala Arg 280 His Leu Ala Arg Lys Phe Thr Glu Lys Ala Ile Ser Asp Ile Asn Lys 295 300 Leu Pro Gln Asn Ser Ala Lys Lys Gln Leu Gln Leu Thr Asn Tyr

```
310
305
                                      315
                                                           320
Leu Leu Lys Arg Lys Ile
               325
     <210> 36
     <211> 247
     <212> PRT
     <213> Streptococus
     <400> 36
Leu Pro Asn Lys Pro Tyr Asp Phe Ser Val Lys Asn Leu Ser Phe Gln
                                   10
Tyr Lys Pro Gln Glu Lys Trp Val Leu His His Leu Asp Leu Asp Ile
Lys Glu Gly Glu Lys Ile Ala Ile Leu Gly Arg Ser Gly Ser Gly Lys
                           40
Ser Thr Leu Ala Ser Leu Leu Arg Gly Asp Leu Lys Ala Ser Gln Gly
                       5.5
Lys Ile Thr Leu Gly Gly Ala Asp Val Ser Ile Val Gly Asp Cys Ile
                   70
Ser Asn Tyr Ile Gly Val Ile Gln Gln Ala Pro Tyr Leu Phe Asn Thr
                                   90
Thr Leu Leu Asn Asn Ile Arg Ile Gly Asn Gln Asp Ala Ser Glu Glu
                               105
Asp Val Trp Lys Val Leu Glu Arg Val Gly Leu Lys Glu Met Val Thr
                          120
Asp Leu Ser Asp Gly Leu Tyr Thr Met Val Asp Glu Ala Gly Leu Arg
                      135
Phe Ser Gly Glu Arg His Arg Ile Ala Leu Ala Arg Ile Leu Leu
                   150
Lys Asp Val Pro Ile Val Ile Leu Asp Glu Pro Thr Val Gly Leu Asp
               165
                                  170
Pro Ile Thr Glu Gln Ala Leu Leu Arg Val Phe Met Lys Glu Leu Glu
                            185
                                                  190
Gly Lys Thr Leu Val Trp Ile Thr His His Leu Lys Gly Ile Glu His
                           200
                                               205
Ala Asp Arg Ile Leu Phe Ile Glu Asn Gly Gln Leu Glu Leu Glu Gly
                       215
                                          220
Ser Pro Gln Glu Leu Ser Gln Ser Ser Gln Arg Tyr Arg Gln Leu Lys
                   230
                                      235
Ala Ala Asp Asp Gly Asp Leu
               245
     <210> 37
     <211> 3480
     <212> DNA
     <213> Streptococcus
      <400> 37
aattetattt ggaggttttt ettgaataaa tggttagtta aggeaagtte ettagttgtt
                                                                    60
ttaggtggta tggttttatc tgcgggttcc cgagttttag cggatactta tgtccgtcca
                                                                   120
attgataatg gtagaattac aacaggtttc aatggttatc ctggacattg tggggtggat
                                                                   180
tatgctgttc cgactggaac gattattagg gcagtggcag atggtactgt gaaatttgca
                                                                   240
ggagctggag ccaacttttc ttggatgaca gacttagcag gaaattgtgt catgattcaa
                                                                   300
catgcggatg gaatgcatag tggttacgct catatgtcac gtgtggtggc taggactggg
                                                                   360
gaaaaagtca aacaaggaga tatcatcggt tacgtaggag caactggtat ggcgacggga
                                                                   420
```

58 / 63

	_	_		ttcaaaatgg		480
_				ttagtggaaa		540
				agaatcaatc		600
				tttggttagt		660
				taccagcatc		720
				ttcaaaaagg		780
				tccaaggaac		840
				ggcttcgcgt		900
				gttttaaatg		960
				ttttatagtc		1020
				tgaagcaatg		1080
				atcagtcgca		1140
cacaagaaac	agatacgacg	tggacagcac	gtactgtttc	agaggtaaag	gctgatttgg	1200
taaagcaaga	caataaatca	tcatatactg	tgaaatatgg	tgatacacta	agcgttattt	1260
cagaagcaat	gtcaattgat	atgaatgtct	tagcaaaaat	taataacatt	gcagatatca	1320
atcttattta	tcctgagaca	acactgacag	taacttacga	tcagaagagt	catactgcca	1380
cttcaatgaa	aatagaaaca	ccagcaacaa	atgctgctgg	tcaaacaaca	gctactgtgg	1440
atttgaaaac	caatcaagtt	tctgttgcag	accaaaaagt	ttctctcaat	acaatttcgg	1500
aaggtatgac	accagaagca	gcaacaacga	ttgtttcgcc	aatgaagaca	tattcttctg	1560
cgccagcttt	gaaatcaaaa	gaagtattag	cacaagagca	agctgttagt	caagcagcag	1620
				ttcagaagtt		1680
aagaggaagt	taaaccaact	cagacgtcag	tcagtcagtc	aacaacagta	tcaccagctt	1740
				accggtaaga		1800
				agaaactggt		1860
agcatgtatc	agctccagca	gttcctgtga	ctacgacttc	aacagctaca	gacagtaagt	1920
tacaagcgac	tgaagttaag	agcgttccgg	tagcacaaaa	agctccaaca	gcaacaccgg	1980
tagcacaacc	agcttcaaca	acaaatgcag	tagctgcaca	tcctgaaaat	gcagggctcc	2040
aacctcatgt	tgcagcttat	aaagaaaaag	tagcgtcaac	ttatggagtt	aatgaattca	2100
gtacataccg	tgcaggtgat	ccaggtgatc	atggtaaagg	tttagcagtc	gactttattg	2160
taggtaaaaa	ccaagcactt	ggtaatgaag	ttgcacagta	ctctacacaa	aatatggcag	2220
caaataacat	ttcatatgtt	atctggcaac	aaaagtttta	ctcaaataca	aatagtattt	2280
atggacctgc	taatacttgg	aatgcaatgc	cagatcgtgg	tggcgttact	gccaaccatt	2340
atgaccatgt	tcacgtatca	tttaacaaat	aatataaaaa	aggaagctat	ttggcttctt	2400
ttttatatgc	cttgaataga	ctttcaaggt	tcttatctaa	tttttattaa	attgaggaga	2460
ttaagctata	agtctgaaac	tactttcacg	ttaaccgtga	ctaaatcaaa	acgttaaaac	2520
				aacagatata		2580
tagatatcta	aaattaaaaa	agataaggaa	gtgagaatat	gccacatcta	agtaaagaag	2640
cttttaaaaa	gcaaataaaa	aatggcatta	ttgtgtcatg	tcaagctttg	cctggggagc	2700
ctctttatac	tgaaagtgga	ggtgttatgc	ctcttttagc	tttggcagct	caagaagcag	2760
gagcggttgg	tataagagcc	aatagtgtcc	gcgacattaa	ggaaattcaa	gaagttacta	2820
atttacctat	catcggcatt	attaaacgtg	aatatcctcc	acaagaacca	tttatcactg	2880
ctacgatgac	agaggtggat	caattagcta	gtttagatat	tgcagtaata	gccttagatt	2940
gtacacttag	agagcgtcat	gatggtttga	gtgtagctga	gtttattcaa	aagataaaag	3000
ggaaatatcc	tgaacagttg	ctaatggctg	atataagtac	ttttgaagaa	ggtaaaaatg	3060
				tggatacaca		3120
				ttgtcaagcc		3180
				tgaaattaat		3240
				agaaatagcg		3300
				caaaataaaa		3360
				gagctgcagc		3420
				agaaggataa		3480
		_	5 5			

<210> 38

<211> 306

<212> PRT

<213> Streptococcus

```
<400> 38
Asn Ser Ile Trp Arg Phe Phe Leu Asn Lys Trp Leu Val Lys Ala Ser
Ser Leu Val Val Leu Gly Gly Met Val Leu Ser Ala Gly Ser Arg Val
Leu Ala Asp Thr Tyr Val Arg Pro Ile Asp Asn Gly Arg Ile Thr Thr
Gly Phe Asn Gly Tyr Pro Gly His Cys Gly Val Asp Tyr Ala Val Pro
                     55
Thr Gly Thr Ile Ile Arg Ala Val Ala Asp Gly Thr Val Lys Phe Ala
Gly Ala Gly Ala Asn Phe Ser Trp Met Thr Asp Leu Ala Gly Asn Cys
                                90
Val Met Ile Gln His Ala Asp Gly Met His Ser Gly Tyr Ala His Met
                            105
Ser Arg Val Val Ala Arg Thr Gly Glu Lys Val Lys Gln Gly Asp Ile
                        120
Ile Gly Tyr Val Gly Ala Thr Gly Met Ala Thr Gly Pro His Leu His
                    135
Phe Glu Phe Leu Pro Ala Asn Pro Asn Phe Gln Asn Gly Phe His Gly
     150 155
Arg Ile Asn Pro Thr Ser Leu Ile Ala Asn Val Ala Thr Phe Ser Gly
       165
                               170 175
Lys Thr Gln Ala Ser Ala Pro Ser Ile Lys Pro Leu Gln Ser Ala Pro
       180 185 190
Val Gln Asn Gln Ser Ser Lys Leu Lys Val Tyr Arg Val Asp Glu Leu
 195
           200 205
Gln Lys Val Asn Gly Val Trp Leu Val Lys Asn Asn Thr Leu Thr Pro
                     215
                             220
Thr Gly Phe Asp Trp Asn Asp Asn Gly Ile Pro Ala Ser Glu Ile Asp
                                   235
Glu Val Asp Ala Asn Gly Asn Leu Thr Ala Asp Gln Val Leu Gln Lys
                                250
Gly Gly Tyr Phe Ile Phe Asn Pro Lys Thr Leu Lys Thr Val Glu Lys
Pro Ile Gln Gly Thr Ala Gly Leu Thr Trp Ala Lys Thr Arg Phe Ala
                         280
Asn Gly Ser Ser Val Trp Leu Arg Val Asp Asn Ser Gln Glu Leu Leu
                    295
Tyr Lys
305
     <210> 39
     <211> 434
     <212> PRT
     <213> Streptococcus
    <400> 39
Met Lys Met Asn Lys Lys Val Leu Leu Thr Ser Thr Met Ala Ala Ser
Leu Leu Ser Val Ala Ser Val Gln Ala Gln Glu Thr Asp Thr Thr Trp
                            25
Thr Ala Arg Thr Val Ser Glu Val Lys Ala Asp Leu Val Lys Gln Asp
                         40
Asn Lys Ser Ser Tyr Thr Val Lys Tyr Gly Asp Thr Leu Ser Val Ile
```

	50					55					60				
	Glu	Ala	Met	Ser	Ile 70	Asp	Met	Asn	Val		Ala	Lys	Ile	Asn	
65 Tle	Δla	Asn	Ile	Asn		Tle	Tvr	Pro	Glu	75 Thr	Thr	Leu	Thr	Val	80 Thr
110	111.0	пор		85			- 7 -		90		1111	БСи	****	95	1111
Tyr	Asp	Gln	Lys	Ser	His	Thr	Ala	Thr	Ser	Met	Lys	Ile	Glu	Thr	Pro
			100					105					110		
Ala	Thr		Ala	Ala	Gly	Gln		Thr	Ala	Thr	Val	-	Leu	Lys	Thr
7 ~~	<i>0</i> 15	115	Co~	17-1	71-	λας	120	T	7707	00.00	T	125	mb	T1.	C
ASII	130	vai	Ser	Val	Ala	135	GIII	пуs	Val	Ser	140	ASII	THE	тте	ser
Glu		Met	Thr	Pro	Glu		Ala	Thr	Thr	Ile		Ser	Pro	Met	Lvs
145	-				150					155					160
Thr	Tyr	Ser	Ser	Ala	Pro	Ala	Leu	Lys	Ser	Lys	Glu	Val	Leu	Ala	Gln
				165	3	_ ~			170		_			175	_
Glu	GIn	Ala	Val 180	Ser	Gin	Ala	Ala		Asn	Glu	Gln	Val		Thr	Ala
Pro	Val.	Lve	Ser	Tle	Thr	Ser	Glu	185 Val	Dro	лΊэ	Λ1 =	Larg	190	Glu	17a l
110	vai	195	DCI	110	1111	DCI	200	vai	110	Αια	AIG	205	GIU	GIU	vaı
Lys	Pro	Thr	Gln	Thr	Ser	Val		Gln	Ser	Thr	Thr		Ser	Pro	Ala
-	210					215					220				
	Val	Ala	Ala	Glu		Pro	Ala	Pro	Val	Ala	Lys	Val	Ala	Pro	Val
225	ma1	** 7			230		** 4		_	235	_				240
Arg	Thr	vaı	Ala	A1a 245	Pro	Arg	vaı	Ата	250	Val	Lys	Val	Val	Thr 255	Pro
Lvs	Val	Glu	Thr		Ala	Ser	Pro	Glu		Val	Ser	Δla	Pro		Val
-1-			260	1				265			501		270		
Pro	Val	Thr	Thr	Thr	Ser	Thr	Ala	Thr	Asp	Ser	Lys	Leu	Gln	Ala	Thr
	_	275					280					285			
Glu		Lys	Ser	Val	Pro		Ala	Gln	Lys	Ala		Thr	Ala	Thr	Pro
Val	290	Gln	Pro	λla	Sar	295	Thr	λαη	ת א	17a]	300	λla	шіс	Dro	Clu
305	AIU	0111	110	AIU	310	+111	1111	ABII	nia	315	AIG	Ата	1112	FIO	320
	Ala	Gly	Leu	Gln		His	Val	Ala	Ala		Lys	Glu	Lys	Val	
				325					330	_	_		_	335	
Ser	Thr	Tyr	Gly	Val	Asn	Glu	Phe		Thr	${ t Tyr}$	Arg	Ala		Asp	Pro
a 3	70	TT	340	T	a 1	T	77-	345	73	m)			350		
GIY	Asp	355	Gly	гàг	GIY	ьeu	360	vaı	Asp	Pne	TIE	765	GIY	гув	Asn
Gln	Ala		Gly	Asn	Glu	Val		Gln	Tvr	Ser	Thr		Asn	Met	Ala
-	370		1			375			-1-		380				
Ala	Asn	Asn	Ile	Ser	Tyr	Val	Ile	Trp	Gln	Gln	Lys	Phe	Tyr	Ser	Asn
385				_	390	_				395					400
Thr	Asn	Ser	Ile		Gly	Pro	Ala	Asn		Trp	Asn	Ala	Met		Asp
Δτα	Glv	Glv	Val	405 Thr	בומ	Δgp	Hie	Tur	410	Hic	17:a 1	Hic	17 n 1	415 Ser	Dhe
~1 g	υ±y	O L Y	420	T 11T	AIU	11011	1113	425	∽oh	1172	val	117.2	430	DET	FIIC
Asn	Lys														
	_														

<210> 40

<211> 232

<212> PRT <213> Streptococcus

<400> 40

Met 1	Pro	His	Leu	Ser 5	Lys	Glu	Ala	Phe	Lys 10	Lys	Gln	Ile	Lys	Asn 15	Gly	
	· Ile	Val	Ser 20	_	Gln	Ala	Leu	Pro 25		Glu	Pro	Leu	Tyr 30		Glu	
Ser	Gly	Gly 35		Met	Pro	Leu	Leu 40		Leu	Ala	Ala	Gln 45		Ala	Gly	
Ala	Val	Gly	Ile	Arg	Ala	Asn 55		Val	Arg	Asp	Ile 60		Glu	Ile	Gln	
Glu 65	Val	Thr	Asn	Leu	Pro 70	Ile	Ile	Gly	Ile	Ile 75	Lys	Arg	Glu	Tyr	Pro 80	
Pro	Gln	Glu	Pro	Phe 85	Ile	Thr	Ala	Thr	Met 90	Thr	Glu	Val	Asp	Gln 95	Leu	
Ala	Ser	Leu	Asp 100	Ile	Ala	Val	Ile	Ala 105	Leu	Asp	Cys	Thr	Leu 110	Arg	Glu	
Arg	His	Asp 115	Gly	Leu	Ser	Val	Ala 120	Glu	Phe	Ile	Gln	Lys 125	Ile	Lys	Gly	
	Tyr 130					135					140					
145					150					155					160	
	Gly			165					170					175		
	Leu		180		_			185		_			190		-	
	Ile	195					200					205				
	Gly 210					215		Ile	Thr	Arg	Pro 220	Lys	Glu	Ile	Ala	
225	Arg	Pne	lle	Ser	G1y 230	Leu	Ser									
		210>														
		211> 212>														
		213>	_	epto	cocci	ıs										
	< 4	400>	41													
Met 1	Ser	Ile	Lys	Lys 5	Ser	Val	Ile	Gly	Phe 10	Cys	Leu	Gly	Ala	Ala 15	Ala	
Leu	Ser	Met	Phe 20	Ala	Cys	Val	Asp	Ser 25	Ser	Gln	Ser	Val	Met 30	Ala	Ala	
Glu	Lys	Asp 35	Lys	Val	Glu	Ile										
		220.	4.2													
		210> 211>		5												
		212>														
	<2	213>	Stre	epto	cocci	ıs										
		400>														
															cagtc gaggta	60 120
															gataca	180
cta	agcgt	ta t	ttca	agaag	gc aa	atgto	caatt	gat	tatga	aatg	tctt	agca	aaa a	aatta	aataac	240
att	gcaga	ata t	caat	ctta	at tt	atco	ctgag	g aca	acao	ctga	cagt	aact	ta d	cgato	cagaag	300
agt	cata	ctg d	ccact	tcaa	at ga	aaaat	cagaa	a aca	accag	gcaa	caaa	atgct	gc 1	tggt	caaaca	360

```
acagctactg tggatttgaa aaccaatcaa gtttctgttg cagaccaaaa agtttctctc
                                                                    420
aatacaattt cggaaggtat gacaccagaa gcagcaacaa cgattgtttc gccaatgaag
                                                                    480
acatattett etgegeeage tttgaaatea aaagaagtat tageacaaga geaagetgtt
                                                                    540
agtcaagcag cagctaatga acaggtatca acagctcctg tgaagtcgat tacttcagaa
                                                                    600
gttccagcag ctaaagagga agttaaacca actcagacgt cagtcagtca gtcaacaaca
                                                                    660
gtatcaccag cttctgttgc cgctgaaaca ccagctccag tagctaaagt agcaccggta
                                                                    720
agaactgtag cagcccctag agtggcaagt gttaaagtag tcactcctaa agtagaaact
                                                                    780
ggtgcatcac cagagcatgt atcagctcca gcagttcctg tgactacgac ttcaacagct
                                                                    840
acagacagta agttacaagc gactgaagtt aagagcgttc cggtagcaca aaaagctcca
                                                                    900
acagcaacac cggtagcaca accagcttca acaacaaatg cagtagctgc acatcctgaa
                                                                    960
aatgcagggc tccaacctca tgttgcagct tataaagaaa aagtagcgtc aacttatgga
                                                                   1020
gttaatgaat tcagtacata ccgtgcaggt gatccaggtg atcatggtaa aggtttagca
                                                                   1080
gtcgacttta ttgtaggtaa aaaccaagca cttggtaatg aagttgcaca gtactctaca
                                                                   1140
caaaatatgg cagcaaataa catttcatat gttatctggc aacaaaagtt ttactcaaat
                                                                   1200
acaaatagta tttatggacc tgctaatact tggaatgcaa tgccagatcg tggtggcgtt
                                                                   1260
actgccaacc attatgacca tgttcacgta tcatttaaca aataa
                                                                   1305
      <210> 43
      <211> 1230
      <212> DNA
      <213> Streptococcus
      <400> 43
caagaaacag atacgacgtg gacagcacgt actgtttcag aggtaaaggc tgatttggta
                                                                     60
aagcaagaca ataaatcatc atatactgtg aaatatggtg atacactaag cgttatttca
                                                                    120
gaagcaatgt caattgatat gaatgtctta gcaaaaatta ataacattgc agatatcaat
                                                                    180
cttatttatc ctgagacaac actgacagta acttacgatc agaagagtca tactgccact
                                                                    240
tcaatgaaaa tagaaacacc agcaacaaat gctgctggtc aaacaacagc tactgtggat
                                                                    300
ttgaaaacca atcaagtttc tgttgcagac caaaaagttt ctctcaatac aatttcggaa
                                                                    360
ggtatgacac cagaagcagc aacaacgatt gtttcgccaa tgaagacata ttcttctgcg
                                                                    420
ccagctttga aatcaaaaga agtattagca caagagcaag ctgttagtca agcagcagct
                                                                    480
aatgaacagg tatcaacagc tcctgtgaag tcgattactt cagaagttcc agcagctaaa
                                                                    540
gaggaagtta aaccaactca gacgtcagtc agtcagtcaa caacagtatc accagcttct
                                                                    600
gttgccgctg aaacaccagc tccagtagct aaagtagcac cggtaagaac tgtagcagcc
                                                                    660
cctagagtgg caagtgttaa agtagtcact cctaaagtag aaactggtgc atcaccagag
                                                                    720
catgtatcag ctccagcagt tcctgtgact acgacttcaa cagctacaga cagtaagtta
                                                                    780
caagegactg aagttaagag egtteeggta geacaaaaag etecaacage aacaeeggta
                                                                    840
gcacaaccag cttcaacaac aaatgcagta gctgcacatc ctgaaaatgc agggctccaa
                                                                    900
cctcatgttg cagcttataa agaaaaagta gcgtcaactt atggagttaa tgaattcagt
                                                                    960
acataccgtg caggtgatcc aggtgatcat ggtaaaggtt tagcagtcga ctttattgta
                                                                   1020
ggtaaaaacc aagcacttgg taatgaagtt gcacagtact ctacacaaaa tatggcagca
                                                                   1080
aataacattt catatgttat ctggcaacaa aagttttact caaatacaaa tagtatttat 1140
ggacctgcta atacttggaa tgcaatgcca gatcgtggtg gcgttactgc caaccattat 1200
gaccatgttc acgtatcatt taacaaataa
                                                                   1230
     <210> 44
      <211> 409
      <212> PRT
      <213> Streptococcus
      <400> 44
Gln Glu Thr Asp Thr Thr Trp Thr Ala Arg Thr Val Ser Glu Val Lys
                                    10
Ala Asp Leu Val Lys Gln Asp Asn Lys Ser Ser Tyr Thr Val Lys Tyr
            20
                                25
Gly Asp Thr Leu Ser Val Ile Ser Glu Ala Met Ser Ile Asp Met Asn
```

		35					40					45			
Val	T.011		Lys	Tla	Λcn	λan		71-	7 00	т1 о	7 ~~		т1.	M	D
vaı	50	AId	цуз	116	ASII	55	116	Ата	Asp	116	60	Leu	ııe	TYP	Pro
Glu	Thr	Thr	Leu	Thr	Val	Thr	Tvr	Asn	Gln	Lvs		Hic	Thr	Δla	Thr
65					70					75					80
Ser	Met	Lys	Ile	Glu	Thr	Pro	Ala	Thr	Asn	Ala	Ala	Gly	Gln	Thr	Thr
				85					90			-		95	
Ala	Thr	Val	Asp	Leu	Lvs	Thr	Asn	Gln	Val	Ser	Val	Ala	Asp	Gln	Lvs
			100		4			105					110	0111	_,_
Val	Ser	Len	Asn	Thr	Tle	Ser	Glu		Met	Thr	Dro	Glu		ת ד ת	Thr
	202	115				501	120		1100	1111	110	125	AIA	Ата	1111
Thr	Tlo		Ser	Dro	Mot	Tara		TT	Com	C - 22	77.		70 7 -	T	T
1111		vai	261	PIO	Mec	135	TILL	IAT	ser	ser		Pro	Ата	ьеu	газ
0	130	a 1	77-7	T	7.7 -		~1	~ 3	~ 7		140				
	ьуѕ	GIU	Val	ьeu		GIN	GIU	GIN	Ата		Ser	GIn	Ala	Ala	
145	~ 7	~ 7		_	150	_ ~	_			155	_				160
Asn	Glu	Gin	Val		Thr	Ala	Pro	Val		Ser	Ile	Thr	Ser	Glu	Val
				165					170					175	
Pro	Ala	Ala	Lys	Glu	Glu	Val	Lys	Pro	Thr	Gln	Thr	Ser	Val	Ser	Gln
			180					185					190		
Ser	Thr	Thr	Val	Ser	Pro	Ala	Ser	Val	Ala	Ala	Glu	Thr	Pro	Ala	Pro
		195					200					205			
Val	Ala	Lys	Val	Ala	Pro	Val	Arg	Thr	Val	Ala	Ala	Pro	Arq	Val	Ala
	210					215					220				
Ser	Val	Lys	Val	Val	Thr	Pro	Lys	Val	Glu	Thr	Gly	Ala	Ser	Pro	Glu
225					230		-			235	-				240
His	Val	Ser	Ala	Pro	Ala	Val	Pro	Val	Thr	Thr	Thr	Ser	Thr	Ala	
				245					250					255	
Asp	Ser	Lvs	Leu	Gln	Ala	Thr	Glu	Val		Ser	Va 1	Pro	Va 1		Gln
		2	260					265	-10				270	21114	0111
Lvs	Δla	Pro	Thr	Δla	Thr	Pro	Val		Gln	Dro	Λla	Car		Thr	7 0 2
-1-		275				110	280	71 <u>1</u> u	0111	110	Ala	285	TILL	TIIL	ASII
Δla	Val		Ala	ије	Dro	Glu		ת ד ת	<i>C</i> 1 <i>v</i>	T 011	C1 n		TT i a	37 n 7	7 7 -
ALG	290	nia	HIU	1113	FIO	295	ASII	Ala	GIY	neu		PIO	птв	vai	Ala
777		Larg	Glu	Tara	37-7		C 0 7	TII aa	(T)= ===	a 1	300	70	a 1	D1 -	a
305	тут	цуѕ	Glu	гуя		Ата	ser	inr	Tyr		vaı	Asn	Glu	Phe	
	Ш	7	77 -	~ 1	310	.	~7	_	•	315	_		_		320
Thr	Tyr	Arg	Ala		Asp	Pro	GIY	Asp		GLY	Lys	Gly	Leu		Val
_			-	325			_		330					335	
Asp	Phe	Ile	Val	Gly	Lys	Asn	Gln	Ala	Leu	${ t Gly}$	Asn	Glu	Val	Ala	Gln
			340					345					350		
Tyr	Ser	Thr	Gln	Asn	Met	Ala	Ala	Asn	Asn	Ile	Ser	Tyr	Val	Ile	\mathtt{Trp}
		355					360					365			
Gln	Gln	Lys	Phe	Tyr	Ser	Asn	Thr	Asn	Ser	Ile	Tyr	Gly	Pro	Ala	Asn
	370					375					380	-			
Thr	Trp	Asn	Ala	Met	Pro	Asp	Arg	Gly	Gly	Val	Thr	Ala	Asn	His	Tyr
385					390	_	_	-	-	395					400
Asp	His	Val	His	Val	Ser	Phe	Asn	Lys							
				405				-							

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

C12N 15/31, C07K 14/315, A61K 39/09, C12N 1/21

(11) International Publication Number:

WO 99/42588

A3

(43) International Publication Date:

26 August 1999 (26.08.99)

(21) International Application Number:

PCT/CA99/00114

(22) International Filing Date:

17 February 1999 (17.02.99)

(30) Priority Data:

60/075,425

20 February 1998 (20.02.98) U

US

(71) Applicant (for all designated States except US): BIOCHEM VACCINS INC. [CA/CA]; 2323 boulevard du Parc Technologique, Sainte-Foy, Québec G1P 4R8 (CA).

(72) Inventors; and

(75) Inventors'Applicants (for US only): BRODEUR, Bernard, R. [CA/CA]; 2401 rue Maritain, Sillery, Québec G1T 1N6 (CA). RIOUX, Clément [CA/CA]; 1012 Jean-Charles Cantin, Ville de Cap Rouge, Québec G1Y 2X1 (CA). BOYER, Martine [CA/CA]; Apt. 204, 25 des Mouettes, Beauport, Québec G1E 7G1 (CA). CHARLEBOIS, Isabelle [CA/CA]; 410 Mirabel, St-Nicolas, Québec G7A 2L5 (CA). HAMEL, Josée [CA/CA]; 2401 rue Maritain, Sillery, Québec G1T 1N6 (CA). MARTIN, Denis [CA/CA]; 4728-G rue Gaboury, St-Augustin-de-Desmaures, Québec G3A 1E9 (CA).

(74) Agents: CÔTE, France et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:

23 March 2000 (23.03.00)

(54) Title: GROUP B STREPTOCOCCUS ANTIGENS

(57) Abstract

Group B streptococcus (GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	ТJ	Tajikistan
\mathbf{BE}	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
\mathbf{BG}	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	$\mathbf{z}\mathbf{w}$	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Interr nal Application No PCT/CA 99/00114

A. CLASSIF	FICATION OF SUBJECT MATTER C12N15/31 C07K14/315 A61K39/0	9 C12N1/21							
	, , , , , , , , , , , , , , , , , , , ,	·							
According to	International Patent Classification (IPC) or to both national classifica	tion and IPC							
B. FIELDS	SEARCHED	· ·							
IPC 6	cumentation searched (classification system followed by classificatio CO7K C12N A61K								
Documentat	ion searched other than minimum documentation to the extent that su	ich documents are included in the fields sea	arched						
Electronio da	ata base consulted during the international search (name of data bas	e and, where practical, search terms used)							
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT								
Category °	Citation of document, with indication, where appropriate, of the rele	vant passages	Relevant to claim No.						
A	MICHEL J L ET AL: "Cloned alpha and beta C-protein antigens of group B Streptococci elicit protective immunity" INFECTION AND IMMUNITY., vol. 59, no. 6, June 1991 (1991-06), pages 2023-2028, XP002107260 AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON., US ISSN: 0019-9567 the whole document								
X Furt	her documents are listed in the continuation of box C.	Patent family members are listed	in annex.						
"A" docume consic "E" earlier of filing of "L" docume which citatio "O" docume other "P" docume later t	ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another in or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but than the priority date claimed actual completion of the international search	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family Date of mailing of the international search report							
Name and	mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Lejeune, R							

Inter: nal Application No
PCT/CA 99/00114

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	PCT/CA 33/00114
C.(Continu Category °	the wlovent persons	Relevant to claim No.
Category		
A	LACHENAUER C S ET AL: "Cloning and expression in Escherichia coli of a protective surface protein from type V group B Streptococci" ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol. 418, 9 December 1997 (1997-12-09), pages 615-618, XP002107261 SPRING ST., NY, US ISSN: 0065-2598 the whole document	1-48
P,X	DATABASE EMBL [Online] Accession number AF062533, 11 February 1999 (1999-02-11) SPELLERBERG B ET AL: "Streptococcus agalactiae Lmb (lmb) gene, complete cds; and unknown gene." XP002125180 98.9% identity between base 1-2514 of SEQ ID NO 13 and base 988-3501 of AF062533 Translation product (AC: Q9ZHG9) has 98.5% identity in 793 AA overlap with SEQ ID NO 15 and 98.5% identity in 715 AA overlap with SEQ ID 16 & SPELLERBERG B ET AL: "Lmb, a protein with similarities to the LraI adhesin family, mediates attachment of Streptococcus agalactiae to human laminin" INFECTION AND IMMUNITY., vol. 67, no. 2, February 1999 (1999-02), pages 871-878, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON., US ISSN: 0019-9567	1-10, 16-23,26
X	DATABASE EMBL [Online] Accession Number L23843, 4 January 1994 (1994-01-04) MACRINA F L ET AL: "ISN IS199 from Streptococcus mutans IS3 (Brathall serotype C) DNA fragment" XP002125181 79.6% identity between base 5212-4314 of SEQ ID NO 13 and base 312-1220 of L23843 Translation has 83.4% identity in 283 AA overlap with SEQ ID NO 21 -/	1,3-7,10

PCT/CA 99/00114

	TO DE DEL EVANT	
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Category °	Citation of document, with indication, where appropriate, of the relevant passages	
X	DATABASE EMBL [Online] Accession Number AF026542, 15 October 1997 (1997-10-15) HYNES W L ET AL: "Streptococcus pyogenes FF22 lantibiotic (scn) gene cluster region containing: scnK, scnR, streptococcin A-FF22 precursor (scnA), scnA1, scnM, scnT, scnF, scnE, scnG genes, complete cds, and tnpA gene, partial cds." XP002125182 88.2% identity between base 2607-2953 of SEQ ID NO 13 and base 10435-10777 of AF026542 Translation product (AC: 031057) has 95.8% identity in 71 AA overlap with SEQ ID NO	1-10, 16-23,26
P,X	DATABASE GENESEQ [Online] Accession Number V52136, 23 October 1998 (1998-10-23) BARASH S C ET AL: "Streptococcus pneumoniae genome fragment SEQ ID NO:3" XP002125183 68.5% identity between base 2539-3319 of SEQ ID NO 37 and base 18492-19271 of V52136 Translation has 74.5% identity in 231 AA overlap with SEQ ID NO 40 & WO 98 18931 A (DOUGHERTY BRIAN A ;HUMAN GENOME SCIENCES INC (US); ROSEN CRAIG A) 7 May 1998 (1998-05-07)	1,3-7,10

ational application No. PCT/CA 99/00114

lm

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Although claims 37-46 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
	see additional sheet As a result of the prior review under R. 40.2(e) PCT,
	no additional fees are to be refunded.
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. X	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
	11-14,16,24,25,27,28,30,31 (completely), 1-10,15,17-23,26,29,32-48 (all partially) i.e. (group of) inventions 1, 3 and 7
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remari	con Protest The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-10,15,17-23,26,29,32-48 (all partially)

An isolated polynucleotide encoding a polypeptide having a sequence selected from the group consisting of SEQ ID 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6 i.e. the open reading frames of clone 1 (SEQ ID NO 1). Also a vector comprising the polynucleotide, a host cell transformed therewith, an isolated polypeptide encoded by the polynucleotide, a vaccine composition comprising said polypeptide and a polynucleotide having a sequence SEQ ID NO 1.

2. Claims: 1-10,15,17-23,26,29,32-48 (all partially)

Same as invention 1, but directed at polypeptides of clone 2 (SEQ ID 7) with sequences SEQ ID NO 8-12.

3. Claims: 1-10,15,17-23,26,29,32-48 (all partially)

Same as invention 1, but directed at polypeptides of clone 3 (SEQ ID 13) with sequences SEQ ID NO 14-21.

4. Claims: 1-10,15,17-23,26,29,32-48 (all partially)

Same as invention 1, but directed at polypeptides of clone 4 (SEQ ID 22) with sequences SEQ ID NO 23-26.

5. Claims: 1-10,15,17-23,26,29,32-48 (all partially)

Same as invention 1, but directed at polypeptides of clone 5 (SEQ ID 27) with sequences SEQ ID NO 28-31.

6. Claims: 1-10,15,17-23,26,29,32-48 (all partially)

Same as invention 1, but directed at polypeptides of clone 6 (SEQ ID 32) with sequences SEQ ID NO 33-36.

7. Claims: 11-14,16,24,25,27,28,30,31 (all completely), 1-10, 15,17-23,26,29,32-48 (all partially)

Same as invention 1, but directed at polypeptides of clone 7 (SEQ ID 37) with sequences SEQ ID NO 38-41.

information on patent family members

Interr pai Application No PCT/CA 99/00114

Patent document cited in search report				atent family nember(s)	Publication date
WO 9818 9 31	A	07-05-1998	AU AU EP EP WO	5194598 A 6909098 A 0942983 A 0941335 A 9818930 A	22-05-1998 22-05-1998 22-09-1999 15-09-1999 07-05-1998